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Abstract 
The requirements for prompt diagnosis of foot-and-mouth disease (FMD) during outbreaks, 
and the need to establish robust laboratory testing capacity within FMD-endemic 
countries, have motivated the development of point-of-care tests (POCTs) to support 
current diagnostic strategies. Despite numerous publications detailing the design of 
platforms and assays for this purpose, the majority have only been evaluated in laboratory 
settings, using protocols incompatible for use in challenging environments. To address 
this gap, this thesis describes the development of an end-to-end molecular toolbox for 
the detection and characterisation of FMD virus (FMDV) RNA in decentralised settings. A 
critical review and multiway comparison of seven assay formats and 11 sample 
preparation methods revealed that reverse transcription loop-mediated isothermal 
amplification (RT-LAMP) and real-time reverse transcription PCR (rRT-PCR) POCT-formats 
exhibited comparable analytical and diagnostic sensitivity to their laboratory-based 
equivalents. Additionally, reagent lyophilisation provided a solution for cold chain and 
storage considerations, whilst not compromising assay performance. Both assays were 
compatible with simple sample preparation methods, removing the requirement for 
nucleic acid extraction. For example, dilution of samples in nuclease-free water enabled 
FMDV RNA to be detected in multiple sample types (epithelial tissue suspensions, serum, 
oesophageal-pharyngeal fluid and lesion swabs), from as early as one day post infection. 
Notably, when the robust field-ready protocols were deployed into challenging low-
resource laboratory and field-settings within East Africa, POCT results (rRT-PCR = 144; 
RT-LAMP = 145) were consistent with clinical observations and a reference rRT-PCR, with 
FMDV detected from acutely infected as well as convalescent cattle. Furthermore, 
transitioning of East Africa-specific FMDV-typing rRT-PCR assays (for serotypes O, A, 
Southern African Territories [SAT] 1 and SAT 2) into a multiplex POCT-format enabled 
rapid identification of FMDV serotype in situ, confirming active outbreaks of both O and 
A. This thesis also describes the development of GoPrime, a novel real-time PCR (rPCR) 
primer/probe validation tool. By parameterising GoPrime with experimental data, 
collected to investigate the effects of primer/probe-template mismatches on cycle 
threshold and limit of detection, it was possible to quantitatively predict the performance 
of rPCR assays in silico. The work of this thesis supports the deployment of molecular 
POCTs into non-specialised, resource-limited and challenging settings for simple, highly 
sensitive and rapid detection and/or characterisation of FMDV. 
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Glossary of Terms 
Carrier Animals in which foot-and-mouth disease virus persists in the 
oropharynx for more than 28 days after infection, and serves as 
a potential source of infection. In order to confirm persistence 
in an animal, virus isolation needs to be performed to test for 
the presence of live virus (OIE, 2012). 
Convalescent  An animal recovering from disease. 
Decentralised settings Low-resource laboratory or field settings. 
Delayed clearance Animals in which the virus persists in the oropharynx after 
recovery from clinical signs.  
Pool A closed geographic region that maintains unique and discrete 
foot-and-mouth disease virus (FMDV) lineages. Seven major 
pools of infection are defined (Paton et al., 2009). Sometimes 
FMDV lineages are transmitted between these pools. 
Reservoir An ecological system in which the pathogen can be permanently 
maintained, and from which infection can be transmitted to the 
target population (Haydon et al., 2002). 
Serotype A group of viruses distinguished by their specific shared 
antigens, as determined by serologic testing. Recovery from 
infection, or vaccination, with one serotype will not protect 
against subsequent infection with another (Alexandersen et al., 
2003a). 
Sensitivity (analytical) The smallest detectable amount of analyte that can be 
measured with a defined certainty (OIE, 2012). Synonymous 
with “limit of detection”. 
Sensitivity (diagnostic) Proportion of known positive samples that test positive in an 
assay (OIE, 2012). Known positive samples which test negative 
are considered false-negative results. 
Specificity (analytical) Degree to which an assay distinguishes between the target 
analyte and other components in the sample matrix (OIE, 2012).  
Specificity (diagnostic) Proportion of known negative samples that test negative in an 
assay (OIE, 2012). Known negative samples which test positive 
are considered false-positive results. 
Topotype Geographically clustered viruses from a single genetic lineage 
which generally share >85% (O, A, C, and Asia 1) or >80% (SAT 
1, SAT 2, and SAT 3) nucleotide sequence identity in the VP1-
coding region (Samuel and Knowles 2001a; 2001b; Ayelet et al. 
2009).
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CHAPTER 1 
 
Foot-and-mouth disease: a review of diagnostic 
strategies for a transboundary disease of global 
importance 
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1.1 Summary 
Sustainable food production, to support a growing human population, is a key global 
priority and is encompassed within the Global Goals for Sustainable Development. 
Livestock infectious diseases pose important threats to the achievements of these global 
goals, with viral diseases such as foot-and-mouth disease (FMD) amongst the most 
important. Consequently, management of these threats is key to sustainable agricultural 
development. Accurate and rapid diagnostic tests are an essential component of 
contingency and surveillance plans to diagnose, control and eradicate FMD. Diagnosis 
involves a pipeline that normally starts with clinical suspicion, followed by collection of 
samples, transport of specimens to a centralised laboratory setting (e.g. national / 
international reference laboratories), analysis of samples using a range of diagnostic tests 
and reporting of results. However, transport of specimens from the field to the laboratory 
can be a lengthy process and logistically challenging in remote locations. These issues can 
delay critical decision-making and reduce the quality of samples. Furthermore, many 
diagnostic tests require well-equipped laboratories, often problematic for endemic 
countries which lack infrastructure and financial resources for disease surveillance and 
diagnostics. These important limitations of centralised diagnostic testing have motivated 
the development of tools for rapid, simple, detection of FMD virus (FMDV), which are 
compatible with use in low-resource settings. Recent advances in the development of 
such technologies for human medicine have provided a range of prototype diagnostic 
solutions, which could be applied to a wide selection of diseases of livestock. Based on a 
critical review of current and emerging diagnostic technologies, this chapter will highlight 
the most promising candidates for revolutionising FMD diagnostics, with a particular focus 
on tests that can be utilised in decentralised settings. 
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1.2 Foot-and-mouth disease 
1.2.1 Disease overview 
Foot-and-mouth disease (FMD) is a highly infectious trans-boundary disease, affecting 
both domesticated and wild cloven-hooved animals. Endemic across most of Asia, Africa 
and parts of South America (FAO, 2016), FMD is characterised by acute fever, coupled 
with the development of lesions primarily on the epithelial surfaces of the feet, mouth, 
nasal region and mammary glands/teats (Alexandersen et al., 2003a). Although the case-
fatality rate of FMD is generally below 5% (Rushton et al., 2012), mortality is often high 
in young animals and debilitating effects are evident through decreases in milk 
production, weight loss and loss of draught power (Knight-Jones and Rushton, 2013; 
Knight-Jones et al., 2016). These reductions in productivity, in combination with the 
severe economic consequences attained through disease control and trade restrictions, 
have resulted in FMD being listed by the World Organisation for Animal Health (OIE) as 
the most important animal disease constraining world trade (OIE/FAO, 2012).  
FMD is caused by foot-and-mouth disease virus (FMDV), a positive-sense, single-stranded 
RNA virus belonging to the family Picornaviridae, genus Aphthovirus. Seven serotypes of 
FMDV are recognised, defined as antigenically distinct groups (determined by serological 
testing), namely: O, A, C, Asia 1 and Southern African Territories (SAT) 1-3, which can be 
further subdivided phylogenetically and geographically into distinct topotypes. FMDV has 
numerous characteristics of a successful pathogen including: a wide host range (FMDV 
affects over 70 species [Fenner et al., 1993]), low infectious dose required for infection, 
rapid replication rate and a high level of viral excretion (Alexandersen et al., 2003a). In 
addition, multiple routes of transmission are evident. FMDV is present in all excretions 
from an infected animal, therefore transmission most commonly occurs though direct 
contact between infected and susceptible animals (Alexandersen et al., 2003b). However, 
transmission can also occur though the indirect exposure to these excretions and via 
untreated meat products from infected animals (Figure 1.1) (OIE, 2012). As such, FMD 
remains the most contagious disease of mammals (OIE, 2012) and requires continuous 
efforts for control, monitoring and eradication. 
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Figure 1.1 Transmission pathways of foot-and-mouth disease virus (FMDV). 
 
1.2.2 Global distribution of FMDV 
Historically, FMD has occurred in most livestock-containing areas of the world (Grubman 
and Baxt, 2004), however current global circulation occurs primarily within three 
continental epidemiological clusters in Asia, Africa and South America (Figure 1.2). 
Although Europe, North and Central America, Greenland and Australasia are currently 
considered FMD-free without vaccination, occasional incursions to such areas have 
occurred: including outbreaks of FMDV in the UK in 2001 (PanAsia O strain) and 2007 (O1 
British Field Strain [BFS]/1967) (Knowles et al., 2001; Cottam et al., 2008), with the last 
FMD introduction into Europe occurring in Bulgaria in 2011 (PanAsia-2 O strain) (Valdazo-
González et al., 2012; Alexandrov et al., 2013) .  
The global distribution of FMDV serotypes is uneven. Serotypes O and A have the widest 
global distribution and are reported in most endemic regions. Conversely serotype C has 
not been isolated since 2004 (Kenya and Brazil) (Rweyemamu et al., 2008a). The SAT 1-3 
viruses are generally restricted to sub-Saharan Africa and Asia 1 is generally confined to 
the Asian continent (Paton et al., 2009). Phylogenetic analysis of FMDV circulating 
worldwide has enabled the definition of seven regional pools (Figure 1.2), each containing 
regionally specific viral topotypes (Paton et al., 2009).  
Movement of FMDV strains is observed between the pools (Figure 1.2), and is viewed with 
concern due to the potential for disease emergence in areas previously naïve to the 
specific strains. For example, recent long-distance “trans-pool” movements have 
included the extensive spread of O/ME-SA/Ind-2001d from the Indian sub-continent (pool 
2), first west into Gulf States of the Middle East (2013), followed by separate introductions 
into countries within North Africa (2014), including Tunisia, Algeria and Morocco which 
had last reported FMD cases in 1999 (Bouguedour and Ripani, 2016). Additional multiple 
independent movements (2015-6) have occurred within mainland South East Asia and the 
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Indian Ocean, with the most recent reports including Eastern parts of Russia and South 
Korea (Subramaniam et al., 2013; Yuvaraj et al., 2013; Knowles et al., 2016). In addition 
to O/ME-SA/Ind-2001d, outbreaks of the A/ASIA/G-VII lineage (also originally found in 
pool 2) have occurred in northern regions of pool 3 (Saudi Arabia, Turkey, Iran, Armenia), 
with initial reports in September 2015 (Das et al., 2016). 
 
Figure 1.2 Conjectured status of foot-and-mouth disease worldwide in 2017. Foot-and-
mouth disease is maintained within three continental clusters: Asia, Africa and South 
America, which are further subdivided into seven regional pools (annotated on the figure). 
Courtesy of Dr Antonello Di Nardo (The Pirbright Institute, UK). (SAT) Southern African 
Territories. 
 
1.2.3 Epidemiological patterns of FMD 
FMD is estimated to circulate in 77% of the global livestock population (Rushton et al., 
2012), with disease distribution roughly reflecting economic development (Jamal and 
Belsham, 2013). Epidemiologically, FMD patterns vary enormously between different 
countries, however the OIE has classified areas into one of the following (OIE, 2016a): 
1. FMD-free country where vaccination is not practised 
2. FMD-free country where vaccination is practised 
3. FMD-free compartment or zone where vaccination is not practised 
4. FMD-free compartment or zone where vaccination is practised 
5. FMD-infected country or zone 
According to the provisions of the OIE (OIE, 2016a), 68 member countries are now  
recognised as FMD free (66 without vaccination and two with vaccination), with FMD-free 
zones recognised in a further 22 member countries (13 without vaccination and nine with 
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vaccination) (OIE, 2017). For instance, zonal FMD-freedom has been achieved within South 
Africa (Brückner et al., 2002), where FMD infection is restricted to Kruger National Park. 
Here, African buffalo (Syncerus caffer) provide a principal reservoir  for FMD for the SAT 
serotypes (Esterhuysen et al., 1985; Thomson et al., 1992): defined as an ecological 
system in which the pathogen can be permanently maintained, and from which infection 
can be transmitted (Haydon et al., 2002).  
Within FMD-endemic countries, the epidemiological situation is often incredibly complex. 
For instance, within East African countries, four FMD serotypes and multiple topotypes 
are known to be currently circulating (Figure 1.3) (Vosloo et al., 2002; Vosloo et al., 2004; 
Ayelet et al., 2009; Kasanga et al., 2012; Namatovu et al., 2015), with the occurrence of 
SAT 3 in wildlife yet to be defined (Dhikusooka et al., 2015).  
 
Figure 1.3 The reported occurrences of foot-and-mouth disease viral serotypes and 
lineages within Kenya, Tanzania and Ethiopia (2010-2017). Based on molecular 
epidemiology reports produced by the Food and Agriculture Organization World Reference 
Laboratory for Foot-and-Mouth Disease (WRLFMD). Courtesy of Dr Antonello Di Nardo (The 
Pirbright Institute, UK). 
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The epidemiology within FMD-endemic regions is further complicated by agro-pastoral 
practices resulting in uncontrolled human and animal movements (over 99% of livestock 
in Tanzania are kept by smallholders [United Republic of Tanzania, 2012], with 73% in 
communal grazing production systems [Kivaria, 2003]), and the presence of wildlife as a 
potential FMD reservoir. For instance, a high prevalence of FMDV infection has been shown 
in African buffalo within East Africa (Anderson et al., 1979; Hamblin et al., 1990; 
Bronsvoort et al., 2008; Ayebazibwe et al., 2010a; Ayebazibwe et al., 2010b; Mkama et 
al., 2014), however their role in transmitting FMDV to livestock remains inconclusive 
(Casey et al., 2013). With the majority of FMDV outbreaks East Africa remaining 
unrecorded, due to factors including (i) a lack of encouragement to report disease, (ii) 
poor diagnostic infrastructure and (iii) logistical and cultural barriers associated with 
transporting samples to centralised facilities, the complete epidemiological situation 
within these regions remains unknown (Vosloo et al., 2002; Namatovu et al., 2013) 
 
1.3 Impacts and control of FMD 
1.3.1 Impacts of FMD 
Although a disease of low mortality, FMD is considered one of the most economically 
devastating diseases of animals worldwide (Sumption et al., 2012). The impacts of FMD 
can be separated into two types: those that arise from the direct effects of the disease 
on production, and those that have indirect effects through the costs of disease control, 
trade restrictions and use of sub-optimal livestock practices (Figure 1.4). However, the 
costs associated with FMD are not evenly distributed globally. In FMD-free countries, the 
costs associated with maintaining FMD-free status or regaining FMD-free status following 
an outbreak (in order to satisfy international trade requirements) can be severe. For 
example, the UK 2001 FMD outbreak is estimated to have cost the national economy US$ 
9.2 billion (FAO, 2002), including US$ 4.2 billion in governmental compensation to the 
agricultural and food chain industry (Thompson et al., 2002). Furthermore, intensive 
vaccination in South America, to maintain FMD-free status, is estimated to cost US$ 0.7 
billion annually (Knight-Jones and Rushton, 2013). 
Production losses are greatest in low to middle income countries (LMIC) with endemic-
FMD infection, where communities are often dependent on the health of their livestock 
(Knight-Jones and Rushton, 2013; Knight-Jones et al., 2016). For instance, at the herd 
level, FMDV infection has shown to decrease the average daily milk yields by 35% per cow, 
only recovering after approximately two months (Lyons et al., 2015). Furthermore, 
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endemically infected countries, with FMD control programs, incur the ongoing costs of 
disease management (e.g. vaccination, movement restrictions and surveillance) (James 
and Rushton, 2002). The annual global impact of FMD in terms of production losses and 
vaccination in endemic regions alone is estimated to amount to between US$6.5 and 21 
billion (Knight-Jones and Rushton, 2013).  
 
 
Figure 1.4 The impacts of foot-and-mouth disease. Adapted from Rushton et al. (2009).  
 
1.3.2 Control of FMD 
The control of FMD has been recognised by the Food and Agricultural Organization of the 
United Nations (FAO) and OIE as a global priority (Sumption et al., 2012). There are a 
variety of control measures that can be adopted, which are largely driven by the countries 
policy, capacity, priorities and FMD status (Paton et al., 2009). For instance, the 
economic burden associated with FMD, including restricted access to lucrative 
international markets, results in prosperous FMD-free countries employing rapid measures 
for disease eradication during outbreaks. For instance, during the UK 2001 FMDV 
outbreak, control measures included a stamping out policy (culling of suspect and in 
contact animals: animals were slaughtered on >10,000 farms [Scudamore and Harris, 
2002]), combined with strict movement restrictions, zoo-sanitary measures and intensive 
surveillance (Anderson, 2002). 
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FMD control in endemic countries however, is often much more complex. Zonal FMD-
freedom has been achieved by some endemic countries, such as South Africa and 
Kazakhstan, through a combination of vaccination, animal movement control and 
separation of wildlife and livestock (Brückner et al., 2002; OIE, 2016b). However, the 
level of enforcement of these methods differs between countries. For instance, although 
vaccination and quarantine are cited as existing FMD control strategies for East Africa 
(Hunter, 1998; Rweyemamu and Astudillo, 2002), they are only rarely implemented. 
Movement restrictions are limited by social customs (communal grazing and pastoralism), 
weak law enforcement on animal movement and the potential role of wildlife as a 
maintenance host (Vosloo et al., 2002; Ayebazibwe et al., 2010b; Maree et al., 2014). 
While livestock vaccination campaigns remain a feasible control approach (Rweyemamu 
et al. 2008b), several major challenges remain in the implementing of effective 
vaccination strategies (Parida, 2009). The immunological diversity present within African 
serotypes necessitates continuous FMDV characterisation to match field strains with 
available vaccines, something that is often challenging for low-resource laboratories 
(Vosloo et al., 2002; Mumford, 2007). Furthermore, access to good quality and affordable 
FMD vaccines can prove problematic. FMD control therefore still presents multiple 
challenges throughout endemic countries.   
With total FMD control unlikely for East Africa in the near future, due to factors including 
(i) poor diagnostic infrastructure, (ii) social customs/attitudes and (iii) highly complex 
epidemiology (Vosloo et al., 2002; Maree et al., 2014), a progressive approach for FMD 
control is required. In order to address such challenges, the FAO and OIE launched a global 
strategy in 2012 to assist countries where FMD is endemic to progressively reduce the 
impact of the disease: The Progressive Control Pathway for FMD (PCP-FMD) (Sumption et 
al., 2012). This framework is built on the principle that countries are at different stages 
in the pathway towards FMDV control and eradication, and has been adopted as a working 
tool by the FAO to help tailor national and regional control programs to specific contexts 
and needs (Figure 1.5). However, with all stages of the PCP-FMD requiring active 
monitoring of FMDV circulation and understanding of FMDV epidemiology, progress along 
the pathway is dependent on countries establishing robust diagnostic testing capacity for 
the detection and characterisation of FMDV. 
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Figure 1.5 Progressive Control Pathway for Foot-and-Mouth Disease (PCP-FMD). Adapted 
from Sumption et al. (2012). 
 
1.4 Current diagnostic strategies 
1.4.1 Clinical diagnosis 
Initial diagnosis of FMD is based on the observation of clinical signs in susceptible livestock 
by their owners and/or veterinarians. Initial FMDV replication occurs close to the site of 
entry (mucosae and lymphoid tissues of the pharyngeal or tonsillar region) with the 
incubation period (time from infection to clinical signs of disease) ranging from 1-14 days 
(most commonly between 2-5 days), depending upon factors such as pathogen dose, virus 
strain, host species, pre-existing immunity and the route of transmission (Alexandersen 
et al., 2003b). Initial clinical signs include fever, dullness and a drop in milk yield for 
dairy animals. Viral dissemination into tissues and organs, results in the development of 
secondary characteristic lesions on the epithelial surfaces of the feet, mouth, nasal region 
and mammary glands/teats. These vesicular lesions can be aged, in order to estimate the 
time of initial infection (OIE, 2012) (Figure 1.6).  
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Figure 1.6 Timeline for estimating the age of foot-and-mouth disease lesions. 
Descriptions are based on those of Kitching and MacKay (1995). Photographs of days 2-6 
were taken during field work in East Africa; day 1 photograph courtesy of Dr Veronica 
Fowler (The Pirbright Institute, UK). 
 
Clinical observations alone however remain insufficient for confirmation of FMD, as 
clinical signs are indistinguishable from other vesicular diseases including swine vesicular 
disease (SVD), vesicular stomatitis (VS), Seneca Valley virus 1 (SVV) and vesicular 
exanthema of swine (VES) (OIE, 2012). Furthermore, the severity of clinical signs varies 
between species: clinical signs are most apparent in cattle followed by pigs, whereas 
sheep, goats and other small ruminants commonly display only mild signs (Kitching, 2002a; 
2002b; Kitching and Hughes, 2002). As such, misdiagnosis or missed detection has been 
common in the history of FMD outbreaks. For example the FMD outbreak in Tunisia in 1989 
was initially misdiagnosed in sheep as bluetongue and only recognised as FMD after it was 
transmitted to cattle (Kitching, 2004), whilst the outbreak in Greece in 1994 went 
unnoticed in sheep for a number of months, again only recognised as FMD following 
transmission to cattle (Kitching, 1998). Therefore, depending on context, following a 
suspect FMD case and where resources permit, samples require transportation to national 
/ international reference laboratories (NRL/IRL) for diagnostic confirmation (laboratory 
confirmation of FMD in endemic settings often does not occur).  
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1.4.2 Samples for diagnostics 
FMDV is present in all excretions and secretions of acutely infected animals, starting 
shortly before the onset of clinical signs and declining after approximately 5 days of 
clinical presentation (Alexandersen et al., 2003a) (Figure 1.7). Epithelium and vesicular 
fluid are the preferred tissues for diagnostics since they contain high viral loads during 
the acute phase of infection. Where collection of these samples is not possible, for 
example before clinical presentation, FMDV can be detected in the oesophageal-
pharyngeal fluid (OP), blood and nasal fluid (Chase-Topping et al., 2013). Animals in which 
FMDV persists in the oropharynx for more than 28 days after infection are known as 
carriers, with virus isolated from OP fluid 28 days post challenge (DPC) used to define 
these (Zhang and Kitching, 2001; Alexandersen et al., 2002). For cattle, approximately 
50% of those infected with FMDV become carriers, however the carrier state usually does 
not persist for more than 9 months (but can last up to 3 years). African buffalo have been 
shown to harbour the virus for 5 years (Alexandersen et al., 2003b). In fatal cases, 
myocardial tissue and blood are the preferred sample type. Samples are collected and 
transported to laboratories following international regulations and guidelines as stated in 
the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (OIE, 2012). 
 
Figure 1.7 Schematic of the foot-and-mouth disease (FMD) diagnostic window. Figure 
shows the temporal distribution of FMD virus (FMDV) in different biological samples, 
represented as real-time reverse transcription PCR (rRT-PCR) cycle threshold (CT) values 
(grey shaded area represents CT values over the diagnostic cut-off [Shaw et al., 2007]). 
(Red) sera; (black) vesicular epithelium; (green) oesophageal-pharyngeal fluid; (purple) 
lesion swabs; (blue) FMDV-specific antibodies in sera. The dotted x-axis line represents 
the incubation period, dependent upon: infectious dose, viral strain, animal species and 
host determinants. Based on data from Alexandersen et al. (2003a) and King et al. (2012). 
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1.4.3 Diagnostic targets 
The FMDV particle consists of a single copy of an RNA genome, encased within a non-
enveloped icosahedral protein capsid, approximately 30 nm in diameter. The ca. 8.5 kb 
RNA genome is composed of a ca. 7 kb open reading frame (ORF), flanked by two non-
coding regions: the 5ʹ untranslated region (UTR), which contains a number of highly 
structured regulatory regions, including the internal ribosome entry site (IRES) and long 
(70-200 nt) poly(C) tract (starting approximately 360 nt from the 5ʹ-end), and the 3ʹ UTR 
containing a heteropolymetric segment and poly(A) tail (Figure 1.8) (Forss et al., 1984).  
 
Figure 1.8 Simplified schematic of the foot-and-mouth disease viral genome. 
Nomenclature and structure based on Rueckert and Wimmer (1984). The FMDV open 
reading frame can be divided into four regions based on initial cleavage products: 
(orange) the 5ʹ L region which encodes the N-terminal polyprotein component; (grey) 
structural protein encoding P1; (blue) non-structural protein encoding region P2; (green) 
and non-structural protein encoding region P3 (Grubman and Baxt, 2004). 
 
The FMDV RNA genome is translated as a single ORF, which following cleavage by viral 
encoded proteases, comprises four structural proteins (VP1, VP2, VP3 and VP4) and at 
least eight non-structural proteins (Lpro, 2A, 2B, 2C, 3A, 3B, 3Cpro, 3Dpol). Sixty copies of 
each structural protein assemble to form the capsid (VP1-3 and internally located VP4) 
(Acharya et al., 1989), to which immunological diagnostic assays can be targeted (either 
directly via antigen capture enzyme-linked immunosorbent assays [Ag-ELISA], or 
indirectly via virus neutralisation tests [VNT] which detect antibodies to these regions). 
Immunological assays can also be used to identify antibodies generated to non-structural 
proteins (Mackay et al., 1998), the results of which can be used to determine 
infection/subclinical infection in non-vaccinated and vaccinated animals. In addition, the 
replication cycle of FMDV is cytolytic, therefore virus isolation (VI) can be used to indicate 
the presence of live virus in specialised cell lines based on the appearance of cytopathic 
effect (CPE). 
Similar to other picornaviruses, the FMDV genome has high sequence variability and can 
evolve rapidly as a consequence of errors introduced during replication (Domingo et al., 
1985). However, differential selection pressures have resulted in both highly conserved 
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(critical for aspects of viral biology) and highly varied (critical for antigenic diversity and 
immune evasion) regions, which can be targeted by sequencing and/or molecular-based 
methods. For example, highly conserved regions including the RNA polymerase (3Dpol-
coding region) (Meyer et al., 1991; Callahan et al., 2002) and regulatory 5ʹ-UTR (Reid et 
al., 2000) enable pan-specific detection of FMDV. Alternatively, highly varied regions of 
the FMDV genome, including the capsid-coding region, allow for FMDV characterisation 
via detection and/or sequencing of viral nucleic acid (Knowles and Samuel, 1988; 
Giridharan et al., 2005; Ahmed et al., 2012; OIE, 2012; Reid et al., 2014; Jamal and 
Belsham, 2015; Bachanek-Bankowska et al., 2016; Knowles et al., 2016).  
 
1.4.4 Laboratory diagnosis 
Laboratory diagnosis is currently performed almost exclusively in dedicated laboratories 
which meet appropriate requirements for handling highly infectious agents. Diagnostic 
assays are performed and interpreted by trained personnel, following the 
recommendations as summarised in the OIE Manual of Diagnostic Tests and Vaccines for 
Terrestrial Animals (OIE, 2012). Although the diagnostic process varies according to 
factors such as sample priority and sample type received, a typical diagnostic workflow, 
as used by the World Reference Laboratory for Foot-and-Mouth Disease (WRLFMD) (The 
Pirbright Institute [TPI]), is depicted below (Figure 1.9; Table 1.1). 
 
Figure 1.9 Typical laboratory work flow for diagnosis of foot-and-mouth disease carried 
out at the World Reference Laboratory for Foot-and-Mouth Disease. Black arrows 
symbolise standard diagnostic procedures, grey arrows symbolise actions for high priority 
samples (e.g. suspect outbreaks requiring rapid diagnosis and result reporting). Original 
sample can be either a tissue homogenate/suspension or original fluid (e.g. oesophageal-
pharyngeal fluid/cell culture supernatant). (VI) virus isolation; (Ag-LFD) antigen-
detection lateral-flow device; (rRT-PCR) real-time reverse transcription PCR; (Ag-ELISA) 
antigen capture enzyme-linked immunosorbent assay. 
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Table 1.1 Current diagnostic assays for foot-and-mouth disease 
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Clinical 
observations 
Clinical signs  N  No equipment necessary 
 Misdiagnosis possible 
 Low specificity 
 Experienced staff required 
 Requires good biosafety 
practices 
Virus isolation Live virus 1-4 days N 
 OIE gold-standard 
 Confirms live virus 
 Time consuming 
 Lacks specificity 
 Need for naïve animal tissue 
(difficult in endemic countries)  
 Requires high containment 
 Cell line variability 
 Experienced staff required  
Ag-ELISA FMDV antigen 4 hours Y  Rapid typing of FMDV 
 Lower analytical sensitivity 
 Only suitable for certain 
sample types 
 Use of animals to generate 
polyclonal antisera 
 Requires high containment 
 Experienced staff required 
Ag-LFD FMDV antigen < 1 hour N 
 Extremely rapid 
 Simple to use 
 Portable 
 No cold storage required 
 Lower analytical sensitivity 
 Only suitable for certain 
sample types 
RT-PCR FMDV RNA 
< 5 
hours 
N 
 High analytical sensitivity 
 Intact virus not required 
 High throughput   
 Uses many sample types  
 Does not distinguish 
viable/non-viable virus 
 Experienced staff and 
equipment required  
Typing RT-PCR FMDV RNA 
< 5 
hours 
Y 
VP1 sequencing FMDV RNA 1-2 days Y  High level of detail  Costly equipment necessary 
 Experienced staff required Whole genome FMDV RNA 1-3 days Y  Maximum level of detail 
Virus 
neutralisation 
FMDV Ab 
(to SP) 
2-3 days Y 
 OIE gold-standard for Ab 
 Limited cross-reactivity 
 Strain specific reagents 
 Time consuming 
 Experienced staff required  
 Cell line variability 
 Requires high containment 
SPC-ELISA 
LPB-ELISA 
FMDV Ab 
(to SP) 
18 hours Y 
 Low containment needed 
 Simple to perform 
 Possible cross-reactivity 
 Use of animals to generate 
polyclonal antisera 
 Experienced staff required  
NSP-ELISA 
FMDV Ab  
(to NSP) 
20 hours N 
 Simple to perform 
 Differentiate infection 
from vaccination 
 Possible cross-reactivity 
 Experienced staff required  
(Ag-LFD) antigen-detection lateral-flow devices; (RT-PCR) reverse transcription PCR; (Ag-ELISA) antigen capture 
enzyme-linked immunosorbent assay; (Ab) antibody; (SP) structural protein; (NSP) non-structural protein; (SPC) solid 
phase competition; (LPB) liquid phase blocking; (OIE) World Organisation for Animal Health.   
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1.4.5 Virus isolation 
The majority of samples received by FMD reference laboratories will undergo VI, with the 
principle that when propagated in susceptible cell lines, clinical samples containing viable 
virus will result in cytopathic effect (CPE) (Figure 1.10). The development of highly 
sensitive cell culture systems, such as primary bovine thyroid (BTY) cells (Snowdon, 1966), 
has resulted in the technique being considered gold-standard (OIE, 2012). However, a 
number of drawbacks are associated with the use of primary cultures (Ferris et al., 2002), 
including the requirement to regularly source fresh tissue to prepare the cell suspensions. 
Established cell lines, including BHK-21 (baby hamster kidney) and IB-RS-2 cells (renal 
swine), are also available (De Castro, 1964; Stoker and Macpherson, 1964), offering 
simplified culturing requirements. However these have reduced analytical sensitivity to 
infection (Clarke and Spier, 1980). Although the only way of confirming live virus, VI is 
time consuming, taking up to four days to generate a result, and variability exists in the 
sensitivity of cell lines to FMDV. For instance, field isolates from the O/CATHAY topotype 
grow poorly on BTY cells (Samuel and Knowles, 2001a). Consequently, samples typically 
require isolation in multiple cell lines to provide confidence in negative results. 
Furthermore, the observation of CPE in susceptible cell lines alone is not sufficient for a 
definitive diagnosis of FMD, as CPE may be caused by alternative factors such as 
contamination with other pathogens. Therefore, confirmation of positives through other 
diagnostic methods is necessary. 
 
 
 
 
 
 
Figure 1.10 Foot-and-mouth disease virus growth in bovine thyroid cells. Photographs 
(courtesy of the World Reference Laboratory for Foot-and-Mouth Disease) depict virus 
isolation results: (left) negative; (middle) early positive, showing signs of cytopathic 
effect; (right) positive, showing clear cytopathic effect. Photographs taken at 10 x 
magnification, scale bar represents 1 mm. 
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1.4.6 Detection and characterisation of FMDV antigen 
For detection and characterisation of FMDV antigen, immunological methods such as the 
antigen capture enzyme-linked immunosorbent assay (Ag-ELISA) are typically employed. 
The indirect-sandwich Ag-ELISA, recommended within the OIE Manual of Diagnostic Tests 
and Vaccines for Terrestrial Animals (OIE, 2012), utilises polyclonal antisera raised in 
rabbits (capture) and guinea pigs (detection) against FMDV antigen from all seven 
serotypes, enabling identification of serotype in less than four hours (Roeder and Le Blanc 
Smith, 1987; Ferris and Dawson, 1988). Although this ELISA largely replaced the 
complement fixation (CF) test, due to improved sensitivity and interpretation (ELISAs are 
not affected by pro- or anti-complementary factors) (Ferris and Dawson, 1988), limited 
analytical sensitivity restricts usefulness to samples with high viral concentrations, with 
positive results obtained for approximately 70-80% of epithelial tissue suspensions that 
contain virus (Reid et al., 1998; Mohapatra et al., 2007; Jamal and Belsham, 2013). As 
such, within advanced laboratories, virus within clinical samples is routinely propagated 
in cell culture prior to Ag-ELISA (with the exception of high priority samples). 
Furthermore, the use of polyclonal antisera as capture and detector ligands leads to 
disadvantages including: a finite supply of stocks (replacement stocks often display 
different reaction characteristics), regular requirement for animals for antibody 
production and cross-reactivity between serotypes (Ferris et al., 2005). Consequently, 
monoclonal antibody (MAb)-based Ag-ELISAs have been developed (Morioka et al., 2009; 
Ferris et al., 2011), with MAbs produced from the immortalised β-cells of immunised 
mice. Recently, a sandwich Ag-ELISA based on recombinant αvβ6 integrin for use as the 
FMDV capture ligand has been developed, using serotype-specific MAbs as detectors. 
When compared with the conventional polyclonal indirect sandwich Ag-ELISA, this 
integrin-based assay displays increased specificity (less cross-reactivity between 
serotypes) while retaining test sensitivity (Ferris et al., 2005; 2011), however it is less 
robust to changes in the FMDV capsid proteins. 
Antigen detection has also been incorporated onto immuno-chromatographic strip tests, 
known as antigen-detection lateral-flow devices (Ag-LFDs) (Ferris et al., 2009). 
Functioning through the binding of both viral antigen and antibody-coated detector 
particles to bands of capturing monoclonal antibody on a membrane (Figure 1.11), Ag-
LFDs can provide rapid results (ca. 10 minutes), and as such are useful for high priority 
samples. There are now eight publications detailing the development and use of Ag-LFDs 
for detection of FMDV antigen (Ferris et al., 2009; 2010; Oem et al., 2009; Jiang et al., 
2011a; 2011b; Yang et al., 2013; 2015; Morioka et al., 2015). In addition, commercially 
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available Ag-LFDs are now obtainable for pan-FMDV detection (SVANODIP® FMDV-Ag) 
through Boehringer Ingelheim (Bracknell, UK) and are moving towards routine use, for 
instance by the WRLFMD for triaging high priority samples for further characterisation 
(Figure 1.11). Ag-LFDs are now recognised in the OIE Manual of Diagnostic Tests and 
Vaccines for Terrestrial Animals (OIE, 2012), however, validation studies show that they 
only offer equivalent diagnostic sensitivity to laboratory-based Ag-ELISAs (Ferris et al., 
2009), which limits their application to the acute clinical phase of disease and samples 
which contain high amounts of intact virus particles.  
 
 
Figure 1.11 The mechanism of antigen-detection lateral-flow devices. A positive result 
is signified by the presence of two red bands (test and lateral-flow device control line); 
negative results are indicated by a single band (the lateral-flow device control line). (Ab) 
antibody; (FMDV) foot-and-mouth disease virus; (Ig) immunoglobulin. In Biological threat 
reduction (T. Beckham, ed.; paper by Howson et al., 2017a). 
 
However, as with all antigen-based detection, there is a continuous requirement to 
ensure reagents have affinity for new emerging viral strains. Furthermore, testing for 
intact viral antigen and/or live virus can be problematic when considering differing 
sample quality and partial degradation that can be caused by poor sample transportation. 
In addition, all the above tests require the use of animals or animal tissue to produce 
assay components. With organisations such as the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (NC3Rs) dedicated to the promotion of 
methods that either avoid/replace the use of living animals, reduce the number of 
animals used, or refine the ways in which the animals are produced (minimise 
suffering/increase welfare), it is important to also consider alternative diagnostic 
procedures (Richmond, 2002). 
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1.4.7 Detection and characterisation of FMDV nucleic acid 
The limitations associated with VI and antigen-based detection has led to the 
development and utilisation of molecular assays in order to complement immunological 
diagnostic methods. Reverse transcription PCR (RT-PCR) has become an established 
laboratory-based tool for the highly sensitive detection and characterisation of FMDV RNA 
(Knowles and Samuel, 1988; Callahan et al., 2002; Reid et al., 2002; Shaw et al., 2007; 
OIE, 2012), relying upon thermocycling, a pair of oligonucleotide primers, the activities 
of two enzymes (reverse transcriptase and DNA polymerase) and amplicon detection. 
Fluorescence-based detection (real-time RT-PCR [rRT-PCR]) has superseded analysis by 
gel-electrophoresis due to decreasing the risk of cross-contamination between assays and 
enabling real-time quantification. Importantly, rRT-PCR can detect low amount of FMDV 
RNA extracted from numerous sample types, including tissues, OP fluid, blood, swabs, 
faeces, aerosols and milk, and is therefore operational across a large clinical window. 
Furthermore, rRT-PCR does not require intact virus particles, therefore can still be used 
for poorly stored samples that exhibit partial degradation. However, this ability results 
in rRT-PCR not being able to distinguish between viable and non-viable virus, which can 
be problematic in situations such as distinguishing between carrier animals and delayed 
viral clearance. When coupled to automatic nucleic extraction, rRT-PCR exhibits 
increased assay throughput and at least equal diagnostic sensitivity to that of VI (Reid et 
al., 2003). For instance, rRT-PCR was employed during the UK 2007 FMDV outbreak to test 
99.1% of 3246 diagnostic samples submitted to the UK National Reference Laboratory for 
FMD (TPI), and is able to detect FMDV in pre-clinical cattle (Reid et al., 2009). 
In order to study the molecular (nucleotide) epidemiology of FMD, nucleotide sequence 
analysis is used to compare the genetic differences between viruses (Knowles and Samuel, 
1988; OIE, 2012). For instance, sequencing of the VP1-coding region, which displays ca. 
30-50% nucleotide sequence difference between the seven serotypes, enables 
phylogenetic analysis to be performed for reasons such as tracing the origin of outbreaks 
and spread of FMD viruses (Beck and Strohmaier, 1987; Dopazo et al., 1988; Samuel and 
Knowles, 2001b; Knowles and Samuel, 2003). Comparison of the whole FMDV genome can 
provide further discrimination between closely related viruses, and although not used 
routinely for sample analysis, has enabled retrospective tracing of transmission pathways 
for outbreak investigations (Cottam et al., 2008; Logan et al., 2014). There have also 
been efforts to design serotype-specific assays (Giridharan et al., 2005; Ahmed et al., 
2012; Reid et al., 2014; Jamal and Belsham, 2015; Bachanek-Bankowska et al., 2016; 
Knowles et al., 2016). Although these do not provide the detail gained through sequencing 
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techniques, these have the potential to help rapidly identify circulating FMDV strains 
(useful for basic epidemiology and informing vaccine matching studies), thus improving 
upon current lengthy laboratory-based typing techniques such as Ag-ELISA (Bachanek-
Bankowska et al., 2016). 
 
1.4.8 Serological tests 
FMD diagnostic laboratories also employ serological assays in order to: (i) certify animals 
for import or export, (ii) demonstrate previous FMDV infection or vaccination through the 
presence / absence of anti-FMDV antibodies, (iii) perform antigenic matching between 
vaccine and field strains (OIE, 2012) and (iv) for routine serosurveillance. Serological 
assays are of two types: those which detect antibodies to FMDV structural proteins (SPs) 
and those which detect antibodies to non-structural proteins (NSPs). Assays that detect 
antibodies to SPs are serotype-specific and signify either FMDV infection or vaccination. 
The current gold-standard assay for detection of antibodies to SPs is the virus 
neutralisation test (VNT), which detects anti-FMDV antibodies through the inhibition of 
viral infectivity in cell culture (Golding et al., 1976). However, VNT assays pose several 
challenges. Different cell lines result in variable degrees of sensitivity and, in contrast to 
other serological tests that use inactivated virus (e.g. purified antigen), the requirement 
for large amounts of live virus means that the test needs to be performed in restrictive 
biocontainment facilities. Alternative assays such as the solid phase competition ELISA 
(SPCE) (Brocchi et al., 1990; Mackay et al., 1998; Chénard et al., 2003; Paiba et al., 2004) 
and liquid phase blocking ELISA (LPBE), (Hamblin et al., 1986; 1987) are therefore 
commonly used to support testing (Table 1.1). 
Assays which detect antibodies to NSPs are pan-specific and signify previous FMDV 
infection, regardless of vaccination status (assuming purified vaccines are used containing 
only SPs). Several assays, including ELISAs, have been established for detection of 
antibodies to FMDV NSPs such as 2C, 3AB and 3ABC involved in viral replication (Shen et 
al., 1999; Bergmann et al., 2000). Although initial NSP-ELISAs required species-specific 
conjugates, these have been updated through the years to be host species-independent 
and utilise monoclonal antibodies (Sørensen et al., 1998; 2005). An LFD for detection of 
antibodies to 3ABC (SVANOVIR® FMDV 3ABC-Ab) has since been developed and is 
commercially available through Boehringer Ingelheim, although further validation is 
required for inclusion in the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial 
Animals (OIE, 2012).  
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1.4.9 Disadvantages of current diagnostic strategies 
Although laboratory-based tests can provide rapid and accurate results, several factors 
affect the utility and practicality of these tests for guiding critical decision-making, 
particularly in low-resource settings. First, transportation of samples to laboratories can 
negatively affect the quality of the specimens and delay or hinder the processes of 
immediate critical decision-making and disease control. This is particularly problematic 
in countries with poor transport infrastructure, but even in the UK alternative control 
methods have been used to gain rapid control of outbreaks by bypassing laboratory 
confirmation, such as the UK 2001 “slaughter on suspicion” policy (a subjective method 
that relied entirely upon clinical observation with retrospective laboratory analysis 
showing no evidence of FMDV on 23% of suspected premises [Ferris et al., 2006]). 
Secondly, many diagnostic procedures necessitate well-equipped laboratories that meet 
restrictive biocontainment requirements. This can be difficult for many countries with 
endemic FMD infection, which often lack infrastructure and financial/human resources 
for sample collection, sample submission, veterinary diagnostics and disease surveillance 
(Vosloo et al., 2002; Paton et al., 2009; Namatovu et al., 2013). As such, laboratories 
within these areas often lack the ability to diagnose FMD adequately (Vosloo et al., 2002; 
Paton et al., 2009). 
The development of simple, portable, diagnostic devices is now considered a priority for 
FMD to (i) help reduce the response time during outbreaks in FMD-free countries 
(recommended within independent reports that have followed outbreaks [Anderson, 
2002; Anon, 2002a; 2002b]), and (ii) improve the diagnostic capacity of endemic 
laboratories (Namatovu et al., 2013). 
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1.5  Future diagnostic strategies 
Within the last decade, many technological advances have been made in the development 
of improved diagnostics for infectious diseases of public health importance. This has 
included the development of point-of-care tests (POCT) for rapid disease diagnosis in 
decentralised settings, such as public health centres and local laboratories. For instance, 
diagnostic assays based on the detection of antigens, antibodies or nucleic acid molecules 
have been developed and successfully introduced for routine surveillance and 
decentralised testing of human diseases such as human immunodeficiency virus infection 
/ acquired immune deficiency syndrome (HIV/AIDS), tuberculosis and malaria (Maltha et 
al., 2013; Reid et al., 2013; Weyer et al., 2013; Morris et al., 2015). In addition to 
providing a rapid diagnosis to expedite medical decision-making, POCTs offer advantages 
for public health including expanded testing capabilities (e.g. access to hard to reach 
communities), reduced potential for sample deterioration and improved patient 
outcomes through reduced patient handling times (Makusha et al., 2015). 
The advantages associated with POCTs have resulted in calls for rapid and simple 
diagnostic tests in response to emergency situations by The World Health Organisation 
(WHO), such as the most recent outbreak of Ebola virus disease (EVD) in West Africa 
(WHO, 2014; Broadhurst et al., 2015; Kurosaki et al., 2016; Semper et al., 2016). It has 
been estimated that if such tests had been available throughout the EVD outbreak, 
despite published assays displaying reduced test accuracy comparatively to laboratory 
equivalents, their use in combination with confirmatory PCR testing could have reduced 
the epidemic in Sierra Leone by over a third (Nouvellet et al., 2015) 
Capitalising on these advances, the veterinary industry is now exploiting the use of similar 
technologies for the detection of important livestock pathogens. The global veterinary 
diagnostics market is subsequently estimated to expand at a compound annual growth 
rate of 8.6% from 2016, to reach US$ 6.71 billion by 2021 (marketsandmarkets.com, 2016). 
A powerful illustration of the effectiveness of rapid POCT diagnostics for veterinary 
diseases was during the latter stages of the rinderpest eradication programme. The use 
of a simple, disposable, antigen-detection test (Ag-LFD) proved invaluable in countries 
such as Pakistan and Somalia, empowering field veterinarians to stamp out the last 
remaining pockets of infection (Brüning et al., 1999). 
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The use of a similar strategy for FMD could aid in both FMD-free countries for rapid 
implementation of control measures and prevention of unnecessary culling (Anderson, 
2002), and in endemic countries for establishing robust laboratory testing capacity 
(Namatovu et al., 2015). As such, there have been numerous advances in decentralised 
diagnostics for FMD in the veterinary field, mainly focusing on antigen/antibody and 
nucleic acid detection technologies. This section describes some of these approaches. 
 
1.5.1 Antigen/antibody detection systems 
Ag-LFDs display many of the characteristics required for POCT use, including being 
portable, disposable, simple to use and relatively inexpensive. Consequently, Ag-LFDs 
have been successfully trialled for decentralised testing during the 2007 UK FMD outbreak 
on an infected premises to confirm FMD-positive cases (Ryan et al., 2008). However, Ag-
LFDs display reduced analytical sensitivity in comparison to molecular diagnostic 
techniques, making confirmation of FMD-negative cases difficult (a combined approach 
with laboratory-based methods would be required). Furthermore, Ag-LFDs present a 
simple alternative method for transport of samples to reference laboratories for further 
testing. For instance, recent studies have shown that nucleic acid can be recovered from 
LFDs following long-term storage at room temperature. This has permitted further 
downstream characterisation, including rRT-PCR, Sanger sequencing and recovery of live 
virus following electroporation (Fowler et al., 2014; Romey et al., 2017). 
 
1.5.2 Real-time reverse transcription PCR 
Due to its routine laboratory use and high sensitivity, much recent progress has been 
made in transitioning rRT-PCR onto POCT platforms (Belák et al., 2010), with a number 
of technologies now commercially available (Table 1.2). For instance, there are now 11 
publications detailing portable rRT-PCR assays for detection of FMDV, with potential for 
use in decentralised laboratories and field settings (Donaldson et al., 2001; Callahan et 
al., 2002; Hearps et al., 2002; Moniwa et al., 2007; King et al., 2008; Paixão et al., 2008; 
Reid et al., 2010; Pierce et al., 2010; Madi et al., 2012; Ambagala et al., 2016; Goller et 
al., 2017).  
Perhaps some of the most promising technologies, although costly, are those that are 
fully automated, integrating nucleic acid extraction, thermal cycling and result reporting 
onto a single instrument. By streamlining assay setup, advantages of such platforms 
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include reduced opportunities for cross-contamination and the requirement for minimal 
onsite expertise. For instance, the prototype Enigma® Field Laboratory (FL) (Enigma® 
Diagnostics, Porton Down, UK), a robust 19 kg platform which can be powered using a 
vehicle auxiliary, combines silica paramagnetic-bead-based nucleic acid extraction with 
rRT-PCR reagents in a single-cartridge (Madi et al., 2012). Its commercially available 
successor, the MiniLabTM (ML) (Enigma® Diagnostics), is aimed at decentralised locations 
(e.g. hospitals /veterinary clinics). Using similar technology to the FL, the ML has 
increased throughput, with the option to add up to six processing modules (Goldenberg 
and Edgeworth, 2015; Goller et al., 2017). Lyophilised assays have been developed for 
FMDV using this platform, in addition to a number of other veterinary diseases of 
importance, including African swine fever virus and classical swine fever virus (Enigma® 
Diagnostics). The use of lyophilised reagents increases compatibility for decentralised 
testing by improving stability, storage and transportability as reagents can remain at 
ambient temperatures. However, at present such reagents remain commercially 
unavailable. 
Not all mobile PCR platforms incorporate nucleic acid extraction. For instance, 
commercially available platforms, including the Cepheid SmartCycler® (Cepheid), T-
CORTM 8 (Tetracore), genesig® (Primerdesign Ltd.), R.A.P.I.D® (Idaho technologies) and 
Genedrive® (Epistem Limited, Manchester, UK) combine amplification and fluorescence-
based detection in a single tube, with sample preparation required separately (Table 1.2). 
Some of these platforms have developed their own simple sample preparation methods, 
for example the Genedrive® uses a paper-based extraction approach (Niemz and Boyle, 
2012). However, the majority of validation exercises on these platforms have been 
undertaken using nucleic acid extracted using either manual kits or robotic platforms, 
which are often unsuitable for decentralised testing in the field or low-resource 
laboratories. For example, the SmartCycler has been successfully trialled for the 
detection of FMDV, in combination with manual nucleic acid extraction kits, in laboratory 
settings (Hearps et al., 2002; Moniwa et al., 2007; Paixão et al., 2008). The adoption of 
PCR assays that are less prone to inhibition (Kermekchiev et al., 2009; Zhang et al., 2010) 
could further increase demand by negating the requirement for complex sample 
preparation, offering an advantage over laboratory-based assays and opening up the real 
possibility for rRT-PCR use in decentralised settings. 
Lyophilised FMDV-specific real-time PCR assay kits are now commercially available for a 
number of these POCT platforms, with both Tetracore and genesig® (Primerdesign Ltd., 
Southampton, UK) offering assays for FMDV (Boyle et al., 2004). However, these kits are 
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only licensed for research purposes at present. Further development and evaluation is 
required for these to enter the diagnostic market.  
 
Table 1.2 Examples of molecular point-of-care testing platforms 
 
1.5.3 Alternative PCR chemistries 
Whilst the transferral of routine rRT-PCR assays onto POCT platforms maintains some level 
of consistency and test confidence between laboratory and POCT assays, numerous 
drawbacks are still evident. For instance, in order to maintain the precise thermal 
regulation required for PCR, sophisticated instrumentation is still necessary, which can 
be expensive and difficult to decontaminate between premises. This requirement has 
resulted in an inevitable trade-off between portability and sample-throughput 
capabilities (Table 1.2). As such, alternative PCR chemistries such as insulated isothermal 
PCR (iiPCR) and Linear-After-The-Exponential PCR (LATE-PCR) have been explored as 
potential veterinary diagnostic solutions. 
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*Enigma® FL 
Enigma 
Diagnostics, UK 
PCR 1 ✓ 6 1 hour 
Car 
auxiliary 
*Enigma® ML 
Enigma 
Diagnostics, UK 
PCR 1 - 6 ✓ 6 1 hour Mains 
SmartCycler® 
Cepheid,  
USA 
PCR 16-96  X 4 < 1 hour Mains 
Genedrive® Epistem Ltd., UK PCR 3 
X 
 
1 < 1 hour Battery 
R.A.P.I.D® Idaho Tech., USA PCR 32 X 3 30 min Mains 
POCKITTM GeneReach, USA iiPCR 8 X 2 < 1 hour Mains 
*BioSeeqTM 
Smiths Detection, 
UK 
LATE-PCR 5 ✓ 4 2 hours Battery 
T-CORTM 8 
Tetracore, 
USA 
PCR 8 X 6 1 – 2 hours Battery 
genesig q16 genesig, UK PCR 16 X 2 1 – 2 hours Mains 
Genie® II 
Genie® III 
OptiGene Ltd., UK LAMP 
16 
8 
X 
1 
2 
< 30 min Battery 
T-8 TwistDx, UK RPA 8 X 8 < 30 min Battery 
*Platform no longer available. (iiPCR) insulated isothermal PCR; (LAMP) loop-mediated isothermal 
amplification; (RPA) recombinase polymerase amplification; (LATE) linear-after-the-exponential; (FL) 
field laboratory; (ML) mini laboratory. Adapted from previous publications (Holland and Kiechle, 2005; 
Dineva et al., 2007). 
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In iiPCR, a horizontal temperature gradient is created across a PCR vessel by heating it 
from the bottom at a fixed temperature, with the top cooled by surrounding air. By 
negating the requirement for conventional thermal cycling, iiPCR reactions can be 
performed using relatively simple, portable platforms such as the commercially available 
POCKITTM nucleic acid analyser (Table 1.2) (GeneReach, MA, USA) (Tsai et al., 2012). 
Recently, POCKITTM-compatible lyophilised real-time RT-iiPCR assays have been 
developed and evaluated for pan-specific detection of FMDV in laboratory settings 
(Ambagala et al., 2016), with comparable sensitivity to laboratory-based rRT-PCR. 
Furthermore, direct detection of FMDV from vesicular fluid samples has been shown to 
yield positive results, somewhat negating the requirement for sample preparation and 
increasing compatibility with field use (Ambagala et al., 2016). The use of other clinical 
materials is yet to be determined. Although rapid, with detectable levels of amplicon 
generated within 30 minutes (Chang et al., 2012), platforms such as the POCKITTM are 
binary end-point systems (report samples only as positive or negative), which, although 
beneficial if used by less-skilled operators (results require no interpretation), reduces 
assay flexibility (quantitative interpretation is not possible). 
LATE-PCR is an advanced form of asymmetric PCR, in which primers are designed for use 
at unequal concentrations to preferentially amplify one strand of the target DNA. 
Therefore following exponential amplification, reactions switch to linear amplification, 
during which single-stranded amplicons are generated for additional thermal cycles, 
thereby increasing the detection signal comparatively to symmetric PCR (Pierce et al., 
2005; Sanchez et al., 2009). Beneficially, LATE-PCR probes can be designed to be 
mismatch-tolerant (beneficial when considering the high mutation rate of RNA viruses 
[Domingo et al., 1985; Drake and Holland, 1999]), aiding the development of reverse 
transcription LATE-PCR (RT-LATE-PCR) assays for pan-FMDV detection (Pierce et al., 2010; 
Reid et al., 2010). In addition to enabling end-point quantification, and sharing equivalent 
analytical sensitivity to rRT-PCR, these assays are compatible with the BioSeeqTM-Vet 
(Smiths Detection, London, UK), a portable diagnostic platform which incorporates 
sample preparation. However, this platform has never been made commercially available 
(Pierce et al., 2010).  
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1.5.4 Isothermal chemistries 
An alternative approach to reducing the size, cost and complexity of molecular POCT 
platforms is to eliminate the requirement for precise thermal regulation and perform 
reactions at a single fixed temperature using isothermal chemistries. Numerous 
isothermal methodologies have been developed (Craw and Balachandran, 2012), with four 
to date applied for the detection of FMDV, namely: loop-mediated isothermal 
amplification (LAMP), recombinase polymerase amplification (RPA), nucleic acid 
sequence based amplification (NASBA) and helicase dependent amplification (HDA). 
LAMP is a rapid nucleic acid amplification technique that utilises a strand-displacing 
polymerase, multiple primers and auto-cycling under isothermal conditions (Notomi et 
al., 2000; Nagamine et al., 2002). Due to high sensitivity and rapid detection, a number 
of reverse transcription (RT-LAMP) assays have been designed for the detection of FMDV 
(Dukes et al., 2006; Li et al., 2009; Shao et al., 2010; Chen et al., 2011a; 2011b; Yamazaki 
et al., 2013; Guan et al., 2013; Madhanmohan et al., 2013; Ding et al., 2014; Ranjan et 
al., 2014; Farooq et al., 2015). However, none are yet commercially available in a kit 
format. Much progress has been made in transitioning LAMP onto portable platforms. This 
is partly due to LAMP chemistry having increased tolerance of inhibitors compared to PCR. 
For example, LAMP has shown higher sensitivity than rRT-PCR when detecting SVD virus 
from porcine faecal RNA extractions (Blomström et al., 2008) and has been used to detect 
FMDV RNA directly from epithelial dilutions and aerosol samples (Waters et al., 2014). 
Furthermore, numerous detection methods are possible. Low-cost, objective, end-point 
detection can be performed using molecular lateral-flow devices (LFDs) (Figure 1.12) 
(Waters et al., 2014) or commercially available portable fluorimeters can be used for 
real-time detection (Genie® II / III: OptiGene Ltd.) (Table 1.2; Figure 1.13).  
 
Figure 1.12 Illustration of reverse transcription loop-mediated isothermal amplification 
using end-point lateral-flow detection. A positive result is signified by the presence of 
two blue bands (test and lateral-flow device [LFD] control); negative results are indicated 
by a single band (LFD control). (Flc) fluorescein; (Ab) antibody; (Ig) immunoglobulin. In 
Biological threat reduction (T. Beckham, ed.; paper by Howson et al., 2017a). 
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Although assays for characterisation of FMDV by RT-LAMP have been published (Chen et 
al., 2011b; Madhanmohan et al., 2013; Ding et al., 2014; Farooq et al., 2015), their design 
is complicated through the requirement for six to eight target regions in highly varied 
regions of the FMDV genome, including the capsid-coding region. 
 
 
 
Figure 1.13 Schematic of loop-mediated isothermal amplification. F1(c)-F3(c) and B1(c)-
B3(c) represent primer binding regions on the target sequence. (c) complementary; (FIP) 
forward internal primer; (BIP) backwards internal primer; (F3) forward external primer; 
(B3) backward external primer; (FLoop) forward loop primer; (BLoop) backward loop 
primer. Arrows represent the 5ʹ-3ʹ nucleotide sequence direction. In Biological threat 
reduction (T. Beckham, ed.; paper by Howson et al., 2017a). 
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In RPA, isothermal amplification of template is achieved through the coupling of 
recombinase-driven primer targeting with strand-displacement synthesis (Figure 1.14) 
(Piepenburg et al., 2006). Tube scanners from TwistDxTM (Cambridge, UK) and Qiagen 
(ESEQuant TS2), in combination with lyophilised regents (TwistDxTM), have enabled RPA 
to enter the POCT market. For instance, during the 2012 FMDV Egypt outbreak, a pan-
FMDV assay and portable reverse transcription RPA (RT-RPA) laboratory was trialled with 
manual RNA extraction (Dynabeads® Silane viral nucleic acid kit, InvitrogenTM), achieving 
98% sensitivity over 45 samples, with an analytical sensitivity of 1436 FMDV RNA molecules 
(Abd El Wahed et al., 2013). However, many available nucleic acid extraction procedures 
are complex and time consuming (Dineva et al., 2007), consequently, validation of RT-
RPA on simple sample preparations is important for transitioning the chemistry into a 
realistic field-ready format. 
 
  
Figure 1.14 Schematic of recombinase polymerase amplification. Arrows represent the 
5ʹ-3ʹ nucleotide sequence direction. In Biological threat reduction (T. Beckham, ed.; paper 
by Howson et al., 2017a). 
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Nucleic Acid Sequence Based Amplification (NASBA) is a continuous isothermal technique 
used primarily to detect single-stranded RNA. The reaction depends on the activities of 
three enzymes: a reverse transcriptase, T7 RNA polymerase and ribonuclease-H, in 
addition to a single pair of specially-designed oligonucleotide primers (Figure 1.15), with 
optimal conditions allowing for 109-1012 fold amplification after two hours (Compton, 
1991; Lau et al., 2006). Using real-time detection methods, assays have been developed 
for numerous animal viruses, including FMDV (Lau et al., 2008), with sensitivity reported 
to be equivalent to that of rRT-PCR. However, to date, validation of these tests remain 
in the research and development phase, using extracted nucleic acid, therefore further 
work is required to transition this chemistry into a POCT format. 
 
  
Figure 1.15 Schematic of nucleic acid sequence based amplification. Arrows represent 
the 5ʹ-3ʹ nucleotide sequence direction. In Biological threat reduction (T. Beckham, ed.; 
paper by Howson et al., 2017a). 
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Helicase dependent amplification (HDA) is an isothermal amplification method that is 
similar to conventional PCR, but utilises the action of a helicase enzyme, rather than 
heat, to denature nucleic acids (Figure 1.16) (Vincent et al., 2004). The addition of 
intercalating dyes has enabled HDA to be performed in real-time (Goldmeyer et al., 
2007), generally taking between 30–90 minutes for relatively short targets (70–120 bp) 
(Boonham et al., 2014). Reverse transcription HDA (RT-HDA) assays for the detection of 
FMDV have been developed and tested in laboratory settings (Jingwei et al., 2014), with 
detection limits reported as 10-fold higher than conventional agarose-gel based RT-PCR. 
However, as yet these assays have not been transferred onto portable platforms, 
therefore more work is required in transitioning and validating this chemistry as a POCT. 
 
 
  
Figure 1.16 Schematic of helicase dependent amplification. Arrows represent the 5ʹ-3ʹ 
nucleotide sequence direction. In Biological threat reduction (T. Beckham, ed.; paper by 
Howson et al., 2017a). 
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1.5.5 Mobile sequencing 
The availability of novel sequencing methods may change the way diagnosis is performed 
in the future, offering a potential way to perform epidemiological tracing in low-resource 
settings. For instance, the MinION (Oxford Nanopore, Oxford, UK) is a commercially 
available, portable sequencer (requires connection to a laptop) that can be used for real-
time biological analysis. This platform was recently applied in the field of human 
diagnostics for real-time genomic surveillance of Ebola virus in local laboratory settings, 
with sequencing results generated in less than 24 hours after receiving Ebola-positive 
samples (Quick et al., 2016). Although not used for initial confirmation of disease 
presence, sequencing was performed on a total of 142 clinical samples, providing a new 
tool for informing epidemiological investigations.  
Sequencing technologies currently still in the development stage (e.g. developments by 
Genapsys, CA, USA and QuantuMDX, Newcastle upon Tyne, UK) may in the future enable 
decentralised sequencing of targeted pathogen genome regions, complete genomes or 
metagenomes, although it is presently unclear if and when they will become commercially 
available. For instance, Oxford Nanopore are currently developing the SmidgION, with 
expected release in late 2017 (Lu et al., 2016), which uses the same nanopore sensing 
technology as the MinION but has been designed for use with smartphones for mobile 
field-based sequence analyses. The future availability of field-based sequencing 
technologies, combined with current knowledge of simple sample preparation strategies, 
such as elution of nucleic acid from LFDs (Fowler et al., 2014), could make in situ 
sequencing a real possibility in the next decade. For FMD, the rapid generation of 
sequencing data could be valuable in epidemiological outbreak tracing and informing 
potential vaccination responses. 
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1.6  Scientific aims 
The benefits of transitioning diagnostic assays into POCT-formats is clear in terms of 
accelerating diagnostic confirmation, strengthening veterinary surveillance systems and 
providing increased flexibility in disease control. However, despite these benefits and 
numerous technological advances, the uptake of molecular POCTs remains low for the 
detection of FMDV, with promising new assays remaining in the research and development 
phase.  
Although assays are regularly reported as suitable for use in low-resource environments, 
there is limited validation of FMDV-specific assays within these settings, with the majority 
validated in laboratories using formats unsuitable for decentralisation. For instance, 
assays typically utilise ‘wet’ reagents, which contain temperature-sensitive enzymes, and 
utilise nucleic acid extracted using either robots or manual extraction kits, both 
incompatible with decentralised use. The first aim of this thesis was therefore to compare 
multiple FMDV-specific assays and protocols, in order to define their current capabilities, 
and secondly transition the most promising of these into formats suitable for POCT. These 
assays were subsequently deployed into endemic settings (field and low-resource 
laboratories) to assess their potential use as real-time surveillance tools (Figure 1.17). 
Most evaluation of POCT platforms has been performed using pan-specific assays, which 
enable confirmation of the presence or absence of FMDV, but lack the ability to distinguish 
between FMDV serotypes. Although critical for managing outbreak scenarios, where rapid 
pan-FMDV confirmation of clinical signs is necessary, such assays have reduced 
applicability for settings where FMD is endemic. In these situations, the disease can 
usually be detected quite accurately on the basis of clinical signs, which are well 
recognised by livestock-keepers and veterinary officers. However, rapid identification of 
serotypes could be very useful in informing specific responses to control, such as reactive 
and targeted vaccination in response to serotype-specific outbreaks. The transfer of 
typing assays (Bachanek-Bankowska et al., 2016) onto portable platforms could provide 
necessary tools for FMDV characterisation in decentralised settings, subsequently forming 
the third aim of the project. 
By targeting the more varied regions of the FMDV genome, there is a continuous need to 
re-evaluate molecular assays to ensure that primers designed sufficiently match emerging 
strains. Due to the logistics associated with doing this via laboratory-evaluation (in terms 
of cost, time and acquisition of suitable samples), the final aim of this thesis was to 
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develop a novel bioinformatics tools to rapidly predict the performance of molecular 
assays in silico. 
 
Chapter 2 
Selection of technologies and methods:  
Defining the capabilities of molecular assays for detection of  
foot-and-mouth disease virus in resource-limited settings 
 Comparison of available technologies and chemistries 
 Development and evaluation of simple sample protocols 
 
Chapter 3 and 4 
Transitioning molecular assays into point-of-care test formats and  
evaluation of real-time monitoring in decentralised settings 
 Transitioning molecular assays into field-ready formats 
 Development of FMDV-typing point-of-care test protocols 
 Deployment and evaluation of technologies in endemic settings 
 
Chapter 5 
Using sequence data to predict the performance of  
real-time PCR assays 
 Evaluation of the effects of primer/probe-template mismatches 
 Development of an in silico approach to evaluate molecular assays 
 Application of this approach to monitor existing FMDV primer sets 
 
Chapter 6 
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Figure 1.17 Thesis overview. 
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CHAPTER 2 
 
Selection of technologies and methods: 
Defining the capabilities of molecular assays for 
detection of foot-and-mouth disease virus in 
resource-limited settings  
 
 
 
Elements of this chapter have been published in the following peer-reviewed article: 
Howson, E.L.A., Kurosaki, Y., Yasuda, J., Takahashi, M., Goto, H., Gray, A.R., Mioulet, 
V., King, D.P. and Fowler, V.L. (2017b). Defining the relative performance of isothermal 
assays that can be used for rapid and sensitive detection of foot-and-mouth disease virus. 
J Virol Methods. doi: 10.1016/j.jviromet.2017.08.013 [Epub ahead of print]. 
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2.1 Summary 
Despite technological advances in the development of point-of-care tests (POCTs) for 
diagnosis of foot-and-mouth disease (FMD), uncertainties still remain about test 
performance and further validation is required to increase confidence in their use. This 
chapter describes the first multiway comparison of assays for the detection of FMD virus 
(FMDV), to define their capabilities for use in resource-limited settings, benchmarked 
against a reference real-time reverse transcription PCR (rRT-PCR). The chemistries 
evaluated included POCT-adapted protocols for rRT-PCR, reverse transcription loop-
mediated isothermal amplification (RT-LAMP) and reverse transcription recombinase 
polymerase amplification (RT-RPA). In this study, the analytical sensitivities of rRT-PCR 
and RT-LAMP were comparable to the reference rRT-PCR (101 RNA copies), while RT-RPA 
was one log10 less sensitive (10
2 RNA copies). Diagnostic performance was evaluated using 
a panel of 35 clinical samples from FMDV-positive animals and eight samples from animals 
infected with other vesicular viruses. Assay concordance for POCT-ready rRT-PCR, RT-
LAMP and RT-RPA was 100%, 86-88% and 67-77%, respectively, when compared to the 
reference rRT-PCR. Discordant samples (false-negatives) consistently had high rRT-PCR 
cycle threshold values (no false-positives were detected for any assay). In order to assess 
the suitability of these methods for field diagnosis, a hierarchy of sample preparation 
methods, from robotic extraction to simple dilution of samples, for epithelial tissue 
suspensions, serum and oesophageal-pharyngeal (OP) fluid were evaluated. Results 
obtained for POCT-ready rRT-PCR and RT-LAMP confirmed that FMDV RNA can be detected 
in the absence of RNA extraction. However, simple sample preparation methods (such as 
the dilution of samples in nuclease-free water), were less encouraging for RT-RPA and 
the reference rRT-PCR, with accurate results only obtained when using RNA extraction. 
Although this evaluation is specific to the assays tested in this study, the performance of 
POCT-ready rRT-PCR and RT-LAMP, in terms of sensitivity and compatibility with multiple 
sample types, provides advantages over alternative pen-side diagnostics such as antigen-
detection lateral-flow devices (Ag-LFDs). As such, POCT-ready RT-LAMP and rRT-PCR were 
selected as the most promising assays for diagnosis of FMD in the field and low-resource 
laboratory settings, and were taken forward for subsequent development, evaluation and 
field testing. 
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2.2 Introduction 
The recent drive to develop decentralised diagnostics for foot-and-mouth disease (FMD) 
has led to a number of research initiatives prioritising the transition of laboratory-based 
assays into formats suitable for use in resource-limited settings. As such, there have been 
numerous publications, in peer-reviewed journals, outlining the development and 
deployment of point-of-care tests (POCTs) for the detection of FMD virus (FMDV) (Belák 
et al., 2010; Sammin et al., 2010; King et al., 2012). Although the advantages of these 
assays are clear in terms of accelerating diagnostic confirmation during FMDV outbreaks 
(Anderson, 2002) and establishing robust laboratory testing capacity in endemic countries 
(Namatovu et al., 2013), uptake of such assays remains low, remaining almost exclusively 
in the research and development phase.  
One of the main barriers preventing the routine use of decentralised diagnostic assays for 
FMD is the lack of validation. Assays are typically evaluated through pairwise concordance 
testing against an established reference test, with molecular assays regularly compared 
against real-time reverse transcription PCR (rRT-PCR). Whilst this approach is useful for 
understanding the diagnostic performance of an assay in isolation, it does not capture the 
variability in test performance that may arise as a result of the use of different reference 
rRT-PCR reagents, extraction protocols, testing conditions and test cut-off values. 
Selection of the most appropriate chemistry / assay for decentralised diagnostics is 
therefore difficult and guidelines for the use of such assays are not yet included within 
the manual of recommended tests of The World Organisation for Animal Health (OIE) (OIE, 
2012), with the exception of antigen-detection lateral-flow devices (Ag-LFDs).  
Furthermore, although assays are reported as suitable for use in decentralised settings 
(in the field or low-resource laboratories) (Callahan et al., 2002; Hearps et al., 2002; 
Moniwa et al., 2007; King et al., 2008; Abd El Wahed et al., 2013; Ambagala et al., 2016), 
the majority of FMDV-specific assays have been validated using protocols only suitable for 
laboratory-based testing. For instance, molecular assays are typically evaluated using 
nucleic acid extracted by either robots or manual extraction kits, unsuitable for use in 
resource-limited settings. A number of alternative simple sample preparation methods 
have been developed: the preparation of epithelial tissue suspensions by dilution in 
nuclease-free water (NFW) has shown to produce accurate reverse transcription loop-
mediated isothermal amplification (RT-LAMP) results (Waters et al., 2014), simple elution 
from disposable immuno-chromatographic strip tests has been successful for preparation 
of epithelial tissue suspensions prior to rRT-PCR (Fowler et al., 2014) and Chelex® 100 has 
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been reported to remove inhibitors of rRT-PCR from serum (Ochert et al., 1994; Walsh et 
al., 2013). Although these methods provide potential solutions for resource-limited 
settings, further evaluation and comparison of these methods for this purpose is required.  
The transition of decentralised diagnostic assays into current diagnostic pipelines (see 
Chapter 1.4.4, Figure 1.9) also needs to be considered to evaluate how these assays could 
work in parallel with (or replace) existing methodologies. For instance, in order to fully 
understand the epidemiology of circulating FMDV strains, even in the presence of POCTs 
for rapid virus detection, FMD samples would still require shipment to suitable 
laboratories for characterisation purposes (e.g. whole genome sequencing and vaccine 
matching). Therefore, POCTs do not completely eliminate the requirement for sample 
submission to laboratories, which is hindered by shipment costs, cold chain maintenance, 
potential sample degradation and packaging requirements for diagnostic material. As 
such, recent publications have proposed Ag-LFDs as a potential non-hazardous transport 
solution as they preserve nucleic acid for downstream characterisation, with preliminary 
data suggesting that, after periods of storage, it is not possible to recover live virus from 
the devices (Fowler et al., 2014; Romey et al., 2017). Similarly, FTA® cards have been 
implemented as a sampling device for the collection, shipment, storage and detection of 
FMDV, as again preliminary data suggests that while live virus is not recoverable, 
characterisation of FMDV RNA is possible (Muthukrishnan et al., 2008; Madhanmohan et 
al., 2015). Consequently, such methods could be used to support decentralised 
diagnostics, with further evaluation of their potential required. 
This chapter presents the first multiway comparison of different molecular assay formats 
for the detection of FMDV, benchmarked against a reference rRT-PCR. Assays included 
POCT-adapted representatives of rRT-PCR, RT-LAMP and reverse transcription 
recombinase polymerase amplification (RT-RPA). In addition, a selection of sample 
preparation methods, including those which could support simplified sample 
transportation to laboratories, were evaluated for use with each of these chemistries in 
order to define their capabilities. These chemistries, assay formats and sample 
preparation methods were selected based on existing literature (Boyle et al., 2004; 
Polichronova et al., 2010; Abd El Wahed et al., 2013; Waters et al., 2014) and because 
they represent realistic options for FMDV-specific decentralised diagnostics. 
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2.3 Materials and Methods 
2.3.1 Ethics statement 
Clinical samples utilised in this chapter (including negative oesophageal-pharyngeal [OP] 
fluid) were either archival samples from previous experimental studies approved by The 
Pirbright Institute (TPI) Ethical Review Committee under the Animal Scientific Procedures 
Act (ASPA) 1986 (as amended), or comprised samples submitted by endemic countries to 
the Food and Agricultural Organization (FAO) World Reference Laboratory for FMD 
(WRLFMD) at TPI. Negative bovine epithelium and blood (serum) were obtained from a 
UK abattoir under the requirements of Article 23 of the Animal By-products Regulation 
(EC) No. 1069/2009 as approved by the Animal and Plant Health Agency (APHA) (reference 
U1230581/ABP).  
 
2.3.2 Reference real-time reverse transcription PCR 
The one-step rRT-PCR, used as the reference test, employed primers and probes as 
previously described to target the highly conserved 3Dpol-coding region of the FMDV 
genome (Callahan et al., 2002), with reagents, parameters and thermal cycling as 
previously reported (Shaw et al., 2007). rRT-PCR reactions were performed in duplicate 
on a bench-top real-time PCR machine (Stratagene Mx3005PTM: Agilent Technologies, CA, 
USA) (Table 2.1). A positive rRT-PCR reaction was indicated by an exponential increase in 
fluorescence (δR) and the cycle threshold (CT) was called when reactions reached δR 
1000. This rRT-PCR method is recommended within The OIE Manual of Diagnostic Tests 
and Vaccines for Terrestrial Animals (OIE, 2012). 
 
Table 2.1 Molecular assay formats compared 
Assay Reagents Reagent form Primers and Probes Platform 
Reference rRT-PCR Shaw et al., 2007 Wet Callahan et al., 2002 Mx3005PTM 
T-CORTM 8 (#1) SSIII-based 
Lyophilised 
Proprietary primer/probe mix 
targeting 3Dpol-coding region 
T-CORTM 8 
T-CORTM 8 (#2) TC-9092-064 
rRT-LAMP ISO-001 + AMV  Wet* Dukes et al., 2006 Genie® II 
RT-LAMP-LFD ISO-001 + AMV Wet* Dukes et al., 2006 Genie® II + LFD 
rRT-RPA-exoRT TwistAmp® exo RT Lyophilised Abd El Wahed et al., 2013 Genie® II 
rRT-RPA-nfo TwistAmp® nfo + RT Lyophilised Abd El Wahed et al., 2013 Genie® II 
(rRT-PCR) real-time reverse transcription PCR; (rRT-LAMP) real-time reverse transcription loop-mediated 
isothermal amplification; (RT-LAMP-LFD) RT-LAMP combined with lateral-flow detection; (rRT-RPA) real-time 
reverse transcription recombinase polymerase amplification; (AMV) Avian Myeloblastosis Virus; (RT) reverse 
transcriptase. *Only available in a wet format. 
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2.3.3 Portable real-time reverse transcription PCR 
Two field-ready rRT-PCR assays from Tetracore Inc. (MD, USA) were evaluated: T-CORTM 
8 (#1) and T-CORTM 8 (#2). T-CORTM 8 (#2) reagents are commercially known as “FMDV 2.0 
reagents with inhibition control” (catalogue number TC-9092-064). These lyophilised 
assays differed in chemistry (Table 2.1), however they contain the same proprietary 
primers and probes, which target two areas within the FMDV 3Dpol-coding region (probes 
labelled with 6-fluorescein amidite [FAM]). In addition, these assays both contain an 
exogenous internal control with corresponding primers and probes (probe labelled with 
Cy®5).  
To each reaction, 20 µl of re-suspension buffer and 5 µl sample were added to give 25 µl 
total volume. Reactions were performed in duplicate on a T-CORTM 8 (Tetracore Inc.) and 
cycling conditions for both assays were as follows: 48°C for 15 minutes, 95°C for 2 
minutes, followed by 45 cycles of 95°C for 10 seconds and 60°C for 40 seconds. CT was 
defined automatically by the T-CORTM 8 software. Positive reactions were defined as those 
which gave a detectable CT in duplicate assays. 
 
2.3.4 Reverse transcription loop-mediated isothermal amplification 
Previously published FMDV-specific real-time RT-LAMP (rRT-LAMP) and RT-LAMP combined 
with lateral-flow detection (RT-LAMP-LFD) assays require reagents from multiple 
suppliers and numerous pipetting stages for assay set-up (Dukes et al., 2006; Waters et 
al., 2014). In order to simplify reactions, and thus increase compatibility with 
decentralised settings, rRT-LAMP and RT-LAMP-LFD in this chapter were performed using 
a commercial master mix from OptiGene Ltd. (Horsham, UK). Due to the change in 
reagents, conditions were initially optimised with regards to the following: master mix 
selection, final primer concentrations, reaction time and the addition of reverse 
transcriptase (Table 2.2) (Appendix 1a). The final protocols used are stated below.  
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Table 2.2 Optimisation of RT-LAMP conditions 
Condition Rationale 
Master mix selection Two commercially available LAMP master mixes (ISO-001 and ISO-004) from 
OptiGene Ltd. (Horsham, UK) were tested. These were selected for their 
compatibility with decentralised settings: reactions require minimal pipetting 
stages and there was potential for reagent lyophilisation at OptiGene Ltd. 
Primer concentrations Four primer concentration ratios were tested (IPs [μM]: Loops [μM]: EPs [μM]): 
1) 2.0 : 1.0 : 0.2 (Dukes et al., 2006; Ding et al., 2014) 
2) 1.6 : 0.8 : 0.2 (Shao et al., 2010; Guan et al., 2013; Yamazaki et al., 2013) 
3) 1.2 : 0.6 : 0.2  
4) 0.8 : 0.4 : 0.2 (Nagamine et al., 2002). 
Reaction time The recommended reaction time for ISO-001 and ISO-004 is 30 minutes. RT-LAMP 
was also evaluated with an extended incubation due to previously published RT-
LAMP assays (using alternative reagents) reporting 60 minute incubations (Dukes 
et al., 2006; Shao et al., 2010; Waters et al., 2014). 
Reverse transcriptase Master mixes ISO-001 and ISO-004 contain a proprietary DNA polymerase (isolated 
from a Geobacillus species) known to contain residual reverse transcriptase 
activity. RT-LAMP reactions were evaluated with and without additional AMV.  
(RT-LAMP) reverse transcription loop-mediated isothermal amplification; (IPs) internal primers; (Loops) loop 
primers; (EPs) external primers; (AMV) Avian Myeloblastosis Virus.  
 
Real-time RT-LAMP (rRT-LAMP): rRT-LAMP (wet reagents) was performed in a total 
reaction mixture of 25 µl, containing: 15 µl isothermal master mix ISO-001 (OptiGene 
Ltd.), primers and concentrations as per Dukes et al. (2006), 2 U Avian Myeloblastosis 
Virus (AMV) reverse transcriptase (New England Biolabs, MA, USA), 5 µl template and 
made up to total volume with NFW (Table 2.1). Reactions were performed in duplicate 
and incubated at 65°C for the manufacturer’s recommended 30 minutes using a Genie® II 
(OptiGene Ltd.). ISO-001 contains an intercalating dye, enabling results to be visualised 
using fluorescence collected at one minute intervals: time to positivity (TP) was 
automated using Genie® Explorer v0.2.1.1 software (OptiGene Ltd.). 
To confirm that amplicons were FMDV specific, annealing analysis was performed. RT-
LAMP products were heated to 98°C for one minute, then cooled to 80˚C ramping at 
0.05˚C per second. Anneal temperature (Ta) calculations were automated using Genie
® 
Explorer v0.2.1.1 software. The primer-specific Ta was initially identified through analysis 
of 210 FMDV-positive rRT-LAMP reactions (88.5°C was the average Ta over 210 FMDV-
positive RT-LAMP reactions, with 98.55% of reactions within +/- 1°C). From these results, 
rRT-LAMP reactions were called positive if amplification had occurred and the LAMP 
product annealed in the temperature range of 87.5-89.5°C. 
RT-LAMP combined with lateral-flow detection (RT-LAMP-LFD): rRT-LAMP-LFD was 
performed by modifying Dukes et al. (2006) RT-LAMP primers as previously described 
(Waters et al., 2014): the 5ʹ termini of the inner LAMP primers (forward internal primer 
[FIP] and backward internal primer [BIP]) were labelled with fluorescein (Flc) and biotin 
(Btn), respectively. Reactions were incubated at 65°C for 30 minutes using a Genie® II 
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(Table 2.1), followed by assay inactivation at 85°C for 5 minutes. All samples were tested 
in duplicate and results were visualised using PCRD-2TM lateral-flow devices (Abingdon 
Health, York, UK) as per manufacturer’s instructions. A positive result was signified by 
the presence of two blue bands (test [T-Line] and LFD control line [C-line]); negative 
results were indicated by the presence of a single band at the C-line (Figure 2.1). If no 
bands were visible, the test was invalid and thus repeated. A TP value is not given for RT-
LAMP-LFD due to the interference of Flc with amplicon detection. 
 
 
Figure 2.1 Interpreting the results of molecular lateral-flow devices (LFD). (A) Negative 
results are indicated by the presence of an LFD control line only (C-line); (B) positive 
results are indicated by the presence of both a test line (T-line) and C-line. 
 
2.3.5 Real-time reverse transcription recombinase polymerase amplification 
TwistAmp® exo RT kit (rRT-RPA-exoRT): rRT-RPA was performed in duplicate using the 
TwistAmp® exo RT kit as manufacturer’s instructions (TwistDx Ltd., Cambridge, UK), with 
primers and probes for FMDV as previously published (Abd El Wahed et al., 2013). 
Reactions were performed in a total reaction volume of 50 µl (containing 5 µl sample) and 
incubated at 42°C for 20 minutes using a Genie® II, with inversion at five minutes to mix. 
TP was defined when reactions reached a threshold increase of δR 1500 (Table 2.1). 
TwistAmp® nfo kit (rRT-RPA-nfo): the TwistAmp® nfo kit (TwistDx Ltd.) was used as 
manufacturer’s instructions, including the addition of 10 U RT Transcriptor (Roche, 
Mannheim, Germany). Reactions were performed in a total reaction volume of 50 µl 
(containing 5 µl sample) with primers and probes as previously published (Abd El Wahed 
et al., 2013). rRT-RPA-nfo was performed in duplicate, incubating each reaction at 39°C 
for 40 minutes using a Genie® II, with inversion at four minutes to mix. TP was calculated 
as above (Table 2.1). 
 
 
 
  
A B 
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2.3.6 Comparison in the performance of assays 
Two different approaches were used to determine analytical sensitivity: an artificial RNA 
standard and RNA extracted from a FMDV cell culture isolate.  
For the artificial RNA standard, the FMDV 3Dpol-coding region was amplified using 
previously described primers 5ʹ-GGA CAG GAC ATG CTC TCA G-3ʹ and 5ʹ-CAG GAA ACA GCT 
ATG ACT TTT TTT TTT TTT TTT TTT TTG-3ʹ (Valdazo-González et al., 2012) from cell 
culture isolate O/UKG/35/2001 (topotype ME-SA, lineage PanAsia). The subsequent PCR 
product was purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare, IL, USA) and inserted into a pGEM®-T vector (Promega, WI, USA). Synthetic 
viral RNA transcripts were produced by in vitro transcription (MEGAscript® T7 
Transcription Kit: InvitrogenTM, Thermo Fisher Scientific, MA, USA) followed by DNase 
digestion using TURBOTM DNase (Ambion®, Thermo Fisher Scientific). Transcripts were 
purified using MEGAclear™ Transcription Clean-Up Kit (Ambion®) prior to quantification at 
A260 using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). A dilution 
series of the RNA standard (106 to 100 copies) was prepared in 0.1 µg/ml carrier RNA 
(Ambion®). 
For the FMDV RNA, RNA was extracted from a FMDV cell culture isolate, consisting of 
clarified bovine thyroid cell lysate infected with an epithelial tissue suspension of FMDV 
O/UAE/2/2003 (topotype ME-SA, lineage Iran-2001). A decimal dilution series (10-1 to 10-
8) of this isolate was performed in bovine epithelial tissue suspensions, prepared from 
cattle tongues (obtained from an abattoir) (10% [w/v] in M25 phosphate buffer: 35 mM 
Na2HPO4, 5.7 mM KH2PO4, pH 7.6). RNA was extracted from each dilution using a 
MagMAX™-96 Viral RNA Isolation Kit (Thermo Fisher Scientific), following an automated 
procedure on a KingFisher™ Flex (Thermo Fisher Scientific). RNA was extracted from 50 
µl sample and eluted in a final volume of 90 µl MagMAX™ elution buffer (Thermo Fisher 
Scientific).  
To determine the relative diagnostic performance of the different assays, RNA was 
extracted (MagMAX™ / KingFisher™ Flex system as described above) from a panel of 
clinical FMDV samples that had previously been submitted to WRLFMD (Table 2.3). These 
samples comprised 35 FMDV-positive samples, representing five serotypes (O, A, Southern 
African Territories [SAT] 1, SAT 2 and Asia 1) from ten countries, and eight epithelial 
tissue suspension samples representing viruses that cause similar characteristic lesions to 
FMDV: swine vesicular disease virus (SVD: UKG/24/1972; UKG/50/1972; UKG/51/1972; 
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UKG/68/1972) and vesicular stomatitis virus (vesicular stomatitis Indiana virus [VSIV] n = 
2; vesicular stomatitis New Jersey virus [VSNJV] n = 2). 
Table 2.3 FMDV clinical samples used for comparison of assays 
Virus Serotype Sample Topotype Lineage Location Year Sample Type 
FMDV O HKN/12/2010 SEA Mya-98 Hong Kong 2015 ES 
  IRN/26/2015 ME-SA PanAsia-2BAL-09 Iran 2015 ES 
  KUW/1/2016 ME-SA PanAsia-2BAL-09 Kuwait 2016 ES 
  KUW/4/2016 ME-SA PanAsia-2BAL-09 Kuwait 2016 ES 
  PAK/30/2015 ME-SA PanAsia-2BAL-09 Pakistan 2015 ES 
  PAK/32/2015 ME-SA PanAsia-2BAL-09 Pakistan 2015 ES 
  PAK/34/2015 ME-SA PanAsia-2BAL-09 Pakistan 2015 ES 
  PAT/4/2015 ME-SA PanAsia Palestine 2015 ES 
 A IRN/21/2015 ASIA G-VII Iran 2015 ES 
  IRN/24/2015 ASIA Iran-05SIS-10 Iran 2015 ES 
  SAU/8/2015 ASIA G-VII Saudi Arabia 2015 ES 
  PAK/31/2015 ASIA Iran-05FAR-11 Pakistan 2015 ES 
  PAK/56/2015 ASIA Iran-05FAR-11 Pakistan 2015 ES 
  TAN/15/2013 AFRICA G-I Tanzania 2013 ES 
  TAN/71/2012 AFRICA G-I Tanzania 2012 ES 
 SAT 1 TAN/22/2014 I (NWZ) unnamed Tanzania 2014 ES 
  TAN/29/2013 I (NWZ) unnamed Tanzania 2013 ES 
  TAN/23/2013 I (NWZ) unnamed Tanzania 2013 ES 
  TAN/50/2012 I (NWZ) unnamed Tanzania 2012 ES 
  KEN/26/2008 I (NWZ) unnamed Kenya 2008 ES 
  KEN/9/2009 I (NWZ) unnamed Kenya 2009 ES 
  KEN/12/2009 I (NWZ) unnamed Kenya 2009 ES 
 SAT 2 ZIM/9/2015 II unnamed Zimbabwe 2015 ES 
  ZIM/21/2015 II unnamed Zimbabwe 2015 ES 
  TAN/3/2011 IV IV Tanzania 2011 ES 
  TAN/64/2012 IV unnamed Tanzania 2012 ES 
  TAN/14/2012 IV unnamed Tanzania 2012 ES 
  TAN/19/2012 IV unnamed Tanzania 2012 ES 
  KEN/2/2007 IV unnamed Kenya 2007 ES 
  SUD/7/2014 VII Alx-12 Sudan 2015 ES 
 Asia 1 IRN/20/2015 ASIA Sindh-08 Iran 2015 ES 
  PAK/33/2015 ASIA Sindh-08 Pakistan 2015 ES 
  PAK/28/2015 ASIA Sindh-08 Pakistan 2015 CC 
  PAK/29/2015 ASIA Sindh-08 Pakistan 2015 OF 
  PAK/43/2015 ASIA Sindh-08 Pakistan 2015 ES 
*(ES) epithelial tissue suspension; (CC) cell culture isolate; (OF) original fluid (unknown type); (SAT) Southern African 
Territories. 
 
2.3.7 Comparison of sample preparation methodologies 
To compare sample preparation methods, three decimal dilution series (10-1 to 10-9) of 
FMDV (cell culture isolate O/UAE/2/2003) were prepared as described above in 10% (w/v) 
bovine epithelial tissue suspension, bovine serum (obtained from a UK abattoir) and 
bovine OP fluid (archival FMDV-negative experimental samples from TPI). Aliquots were 
stored at -80°C until use. All sample preparation methods were performed on the 
reference rRT-PCR, T-CORTM 8 (#1) and (#2) reagents, rRT-LAMP and rRT-RPA-exoRT. Of 
each preparation method, 5 µl of sample was added to each assay. 
A hierarchy of sample preparation methods were selected for comparison, ranging from 
sophisticated laboratory nucleic extraction methods (MagMax™, MagMax™ [manual] and 
QIAamp®) to simpler methods such as dilution of samples in NFW. Alternate methods, such 
as the use of a syringe filter, Chelex® 100 and elution from Ag-LFDs were selected as they 
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had been previously described as simple techniques for PCR inhibitor removal (Ochert et 
al., 1994; Wu and Kado, 2004; Walsh et al., 2013; Fowler et al., 2014). 
MagMax™: This protocol was used as the reference sample preparation procedure. RNA 
extraction was performed as described previously (Chapter 2.3.6). RNA was extracted 
from 50 µl sample and eluted in 90 µl of MagMAX™ elution buffer.  
MagMax™ (manual): RNA was extracted following manufacturer’s manual guidelines with 
a DynaMag™-Spin magnet (Thermo Fisher Scientific). RNA was extracted from 50 µl sample 
and eluted in 90 µl of MagMAX™ elution buffer.  
QIAamp®: The QIAamp® Viral RNA Mini Kit (Qiagen, Hilden, Germany) was used according 
to manufacturer’s guidelines. RNA was extracted from 140 µl of sample (using the spin 
column protocol) and eluted in a final volume of 60 µl QIAamp® buffer AVE (Qiagen). 
Neat: Sample was added directly to reactions. 
Dilutions: Samples were processed by diluting either 1 in 5, 1 in 10 or 1 in 20 in NFW 
(Waters et al., 2014). 
Filter: Samples were diluted 1 in 5 and 1 ml of sample passed through a Acrodisc® 25 mm 
syringe filter (w/ 0.1 µm Supor® Membrane) (Pall Life Sciences, MI, USA). 
Chelex® 100: 50 µl of 50% (w/v) Chelex® 100 was added to 500 µl of diluted sample (1 in 
5). Samples were vortexed, allowed to settle for five minutes and the supernatant used 
in assays. For Chelex® 100 (heat) samples were heated at 56°C for 10 minutes prior to 
processing as above, in order to denature the FMDV capsid and release RNA prior to 
inhibitor removal. 
LFD: (epithelium only) 200 µl of each sample was added to SVANODIP® FMDV-Ag LFDs 
(Boehringer Ingelheim, Bracknell, UK), which were incubated at room temperature (25°C) 
for 72 hours to mimic extreme field conditions. Nucleic acid was extracted from the 
loading pad and wicking strip of the Ag-LFDs as previously described (Fowler et al., 2014). 
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2.3.8 Alternatives for sample collection and transportation 
Use of Ag-LFDs for molecular detection of FMDV:  
To ascertain whether Ag-LFDs can be used for long-term transport and storage of FMDV, 
rRT-PCR (reference and T-CORTM 8 [#1] and [#2]), rRT-LAMP and rRT-RPA-exoRT assays 
were performed on nucleic acid template extracted from 20 archival Ag-LFDs. These Ag-
LFDs had been collected within the Serengeti District, Tanzania in August to September 
2013 (kindly provided by Paulo F. Raphael [Sokoine University of Agriculture, Tanzania] 
and Tiziana Lembo [The University of Glasgow, UK]). Epithelial samples, from cows 
displaying acute signs of FMD, had been processed in the field using the SVANODIP® FMDV-
Ag Extraction kit (Boehringer Ingelheim) and applied to the SVANODIP® FMDV-Ag LFDs 
according to manufacturer’s guidelines. These Ag-LFDs were stored at The Nelson 
Mandela African Institution of Science and Technology (Arusha, Tanzania), in individual 
fabric pouches at room temperature for two years (dry conditions), prior to shipment to 
WRLFMD. Nucleic acid was recovered as previously described from the loading pad and 
wicking strip of the Ag-LFDs as previously described (Fowler et al., 2014), by suspending 
the sections in 100 µl of RNase inhibitor (20 U/µl, Applied BiosystemsTM, Thermo Fisher) 
at 1:50 in NFW for five minutes. Tubes were spun at 3489 x g for two minutes to obtain 
the eluate, which quality checked using a NanoDrop ND-1000 spectrophotometer (at A260) 
and Agilent Bioanalyzer 2100 RNA nanochip (Agilent Technologies) and used as template 
in reactions. 
 
FTA® cards for non-invasive saliva sampling:  
To assess the potential of FTA® cards for saliva sampling, FTA® DMPK-B cards were 
evaluated (catalogue number WB129242: WhatmanTM, GE Healthcare). FTA® DMPK-B cards 
were selected as they contain chemicals to lyse cells and denature proteins on contact, 
and have a larger sample collection area than alternative DMPK cards. For initial analysis 
of extraction methods, a decimal dilution series (10-1 to 10-8) of FMDV (cell culture isolate 
O/UAE/2/2003) was prepared in bovine epithelial tissue suspensions as above (Chapter 
2.3.6). Of each dilution, 200 µl was loaded onto individual FTA® cards and dried at room 
temperature for three hours in dark settings. Three extraction methods were compared 
(Table 2.4) for use in the reference rRT-PCR. 
To determine the ability of FTA® DMPK-B cards for non-invasive saliva swabbing, samples 
were collected from two unvaccinated intradermolingual needle challenged cattle (FMDV 
Chapter 2 
 
48 
 
challenge virus: A/IRAN/22/2015 [topotype ASIA, lineage G-VII]), by swabbing the cards 
around the external oral regions of cattle (lips and chin). Samples were collected daily 
from the day of challenge to five days post challenge. FTA® DMPK-B cards were dried and 
stored for approximately one week at room temperature. RNA was extracted from cards 
following the QIAamp® extraction protocol (Table 2.4), with the eluate used as template 
in the reference rRT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4 FTA® DMPK-B card extraction methods compared 
Name Protocol Reference 
Extraction RNA was extracted from the FTA® cards using a QIAamp® Viral RNA 
Mini Kit. In brief, eight punches of the FTA® card (each with a 2 mm 
diameter) were incubated overnight (4°C) in 140 µl NFW plus 560 µl 
of QIAamp® lysis buffer. Extraction was performed as manufacturer’s 
instructions (using the spin column protocol), eluting in a final volume 
of 60 µl QIAamp® buffer AVE. 
QIAamp® Viral RNA 
Mini Handbook  
(Fourth edition, 
December 2014) 
Elution A small section of the FTA® card (1 cm2) was cut and suspended in 100 
µl of RNase inhibitor (20 U/µl, Applied BiosystemsTM, Thermo Fisher) 
at 1:50 in NFW. After five minutes of soaking the tubes were spun at 
3489 x g for two minutes. The elution wash was used as template in 
reactions. 
Adapted from Fowler 
et al. (2014) 
Punch A small punch of the FTA® card (diameter of 2 mm) was washed three 
times with 200 µl WhatmanTM FTA® purification Reagent (GE 
Healthcare) and then further three times with 200 µl TE buffer 
(InvitrogenTM). Each wash consisted of a five minute incubation. 
Punches were dried for one hour at room temperature, before being 
used directly as the template in reactions. 
Muthukrishnan et al. 
(2008) 
Initial extraction methods trialled for use of FTA® DMPK-B cards 
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2.4 Results 
2.4.1 Optimisation of rRT-LAMP and RT-LAMP-LFD 
Both master mixes (ISO-001 and ISO-004) displayed comparable analytical sensitivity in 
rRT-LAMP and RT-LAMP-LFD when used in a wet format, using the recommended 
incubation time of 30 minutes. Both consistently detected down to 10-5 of a dilution series 
of FMDV RNA, with ISO-001 detecting down to 10-6 in one of the two replicates (Appendix 
1a). Increasing the incubation time to 60 minutes led to a one log10 improvement in 
analytical sensitivity for ISO-001 reagents in one of the two replicates (to match that of 
ISO-004), however non-specific amplification (shown by Ta analysis) was evident from 50 
minutes in 1/4 rRT-LAMP FMDV-negative assays for ISO-001 and 2/4 rRT-LAMP FMDV-
negative assays for ISO-004 (Appendix 1a). Further optimisation for ISO-001 rRT-LAMP 
reagents revealed that reactions with a primer ratio of 2 µM internal primers: 1 µM loop 
primers: 0.2 µM external primers exhibited a two log10 increase in analytical sensitivity 
when compared to other ratios tested (Appendix 1a). Furthermore, by omitting AMV RT 
for ISO-001 rRT-LAMP reagents, the detection limit was reduced by two log10 (Appendix 
1a).  
In light of these results, all further analysis of rRT-LAMP and RT-LAMP-LFD was performed 
using the conditions as stated in Table 2.5. 
 
 
 
 
 
Table 2.5 Optimised rRT-LAMP and RT-LAMP-LFD conditions 
Component Working Stock µl per reaction Final concentration 
ISO-001 master mix  15  
Forward external primer (F3) 5 pmol/μl 1 0.2 µM 
Backward external primer (B3) 5 pmol/μl 1 0.2 µM 
Forward loop primer (FLoop) 25 pmol/μl 1 1.0 µM 
Backward loop primer (BLoop) 25 pmol/μl 1 1.0 µM 
Forward internal primer1 (FIP) 50 pmol/μl 1 2.0 µM 
Backward internal primer2 (BIP) 50 pmol/μl 1 2.0 µM 
*AMV reverse transcriptase 10,000 U/ml 0.2 2 U 
Incubation time   30 minutes 
All primer sequences were as published in Dukes et al. (2002). (rRT-LAMP) real-time reverse transcription 
loop-mediated isothermal amplification; (RT-LAMP-LFD) RT-LAMP combined with lateral-flow detection; 
(AMV) Avian Myeloblastosis Virus. Internal primers for the RT-LAMP-LFD assays were modified according to 
Waters et al. (2014) by labelling the 5ʹ termini with either fluorescein1 or biotin2.  
Chapter 2 
 
50 
 
2.4.2 Comparison in the performance of assays 
Using an artificial RNA standard, the analytical sensitivities of rRT-PCR (all formats), RT-
LAMP (all formats) and rRT-RPA-exoRT were 101, 101, and 102 copies, respectively (Figure 
2.2A). A log10 reduction in analytical sensitivity was evident for rRT-RPA-nfo compared to 
rRT-RPA-exoRT, detecting down to 103 copies (Figure 2.2A). A TP value was not defined 
for RT-LAMP-LFD due to the interference of the fluorescein-labelled inner primer 
(required for molecular LFD detection) with the intercalating dye used for real-time 
amplicon detection on the Genie® II. 
  
Figure 2.2 Analytical sensitivity of molecular assay formats. (A) RNA standard; (B) FMDV 
RNA (extracted) diluted in bovine epithelium. (●) Reference real-time reverse 
transcription PCR (rRT-PCR); (●) T-CORTM 8 (#1); (■) T-CORTM 8 (#2); (▲) real-time reverse 
transcription loop-mediated isothermal amplification (rRT-LAMP); (◆) real-time reverse 
transcription recombinase polymerase amplification (rRT-RPA)-exoRT; ◆ rRT-RPA-nfo. 
Grey shaded area (reference rRT-PCR only) represents cycle thresholds values over the 
diagnostic cut-off of CT < 32 (Shaw et al., 2007). Each point represents the mean of two 
duplicates; half shaded points represent duplicates where one was positive and the other 
negative; error bars display the range. For RT-LAMP combined with lateral-flow detection 
(RT-LAMP-LFD): (C)-line and (T)-line = positive result; (C)-line only = negative result.  
A 
B 
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Both sets of T-CORTM 8 reagents (#1 and #2) gave equivalent analytical sensitivity with the 
artificial RNA standard, however the change in fluorescence detected in the FAM channel 
(FMDV-detection) was consistently higher for T-CORTM 8 (#2) reagents (Figure 2.3). 
Furthermore, the internal control was consistently amplified in all T-CORTM 8 (#2) 
reactions, whereas internal control amplification was inhibited in T-CORTM 8 (#1) reactions 
with a high copy number of FMDV RNA standard (Figure 2.3). 
 
Figure 2.3 Amplification plots for the T-CORTM 8 (#1 and #2) assays formats. Analytical 
sensitivity was determined using an artificial foot-and-mouth disease virus (FMDV) RNA 
standard (one duplicate shown). (A) T-CORTM 8 (#1) FMDV-detection plot; (B) T-CORTM 8 
(#1) internal control detection plot; (C) T-CORTM 8 (#2) FMDV-detection plot; (D) T-CORTM 
8 (#2) internal control detection plot. Assays were performed on an RNA standard 
(copies/μl), 106 (light blue); 105 (green); 104 (yellow); 103 (orange); 102 (red); 101 (pink); 
100 (purple); negative (dark blue). (FAM) with 6-fluorescein amidite; (Cy5) Cy®5. 
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When using RNA extracted from a dilution series of a cell culture of FMDV isolate 
O/UAE/2/2003 spiked into epithelial tissue suspensions to determine assay performance, 
the analytical sensitivities of isothermal assays were reduced in comparison to rRT-PCR 
(total detection limit of 10-7 of the FMDV dilution series): rRT-LAMP (all formats): 10-4; 
rRT-RPA-exoRT: 10-3; rRT-RPA-nfo: 10-2 (Figure 2.2B). Both T-CORTM 8 assays (#1 and #2) 
displayed equivalent analytical sensitivity to the reference rRT-PCR (10-7), however the 
internal control was inhibited in the T-CORTM 8 (#1) reactions in 10-1 and 10-2 dilutions 
(data not shown). 
To determine if the reduction in analytical sensitivity was a consequence of mismatches 
in primer/probe binding regions, a sequence comparison of 3Dpol-coding regions between 
O/UKG/35/2001 (artificial RNA standard [GenBank accession number AJ539141.1]) and 
O/UAE/2/2003 (FMDV RNA dilution [unpublished data from The Pirbright Institute: TPI]) 
was performed. For rRT-PCR (Callahan et al., 2002), no mismatches were present in the 
primer/probe binding regions for either sequence (Table 2.6). For rRT-LAMP, eight 
nucleotide differences were present between O/UKG/35/2001 and O/UAE/2/2003 within 
the primer target regions (Table 2.7), one of which affected two rRT-LAMP primers (total 
of nine primer-template mismatches for O/UAE/2/2003). Five mismatches were present 
within the rRT-RPA target regions (Abd El Wahed et al., 2013), however these mismatches 
were consistent between O/UKG/35/2001 and O/UAE/2/2003 (table 2.8).  
 
 
 
 
Table 2.6 rRT-PCR target sequence comparison 
Primer Genome position* Sequence (Primers in the 5ʹ-3ʹ) 
Forward primer 7863-7884 ACTGGGTTTTACAAACCTGTGA 
O/UKG/35/2001  ACTGGGTTTTACAAACCTGTGA 
O/UAE/2/2003  ACTGGGTTTTACAAACCTGTGA 
   
Probe 7914-7933 TCCTTTGCACGCCGTGGGAC 
O/UKG/35/2001  TCCTTTGCACGCCGTGGGAC 
O/UAE/2/2003  TCCTTTGCACGCCGTGGGAC 
   
Reverse primer 7953-7969 GCGAGTCCTGCCACGGA  
O/UKG/35/2001(rc)  GCGAGTCCTGCCACGGA 
O/UAE/2/2003(rc)  GCGAGTCCTGCCACGGA 
(rRT-PCR) real-time reverse transcription PCR. Nucleotide sequences in black indicate the Callahan et al. 
(2002) primers/probe in the 5ʹ-3ʹ direction. Nucleotide sequences in grey indicate the target regions within 
O/UKG/35/2001 (GenBank accession number AJ539141.1 [nucleotides 7847-8026]) and O/UAE/2/2003 
(unpublished sequence, personal communication from The Pirbright Institute). (rc) sequence shown in the 
reverse complement; *genome position according to the FMD virus strain O/UKG/35/2001 (Genbank 
Accession number AJ539141.1). 
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Table 2.7 rRT-LAMP target sequence comparison 
Primer Genome position* Sequence (Primers in the 5ʹ-3ʹ) 
Forward external  primer 7850–7869 CATGGACTATGGAACTGGGT   
O/UKG/35/2001  CATGGACTATGGAACTGGGT     
O/UAE/2/2003  CATGGACTATGGAACTGGGT 
   
Backward external primer 8006-8022 GGCCCTGGAAAGGCTCA           
O/UKG/35/2001 (rc)  GGCCCTGGAAAGGCTCA 
O/UAE/2/2003 (rc)  GCCCCTGGAAGGGTTCA   
   
Forward internal primer (F1c) 7909-7929 CACGGCGTGCAAAGGAGAGGA  
O/UKG/35/2001 (rc)  CACGGCGTGCAAAGGAGAGGA 
O/UAE/2/2003 (rc)  CACGGCGTGCAAAGGAGAGGA 
   
Forward internal primer (F2) 7873–7892 ACAAACCTGTGATGGCTTCG  
O/UKG/35/2001  ACAAACCTGTGATGGCTTCG   
O/UAE/2/2003  ACAAACCTGTGATGGCCTCA 
   
Backward internal primer (B1c) 7940-7961 GGAGAAGTTGATCTCCGTGGCA  
O/UKG/35/2001  GGAGAAGTTGATCTCCGTGGCA  
O/UAE/2/2003  GGAGAAGTTGATCTCCGTGGCA 
   
Backward internal primer (B2) 7988–8005 AAGAGACGCCGGTACTCG  
O/UKG/35/2001 (rc)  AAGAGACGCCGGTACTCG   
O/UAE/2/2003 (rc)  AAGAGACGCCGGTACTCG   
   
Forward loop primer 7891–7908 TAGCCTCGAGGGTCTTCG       
O/UKG/35/2001 (rc)  TAGCCTCGAGGGTCTTCG  
O/UAE/2/2003 (rc)  TAGCCTCAAGAGTCTTTG 
   
Backward loop primer 7962–7979 GGACTCGCCGTCCACTCT 
O/UKG/35/2001  GGACTCGCCGTCCACTCT  
O/UAE/2/2003  GGACTCGCTGTCCACTCT 
(rRT-LAMP) real-time reverse transcription loop-mediated isothermal amplification. Nucleotide sequences 
in black indicate the Dukes et al. (2006) primers in the 5ʹ-3ʹ direction. Nucleotide sequences in grey indicate 
the target regions within O/UKG/35/2001 (GenBank accession number AJ539141.1 [nucleotides 7847-
8026]) and O/UAE/2/2003 (unpublished sequence, personal communication from The Pirbright Institute). 
(rc) sequence shown in the reverse complement; *genome position according to the FMD virus strain 
O/UKG/35/2001 (Genbank Accession number AJ539141.1); red underlined bases indicate primer-template 
mismatches. 
   
Table 2.8 rRT-RPA target sequence comparison 
Primer Genome position* Sequence (Primers in the 5ʹ-3ʹ) 
Forward primer 7850-7883 CATGGATTATGGAACTGGGTTTTACAAACCTGTG   
O/UKG/35/2001  CATGGACTATGGAACTGGGTTTTACAAACCTGTG 
O/UAE/2/2003  CATGGACTATGGAACTGGGTTTTACAAACCTGTG 
   
Probe (part 1) 7903-7934 GGTCCCACGGCGTGCGAAGGAGAGGATGGCTT      
O/UKG/35/2001 (rc)  GGTCCCACGGCGTGCAAAGGAGAGGATAGCCT 
O/UAE/2/2003 (rc)  GGTCCCACGGCGTGCAAAGGAGAGGATAGCCT 
   
Probe (part 2) 7938-7953 AGATCAACTTCTCCTG 
O/UKG/35/2001 (rc)  AGATCAACTTCTCCTG 
O/UAE/2/2003 (rc)  AGATCAACTTCTCCTG 
   
Reverse primer 7942-7964 TCCTGCCACAGAGATCAACTTCT   
O/UKG/35/2001(rc)  TCCTGCCACGGAGATCAACTTCT  
O/UAE/2/2003(rc)  TCCTGCCACGGAGATCAACTTCT 
(rRT-RPA) real-time reverse transcription recombinase polymerase amplification. Nucleotide sequences in 
black indicate the Abd El Wahed et al. (2013) primers/probe in the 5ʹ-3ʹ direction. Nucleotide sequences 
in grey indicate the target regions within O/UKG/35/2001 (GenBank accession number AJ539141.1 
[nucleotides 7847-8026]) and O/UAE/2/2003 (unpublished sequence, personal communication from The 
Pirbright Institute). (rc) sequence shown in the reverse complement; *genome position according to the 
FMD virus strain O/UKG/35/2001 (Genbank Accession number AJ539141.1);  red underlined bases indicate 
primer/probe-template mismatches. 
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Initial assessment of relative diagnostic performance showed the agreement between 
each assay and the reference rRT-PCR for RNA extracted from clinical samples were as 
follows (n = 43): T-CORTM 8 (#1): 43/43 (100%); T-CORTM 8 (#2): 43/43 (100%); rRT-LAMP: 
38/43 (88%); RT-LAMP-LFD: 37/43 (86%); rRT-RPA-exoRT: 33/43 (77%); rRT-RPA-nfo: 
29/43 (67%). False-negative samples consistently displayed high rRT-PCR CT values (Figure 
2.4). All assays yielded negative results against SVDV, VSNJV and VSIV isolates.  
 
 
Figure 2.4 Initial assessment of relative diagnostic performance (n = 43). The grey shaded 
area highlights reference real-time reverse transcription PCR (rRT-PCR) cycle threshold 
(CT) values over the FMDV diagnostic threshold of CT < 32 (Shaw et al., 2007). For T-COR
TM 
8: (black) internal controls positive; (grey) internal control positive in one duplicate; 
(white) internal controls negative. Each point represents the mean of two duplicates, 
however samples that share the same CT or time to positivity (Tp) appear as a single point. 
(rRT-LAMP) real-time reverse transcription loop-mediated isothermal amplification; (RT-
LAMP-LFD) RT-LAMP combined with lateral-flow detection; (rRT-RPA) real-time reverse 
transcription recombinase polymerase amplification. 
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The exogenous internal control (detected in the Cy®5 channel) was positive in both 
duplicates for 19/43 samples tested using the T-CORTM 8 (#1) assay. Assays where the 
internal control failed to be amplified all displayed low CT values for FMDV detection (CT 
values between 13.2 and 23.2) (Figure 2.4), with failure likely due to amplification of the 
FMDV target outcompeting that of the internal control. When using the T-CORTM 8 (#2) 
assay, only one sample displayed a negative internal control result for one duplicate 
(FMDV detected at CT 19.5), with all other samples displaying positive exogenous internal 
control results in both duplicates (Figure 2.4). 
 
2.4.3 Comparison of sample preparation methodologies 
Eleven simple methods were compared for preparation of samples prior to molecular 
analysis, using the MagMax™ / KingFisher™ system as the reference sample preparation 
procedure. Sample preparation methods were performed on the reference rRT-PCR, T-
CORTM 8 (#1) and (#2) reagents, rRT-LAMP and rRT-RPA-exoRT (rRT-RPA-nfo was not tested 
due to poor analytical sensitivity). The use of simple extraction kits for all assays 
(QIAamp® and MagMax™ [manual]) achieved comparable analytical sensitivity across all 
sample types to automated nucleic acid extraction (Figure 2.5, Appendix 2). 
Using epithelial tissue suspensions, all simple sample preparation methods resulted in 
complete inhibition of the reference rRT-PCR. For the T-CORTM 8 reagents (#1 and #2) and 
rRT-LAMP, dilution of epithelial tissue suspensions in NFW resulted a one log10 reduction 
in analytical sensitivity comparatively to the use of extracted RNA, with the use of both 
Chelex® 100 and syringe filters further decreasing the limit of detection (LOD). A one log10 
reduction was also evident for rRT-RPA-exoRT when using diluted epithelial tissue 
suspensions, however non-specific amplification was evident. This was removed by pre-
processing of samples through a syringe filter. Ag-LFDs displayed a reduced LOD 
comparatively to molecular methods, however elution from Ag-LFDs produced positive 
results in all molecular assays (Figure 2.5, Appendix 2).  
Serum could be added neat to the reference rRT-PCR, T-CORTM 8 reagents and rRT-LAMP, 
however dilution in NFW and/or the use of Chelex® 100 or a syringe filter was required to 
minimise the reduction in LOD (either a one or two log10 reduction in LOD was evident). 
For rRT-RPA-exoRT, all simple serum preparation methods resulted in complete assay 
inhibition with nucleic acid extraction required, using any of the three RNA extraction 
methods tested, in order for amplification to be observed (Figure 2.5, Appendix 2).  
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When using OP fluid, a one to two log10 reduction in analytical sensitivity was evident for 
all rRT-PCR assays and rRT-LAMP when OP fluid was diluted in NFW prior to analysis: 1 in 
10 dilutions resulted in the smallest decrease in LOD. The additional use of syringe filters 
or Chelex® 100 resulted in a further decrease. For rRT-RPA-exoRT, extraction of RNA from 
OP fluid was required, with the use of simple OP fluid preparations resulting in complete 
assay inhibition (Figure 2.5, Appendix 2). 
The exogenous internal control was positive in T-CORTM 8 (#2) assays for all sample types, 
across all sample preparation methods, with the exception of when samples were added 
neat to reactions. Detection of the internal positive control was inhibited in the T-CORTM 
8 (#1) assays both when samples were added to reactions neat, or when reactions were 
strongly positive for FMDV (low CT values for FMDV detection) (Figure 2.5). 
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Figure 2.5 Comparison of sample preparation methods. The Y-axis represents the decimal 
dilution series (10-1 to 10-9) of foot-and-mouth disease virus (FMDV) in either epithelial 
tissue suspensions, sera or oesophageal-pharyngeal fluid. Black squares represent FMDV-
positive reactions; blue squares represent dilutions where one duplicate was FMDV-
positive; white squares represent FMDV-negative reactions. For the reference real-time 
reverse transcription PCR (rRT-PCR) only, grey boxes highlight cycle threshold values over 
the FMDV diagnostic threshold of CT < 32 (Shaw et al., 2007). (N) non-specific application; 
(c) for T-CORTM 8 assays the exogenous internal control was negative in at least one 
duplicate; +/- represent antigen-detection lateral-flow device (Ag-LFD) results. (rRT-
LAMP) real-time reverse transcription loop-mediated isothermal amplification; (rRT-RPA) 
real-time reverse transcription recombinase polymerase amplification. 
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2.4.4 Alternatives for sample collection and transportation 
Use of Ag-LFDs for molecular detection of FMDV:  
From the 20 archival Ag-LFDs collected within the Serengeti District, Tanzania (August to 
September 2013), FMDV RNA was detected by rRT-PCR (reference, T-CORTM 8 [#1] and 
[#2]) in the elution wash from all Ag-LFDs (Figure 2.6C; Figure 2.6D). For rRT-LAMP, FMDV 
RNA was detected in the elution wash from 19/20 Ag-LFDs (false-negative had a reference 
rRT-PCR CT value of 27.12) (Figure 2.6A). For rRT-RPA-exoRT, 18/20 Ag-LFDs gave FMDV-
positive results (two false-negatives had reference rRT-PCR CT values of 27.12 and 25.79) 
(Figure 2.6B). 
 
Figure 2.6 Use of antigen-detection lateral-flow devices for storage of foot-and-mouth 
disease virus. Comparison between the reference real-time reverse transcription PCR 
(rRT-PCR) and point-of-care test (POCT)-ready assays across 20 Ag-LFDs. The grey shaded 
area highlights reference rRT-PCR cycle threshold values over the diagnostic threshold of 
CT < 32 (Shaw et al., 2007). For T-COR
TM 8 assays: (black) internal controls positive; 
(white) internal controls negative. Each point represents the mean of two duplicates. 
(rRT-LAMP) real-time reverse transcription loop-mediated isothermal amplification; (rRT-
RPA) real-time reverse transcription recombinase polymerase amplification. 
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FTA® cards for non-invasive saliva sampling:  
When evaluating FTA® DMPK-B cards, QIAamp® nucleic acid extraction enabled the highest 
analytical sensitivity to be achieved out of the three extraction methods trialled, 
detecting down to 10-7 of a FMDV RNA dilution series (reactions performed on the 
reference rRT-PCR). A two log10 reduction was evident for elution from FTA
® DMPK-B cards 
in 1:50 RNase inhibitor to NFW comparatively to QIAamp® extraction (detecting down to 
10-5), with the use of punched disks in assays leading to a three log10 reduction in 
analytical sensitivity (reliably detecting down to 10-4, with one duplicate detected at 10-
5) (data not shown). 
When using FTA® DMPK-B cards used for collection of clinical saliva samples (external oral 
swabs from unvaccinated intradermolingual needle challenged cattle), the reference rRT-
PCR (in combination with QIAamp® extraction) resulted in FMDV being detected in samples 
from both cattle from one day post challenge (DPC) until sampling was concluded at five 
DPC (Figure 2.7). 
 
Figure 2.7 Determination of the clinical detection window for FTA® DMPK-B cards used 
as oral swabs. Samples originated from two unvaccinated cattle needle-challenged cattle 
with FMDV A/IRAN/22/2015: (circle) animal number one; (square) animal number two. 
(black) real-time reverse transcription PCR results, each point represents the mean of 
two replicates (range bars were not visible below the points); (grey) rectal temperature 
of each animal in °C; (grey box) onset of clinical signs. Half shaded points represent 
duplicates where one was positive and the other negative 
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2.5 Discussion 
The requirement for decentralised detection of FMDV in field and low-resource settings 
has led to an increased interest in evaluating simple-to-use diagnostic platforms that can 
be deployed closer to farms that are experiencing clinical suspicion of FMD. However, the 
lack of publications comparing multiple FMDV-specific assays, in addition to a lack of 
standardisation between laboratory evaluations, has led to difficulties in defining the 
relative performance of new assays and technologies. Furthermore, published POCTs 
often use nucleic acid extraction protocols incompatible with low-resource settings. This 
chapter details a comparison of multiple POCT-ready assays (including representatives of 
rRT-PCR, RT-LAMP and rRT-RPA) and POCT-compatible sample preparation procedures, in 
order to define their current capabilities and select the most appropriate technologies 
and protocols for subsequent evaluation and field testing. 
The analytical sensitivities of POCT-ready assays were equivalent to previously published 
results when using an artificial FMDV RNA standard, with rRT-PCR and RT-LAMP assay 
formats displaying comparable analytical sensitivity to the reference rRT-PCR (Callahan 
et al., 2002; Shaw et al., 2007; Waters et al., 2014) and rRT-RPA-exoRT one log10 less 
sensitive (Abd El Wahed et al., 2013). Although other studies have employed longer RT-
LAMP incubation periods of 60 minutes to enable assays to run to completion (Dukes et 
al., 2006; Waters et al., 2014), results in this chapter showed that the extension of RT-
LAMP from 30 to 60 minutes led to a decrease in assay specificity (as determined by 
incorrect Ta). Due to the costs associated with responding to a false-positive FMD 
diagnosis, in addition to the eventual aim of deploying RT-LAMP in field and low-resource 
settings (require compatibility with crude sample preparation methods and minimal 
expertise), a time threshold of 30 minutes was used to reduce the risk of non-specific 
amplification. The poor performance of the TwistAmp® nfo kit is likely due to the absence 
of Exonuclease III (present within the TwistAmp® exo RT kit), which contains 3ʹ-5ʹ 
exonuclease activity to enhance fluorescent probe degradation during amplification.   
During evaluation of analytical sensitivity, it was apparent that the template of choice 
impacted upon apparent assay performance, with more variation evident between assays 
when using RNA extracted from cell culture isolate O/UAE/2/2003 spiked into epithelial 
tissue suspensions comparatively to artificial RNA standards. The reduction in analytical 
sensitivity for RT-LAMP could be due to an increased number of primer/template 
mismatches evident for O/UAE/2/2003 (FMDV RNA dilution) compared to O/UKG/35/2001 
(artificial RNA standard). However for rRT-RPA, the sequence differences between 
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O/UAE/2/2003 and O/UKG/35/2001 did not affect primer/probe target regions. 
Furthermore, when evaluating relative diagnostic sensitivity (using FMDV RNA isolated 
from clinical samples), similar variation between assays was evident. This variation 
between assays therefore could be related to the presence of host-derived nucleic acid 
and/or nucleic acid structures present in RNA extracted from clinical samples (absent 
from RNA standards), however further work is required to confirm this. These results 
should be considered when evaluating new assays, to prevent the false overestimation of 
assay performance if determined using an RNA standard only. 
Sample preparation remains the bottleneck of POCT nucleic acid detection, with current 
procedures being complex, time-consuming and requiring both dedicated laboratory 
spaces and specialised equipment (Dineva et al., 2007). Both manual nucleic extraction 
kits gave comparable analytical sensitivity to automated procedures for each of the POCT-
ready assays, however the requirement for multiple stages and basic equipment limits 
their use to laboratory settings. Therefore, although suitable for low-resource 
laboratories, more simplistic sample preparation methods are still required for field-
based detection of FMDV. 
Previous publications have shown that RT-LAMP is able to detect FMDV from air sampler 
fluid and epithelial tissue suspensions following dilution in NFW (Waters et al., 2014), and 
PCR assays are able to amplify DNA from crude clinical samples using mutants of Taq 
polymerase (Kermekchiev et al., 2009; Zhang et al. 2010). Results obtained in this study 
confirmed this for rRT-LAMP and rRT-PCR (T-CORTM 8 assays) using OP fluid, serum and 
epithelial tissue suspensions. This offers advantages over current POCTs such as Ag-LFDs 
(only evaluated for use with epithelium and vesicular fluid) by being applicable across a 
larger diagnostic window of detection. However, the use of simple sample preparation 
procedures resulted in slight reductions in analytical sensitivity, with dilution in NFW 
resulting in a one to two log10 decrease in LOD. Although a one log10 decrease in LOD is 
consistent with the dilution factor, a two log10 decrease in LOD suggests partial assay 
inhibition, in addition to the effects of dilution factor. However, even in the absence of 
RNA extraction, T-CORTM 8 assays consistently displayed analytical sensitivity comparable 
to that of the reference rRT-PCR when considering a diagnostic threshold (Shaw et al., 
2007).  
Simple sample preparation methods were less encouraging for RT-RPA-exoRT, with both 
sera and OP fluid inhibiting assays when RNA extraction was omitted. When using 
epithelial tissue suspensions, amplification in the rRT-RPA-exoRT assay was evident 
following dilution in NFW, however syringe filters were required to prevent non-specific 
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amplification. Similarly, the use of simple epithelial tissue suspension preparations 
resulted in complete inhibition of the reference rRT-PCR.  
An important point of consideration for POCTs, especially with the use of crude sample 
preparations, is to ensure that assays are not affected by potential inhibitors present 
within the sample. As such, the T-CORTM 8 assays contain an exogenous internal control. 
Throughout evaluation, the T-CORTM 8 (#2) assay displayed superior performance to the 
T-CORTM 8 (#1) assay when considering amplification of the internal control, which was 
repeatedly inhibited in the T-CORTM 8 (#1) assay when samples were strongly positive for 
FMDV (likely due to competitive inhibition differentially affecting the two chemistries). 
Furthermore, amplification efficiency was consistently higher for T-CORTM 8 (#2) reagents, 
with an increased detected change in fluorescence in the FAM channel (FMDV-detection) 
compared to T-CORTM 8 (#1) reagents. 
Although Ag-LFDs displayed reduced analytical sensitivity compared to molecular 
detection methods for FMDV (consistent with Ferris et al. [2009]), data presented in this 
chapter supports the use of Ag-LFDs beyond that of a POCT tool. The ability to detect 
FMDV from these devices following lengthy storage, in addition to Ag-LFDs having 
previously been implicated as a possible transport solution (no requirement for special 
temperature storage requirements) (Fowler et al., 2014), suggests that they may have 
potential use as a simple way to archive samples for later FMDV detection and 
characterisation. For example, they could be useful for the dry, non-hazardous 
transportation of samples from field-settings and FMD-endemic countries to international 
reference laboratories. Similarly, data presented supports the use of FTA® cards for non-
invasive saliva collection, increasing the number of sample types they have displayed 
compatibility with (previous FMDV-specific studies have implicated their use with cell 
culture supernatant and impression smears from epithelium) (Muthukrishnan et al., 2008; 
Madhanmohan et al., 2015). However, samples were only collected up to 5 DPC (for 
animal welfare reasons). In order to ascertain whether FTA® cards are still applicable for 
later stage infection, further evaluation is required. Nonetheless, such methods could 
help to integrate POCTs into current FMD diagnostic strategies, as they provide a means 
to retrospectively confirm the diagnosis made in decentralised settings, by overcoming 
many of the pitfalls associated with sample transportation to centralised laboratories. 
However, further validation is required to assure FMDV inactivation for these alternative 
sample types 
In conclusion, this chapter presents the first analysis of multiple POCT-ready assay 
formats in order to define their current capabilities, benchmarked against the reference 
Chapter 2 
 
63 
 
rRT-PCR. Although this evaluation is specific to the conditions/primers tested in this 
analysis, current POCT-ready rRT-PCR assays display comparable diagnostic performance 
to the reference rRT-PCR (which is maintained without extraction and assuming a 
diagnostic cut-off), forming a viable option for diagnosis of FMD in both field settings and 
low-resource laboratories. RT-LAMP is comparable to the diagnostic rRT-PCR when using 
nucleic acid extraction methods and considering a diagnostic cut-off value, however if 
used in the absence of these may be subject to reductions in analytical sensitivity. 
Consequently, although RT-LAMP is suitable for rapid confirmation of FMD-positives in the 
field, its application to FMDV surveillance may be better suited to low-resource 
laboratories where RNA extraction is possible. The inability to perform rRT-RPA in the 
absence of extraction limits its use to laboratory settings. Based on these analyses, RT-
LAMP and rRT-PCR T-CORTM 8 (#2) reagents were selected as the most appropriate assays 
for POCT, therefore taken forward in this project for subsequent development, evaluation 
and field testing.
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CHAPTER 3 
 
Transitioning isothermal assays into point-of-
care test formats and evaluation of these tests 
in decentralised settings 
 
 
 
Elements of this chapter have been published in the following peer-reviewed article: 
Howson, E.L.A., Armson, B., Madi, M., Kasanga, C.J., Kandusi, S., Sallu, R., Chepkwony, 
E., Siddle, A., Martin, P., Wood, J., Mioulet, V., King, D.P., Lembo, T., Cleaveland, S. 
and Fowler, V.L. (2017c). Evaluation of two lyophilized molecular assays to rapidly detect 
foot-and-mouth disease virus directly from clinical samples in field settings. Transbound 
Emerg Dis, 64(3): 861-71. doi: 10.1111/tbed.12451. 
 
Results from this chapter have been presented at: 
EuFMD Research Group Open Session 2014, Cavtat, Croatia. Oral presentation: Realising 
the potential of simple isothermal molecular tools for field diagnosis of foot-and-mouth 
disease. 
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3.1 Summary 
In order to detect foot-and-mouth disease virus (FMDV) RNA in decentralised settings, it 
is anticipated that assays must fulfil the three steps of a molecular test (sample 
preparation, amplification and detection), be in the format of a ‘ready-to-use kit’ and 
utilise reagents compatible with the environmental conditions found in the countries of 
deployment. In this context, FMDV-specific reverse transcription loop-mediated 
isothermal amplification (RT-LAMP) assays compatible with simple sample preparation 
and visualisation methods have been developed, which share equivalent analytical 
sensitivity with laboratory-based real-time reverse transcription PCR (rRT-PCR). However, 
these tests have not yet been transitioned into stabilised formats, which limits their 
deployment into low-resource laboratories or field settings, as maintenance of a cold-
chain is required. To address this gap, this chapter describes the transfer of RT-LAMP 
assays into lyophilised formats, development of robust field-ready protocols and 
evaluation of these within FMD-endemic settings. Lyophilisation of reagents did not 
adversely affect the performance of RT-LAMP using either real-time analysis (portable 
fluorimeter) or end-point molecular lateral-flow detection. Furthermore, robust field-
ready protocols enabled RT-LAMP assays to detect FMDV RNA from clinical samples taken 
from cattle as early as one day post infection, both in the presence and absence of nucleic 
acid extraction. Importantly, when these RT-LAMP protocols were deployed into 
challenging laboratory and field settings within East Africa, RT-LAMP results (n = 145) 
were consistent with clinical observations and a reference rRT-PCR, with FMDV RNA 
detected in a range of clinical samples (serum, epithelium and oesophageal-pharyngeal 
fluid) from acutely infected, as well as convalescent cattle. These data support the 
deployment of RT-LAMP into decentralised settings to improve local diagnostic capacity 
and provide methods for simple and rapid confirmation of foot-and-mouth disease in the 
field.  
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3.2 Introduction 
The analytical sensitivity, rapidity and easy operation of loop-mediated isothermal 
amplification (LAMP) have resulted in numerous publications detailing the design of 
diagnostic assays for diseases of veterinary importance. For instance, LAMP and reverse 
transcription-LAMP (RT-LAMP) assays have been developed to detect numerous livestock 
pathogens, including African swine fever virus (James et al., 2010), swine vesicular 
disease virus (SVDV) (Blomström et al., 2008), vesicular stomatitis New Jersey virus 
(VSNJV) (Fowler et al., 2016), bluetongue virus (Mulholland et al., 2014; Mohandas et al., 
2015; Maan et al., 2016) and foot-and-mouth disease virus (FMDV) (Dukes et al., 2006; Li 
et al., 2009; Shao et al., 2010; Chen et al., 2011a; 2011b; Yamazaki et al., 2013; Guan 
et al., 2013; Madhanmohan et al., 2013; Waters et al., 2014; Ding et al., 2014; Ranjan et 
al., 2014; Farooq et al., 2015).  
As discussed in Chapter 1, efforts have been made in transitioning some of these FMDV-
specific RT-LAMP assays into point-of-care test (POCT) formats, suitable for use in 
decentralised settings (low-resource laboratories or field settings). Previous publications 
(Dukes et al., 2006; Waters et al., 2014) and results detailed in Chapter 2, demonstrate 
that current FMDV-specific RT-LAMP assays have the potential for use in challenging 
environments, as they are compatible with simple sample preparation, amplification and 
detection protocols. For instance, FMDV-specific RT-LAMP assays can be performed in the 
presence or absence of RNA extraction, are compatible with multiple sample types and 
objective analysis of results can be achieved either in real-time, using a portable 
fluorimeter, or at end-point using molecular lateral-flow devices (LFDs) (Waters et al., 
2014).  
However, currently published assays, even those proposed for use in field settings, have 
been validated using ‘wet’ reagents which contain temperature sensitive enzymes, 
incompatible for storage in low-resource laboratories or field deployment (Dukes et al., 
2006; Shao et al., 2010; Yamazaki et al., 2013; Waters et al., 2014). Furthermore, FMDV-
specific RT-LAMP assays are not yet in commercially available kit formats, requiring 
multiple reagents (often from multiple suppliers) and pipetting stages for reaction 
preparation. Methods are now available to lyophilise reagents, already tested in a number 
of LAMP assays (Boehme et al., 2007; Mair et al., 2013), with benefits including improved 
stability, storage, transportability and ease of use. 
To date, evaluations of FMDV-specific RT-LAMP assays have been restricted to laboratory 
settings, using protocols incompatible with field-use (assays require RNA extraction). 
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Consequently, the capabilities of current RT-LAMP assays for use in decentralised settings 
are poorly defined due to a lack of dedicated validation studies. In order to develop robust 
protocols for successful decentralisation of FMDV-specific assays, evaluation of assays in 
the intended scenarios of use is required (both FMDV surveillance in low-resource 
laboratories and rapid confirmation of FMD in the field). 
This chapter describes the (i) transfer of RT-LAMP assays (Dukes et al., 2006; Waters et 
al., 2014) into lyophilised formats, (ii) development of robust field-ready protocols and 
(iii) evaluation of these in decentralised settings. In order to ascertain the diagnostic 
clinical window of detection (time points post-infection where FMDV RNA can be 
detected), the compatibility of RT-LAMP with different sample types was evaluated 
(epithelial tissue suspensions, serum, oesophageal-pharyngeal [OP] fluid). Assays were 
performed both in low-resource laboratory and field settings in East Africa (Tanzania and 
Kenya), and results were compared against existing POCTs. 
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3.3 Materials and Methods  
3.3.1 Ethics statement 
Clinical samples utilised in this chapter were either archival samples from previous 
experimental studies approved by The Pirbright Institute (TPI) Ethical Review Committee 
under the Animal Scientific Procedures Act (ASPA) 1986 (as amended), or comprised 
samples submitted by endemic countries to the Food and Agricultural Organization (FAO) 
World Reference Laboratory for FMD (WRLFMD) at TPI, UK. Negative bovine epithelium 
was obtained from a UK abattoir as described previously (Chapter 2.3.1).  
Field sampling was carried out in accordance with ASPA guidelines and local country rules. 
For Tanzania, permission was granted from the Tanzania Commission for Science and 
Technology (permit no. 2014-368-ER-2005-141). For Kenya, sampling was carried out as 
part of a training programme run by The European Commission for the Control of Foot-
and-Mouth Disease (EuFMD), with permission from the Kenyan Director of Veterinary 
Services. 
 
3.3.2 Reference real-time reverse transcription PCR 
Laboratory-based: The one-step rRT-PCR, used as the reference test, was performed as 
stated previously (Chapter 2.3.2). This rRT-PCR method is recommended within World 
Organisation for Animal Health (OIE) Manual of Diagnostic Tests and Vaccines for 
Terrestrial Animals (OIE, 2012).  
Decentralised settings: For the reference test in decentralised settings, rRT-PCR was 
performed as previously described (Madi et al., 2012) using an Enigma® Field Laboratory 
(FL) instrument (Enigma Diagnostics Ltd., Salisbury, Wiltshire). This platform integrates 
automated nucleic acid extraction (from 500 µl of sample), thermal cycling and result 
reporting. rRT-PCR reagents were provided in a lyophilised format by Enigma Diagnostics 
Ltd. Within field settings, the Enigma® FL was powered via a 15 V connection with a 
vehicle auxiliary (Figure 3.1), within low-resource laboratory settings, the Enigma® FL was 
mains powered. 
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Figure 3.1 Real-time reverse transcription PCR in decentralised settings. (A) low-resource 
laboratory (Sokoine University of Agriculture, Morogoro, Tanzania) and (B) field-settings 
in a Maasai herd (Morogoro, Tanzania). 
 
3.3.3 Reverse transcription loop-mediated isotheral amplification 
Laboratory-based: Real-time RT-LAMP (rRT-LAMP) and RT-LAMP combined with lateral-
flow detection (RT-LAMP-LFD) were performed as stated previously (Chapter 2.3.4). 
Reactions were incubated using either a Genie® II (OptiGene Ltd., Horsham, UK) (Figure 
3.2) or bench-top real-time PCR machine (Stratagene Mx3005PTM: Agilent Technologies, 
CA, USA). Following incubation, all annealing analysis was performed as previously stated 
using the Genie® II (Chapter 2.3.4) (Figure 3.2). 
Lyophilised reagents were developed by OptiGene Ltd. using isothermal master mix ISO-
001 with the addition of primers (as stated previously in Chapter 2.3.4), stabilising sugars 
and Avian Myeloblastosis Virus (AMV) reverse transcriptase. Lyophilised pellets were re-
suspended with 15 µl of re-suspension buffer, 5 µl sample and made up to 25 µl total 
volume with nuclease-free water (NFW). Reactions were performed in duplicate on the 
Genie® II, using the parameters as described above. 
  
A B 
Chapter 3 
 
71 
 
 
Figure 3.2 Real-time reverse transcription loop-mediated isothermal amplification (rRT-
LAMP) reactions viewed using Genie® Explorer v0.2.1.1 software (OptiGene Ltd.). (A) rRT-
LAMP amplification curve; (B) rRT-LAMP amplification rate (time to positivity is called at 
the peak rate of amplification); (C) rRT-LAMP amplicon anneal derivative (anneal 
temperature is called at the peak of change in fluorescence). 
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Decentralised settings: In decentralised settings (Figure 3.3), RT-LAMP and RT-LAMP-LFD 
were performed on the Genie® II using the lyophilised reagents as described above.  
 
Figure 3.3 Real-time reverse transcription loop-mediated isothermal amplification during 
field evaluation in a Maasai herd (Morogoro, Tanzania).  
 
3.3.4 Antigen-detection lateral-flow devices 
In the field, in addition to a reference rRT-PCR (Engima® FL), rRT-LAMP and RT-LAMP-LFD 
results were compared against an existing, commercially available POCT, the SVANODIP® 
FMDV-Ag LFD (Boehringer Ingelheim, Bracknell, UK). Six drops of homogenised epithelium 
from the SVANODIP® FMDV-Ag Extraction Kit (Ag-LFD) (Boehringer Ingelheim) were added 
to the Ag-LFD as previously published (Ferris et al., 2009) and following manufacturer’s 
guidelines. Ag-LFDs were incubated for 10 minutes at ambient temperature prior to 
interpretation of results. A positive result was indicated by the presence of two visual 
bands (FMDV-test line and LFD-control line, Figure 3.4A), a negative result was indicated 
by the presence of a single band (LFD control line, Figure 3.4B). 
 
 
Figure 3.4 Interpreting the results of antigen-detection lateral-flow devices. (A) foot-
and-mouth disease virus (FMDV)-positive results were indicated by the presence of both 
a test line (T-line) and a control line (C-line); (B) FMDV-negative results were indicated 
by the presence of a control line only.  
  
A B 
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3.3.5 Laboratory evaluation of rRT-LAMP and RT-LAMP-LFD reagents 
All samples for laboratory evaluation of rRT-LAMP and RT-LAMP-LFD are summarised in 
Appendix 3a. 
 
Initial determination of assay performance: 
The analytical and diagnostic sensitivities of the wet rRT-LAMP and RT-LAMP-LFD reagents 
had been previously evaluated and described in Chapter 2.4.2. To select the best reagents 
for lyophilisation, an initial comparison of ISO-001 and ISO-004 master mixes (OptiGene 
Ltd.) were compared in wet and lyophilised formats using a dilution series of RNA 
extracted from a FMDV cell culture isolate (as described in Chapter 2.3.6) (Appendix 1b). 
The analytical sensitivities of the selected lyophilised rRT-LAMP and RT-LAMP-LFD 
reagents were then established using both an artificial RNA standard and RNA extracted 
from a FMDV cell culture isolate (as described in Chapter 2.3.6).  
 
Determination of the diagnostic window of detection: 
The diagnostic window of detection (time points post-infection when FMDV can be 
detected within clinical samples) was determined using archival experimental bovine sera 
(n = 19) and OP fluid samples (n = 21). In these studies, calves were either challenged 
directly (via intradermolingual injection) or indirectly (via housing with an infected donor 
displaying clinical signs of FMD) with FMDV (isolate O/UKG/34/2001) (DEFRA grant 
SE2814). Samples from this transmission study were collected daily from initial infection 
until six days post challenge (DPC), where cattle reached their experimental end-point 
(lesions present on three feet), and stored at -80°C. Nucleic acid was extracted fresh 
from 200 µl of each sample using the MagNA Pure LC and Total Nucleic Acid Isolation Kit 
(Roche, Burgess Hill, UK) as manufacturer’s instructions. Nucleic acid was eluted in a final 
volume of 50 µl MagNA Pure elution buffer (Roche), which was used as template in rRT-
LAMP (wet) and the reference rRT-PCR. These samples were also used for further 
evaluation of the simple sample preparation procedures (dilution of samples in NFW) 
developed in Chapter 2 on clinical samples (Chapter 2.3.7). 
Archival field epithelial tissue suspensions (prepared at 10% [w/v] in M25 phosphate 
buffer: 35 mM Na2HPO4, 5.7 mM KH2PO4, pH 7.6) were selected based on previous RT-
LAMP validation studies (Waters et al., 2014) and used to evaluate the performance of 
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rRT-LAMP and RT-LAMP-LFD (lyophilised) on epithelial samples (Table 3.1). Again, rRT-
LAMP was evaluated using both extracted RNA (extracted using the MagNA Pure LC / Total 
Nucleic Acid Isolation Kit as above) and using the simple sample preparation procedures 
developed in Chapter 2 (Chapter 2.3.7). 
 
Table 3.1 Clinical epithelial samples used for initial validation of lyophilised reagents 
Serotype Sample Topotype Lineage Location Year 
Asia 1 TUR/2/2013 ASIA Sindh-08 Turkey 2013 
A IRN/24/2012 ASIA Iran-05SIS-10 Iran 2012 
 TUR/7/2013 ASIA Iran-05SIS-10 Turkey 2013 
 TUR/4/2013 ASIA Iran-05SIS-10 Turkey 2013 
SAT 1 TAN/50/2012 I (NWZ) unnamed Tanzania 2012 
SAT 2 TAN/14/2012 IV unnamed Tanzania 2012 
 BOT/15/2012 III unnamed Botswana 2012 
(SAT) Southern African Territories; (NWZ) North West Zimbabwe.  
 
3.3.6 Evaluation of rRT-LAMP on FMDV surveillance samples 
Chapter 2 demonstrated that RT-LAMP was suitable for rapid confirmation of FMD-
positives in the field (using simple sample preparation methods) and FMDV surveillance in 
low-resource laboratories (where RNA extraction is possible). Therefore, the performance 
of rRT-LAMP was evaluated using RNA extracted from FMDV surveillance samples (not all 
samples would be from animals displaying clinical signs of FMD). Archival cattle OP fluid 
field samples (n = 158), collected between September 2011 and November 2013 
(serotypes O, A, Southern African Territories [SAT] 1 and SAT 2), were received from Dr 
Tiziana Lembo and Prof. Sarah Cleveland (The University of Glasgow) from BBSRC project 
BB/H009302/1 (a Combating Infectious Diseases of Livestock for International 
Development [CIDLID] research initiative assessing new approaches for strategic control 
of FMD in East Africa). In addition, archival buffalo samples (serum = 38; OP fluid = 50) 
were received from Dr Nicholas Juleff and Dr Eva Perez (TPI) as part of an African buffalo 
FMDV persistence study within Kruger National Park (KNP) (Maree et al., 2016). In this 
study, buffalo were challenged directly (via intradermolingual injection) with three FMDV 
isolates (KNP/196/91/1 [SAT 1]; KNP/19/89/2 [SAT 2]; KNP/1/08/3 [SAT 3]). OP fluid and 
serum were collected (samples received from the day of challenge up to 109 days post-
challenge) and stored as previously published (Kitching and Donaldson, 1987). For both 
sets of samples, total nucleic acid was extracted using the MagNA Pure LC / Total Nucleic 
Acid Isolation Kit as above (Chapter 3.3.5) and used as template in rRT-LAMP (wet) and 
the reference rRT-PCR. 
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3.3.7 Evaluation of rRT-LAMP and RT-LAMP-LFD in endemic laboratory settings 
To evaluate the performance of assays in low-resource laboratory settings (Sokoine 
University of Agriculture, Morogoro, Tanzania), lyophilised rRT-LAMP/RT-LAMP-LFD (using 
1 in 5 dilutions in NFW), rRT-PCR (Engima® FL) and Ag-LFDs were tested using 14 archival 
epithelial tissue suspensions collected from the field. Samples were provided by The 
Tanzania Veterinary Laboratory Agency (TVLA, Dar es Salaam, Tanzania) and suspensions 
were prepared in phosphate-buffered saline (pH 7.2). Samples represented the following 
serotypes and regions (previously serotyped at TVLA): O (Musoma Rural; Tabora; Mara; 
Njombe; Kilimanjaro; Mtwara), A (Kagera), SAT 1 (Dar es Salaam; Morogoro), SAT 2 
(Morogoro) and three un-typed samples (Figure 3.5).  
 
Figure 3.5 Field sampling locations of the archival epithelial tissue suspensions. These 
suspensions were used for assay evaluation in low-resource laboratory settings. Blue 
points represent the location of small holder farms; green shading represents national 
parks; red shading represents regions. 
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3.3.8 Field evaluation of rRT-LAMP and RT-LAMP-LFD reagents 
Field evaluation was carried out in Tanzania and Kenya, with Ankole-cross, Zebu and 
Zebu-cross cattle. Research locations were selected on the basis of existing collaborations 
with investigators working on the epidemiology of FMD and individual farms were selected 
opportunistically following reports of FMDV infection (Figure 3.6). Serum, OP fluid and 
mouth/foot epithelium (where possible) samples were collected from cattle across 
different stages of infection (acute, convalescent and recovered). For each animal, the 
time since the start of clinical signs was estimated based on aging of the oldest lesion 
(using FAO guidelines [DEFRA, 2005]) and known clinical history (provided by livestock 
owners and veterinary officers). Samples were also collected from cattle in the affected 
herds which were asymptomatic at the time of sampling (with no recent clinical history 
of FMD). The number of samples collected was the maximum amount that could be 
logistically collected in terms of livestock availability and the working time frame.  
In total, samples from 60 individual cattle from 10 farms across East Africa were analysed 
in situ (Appendix 3b). This work comprised eight cattle from two Maasai small holdings 
from the Mvomero and Morogoro Rural Districts (Morogoro Region, Tanzania, June 2014), 
41 cattle from seven small holdings located in the Serengeti District (Mara Region, 
Tanzania, October 2014) and 11 cattle from three farms in Nakuru County, Kenya (October 
2013 and December 2014). Five of the cattle from Serengeti District (Tanzania) were 
sampled on two separate occasions, six days apart. For analysis, cattle were grouped into 
one of four categories: 1-7 days post onset of clinical signs (n = 16), 8-14 days post onset 
of clinical signs (n = 10), 15+ days post onset of clinical signs (n = 27) and clinically normal 
with no recent clinical history of FMDV infection (n = 12). 
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Figure 3.6 Sampling locations in East Africa. Blue points represent the location of small 
holder farms; green shading represents national parks; red shading represents 
regions/counties. 
 
Samples were collected and processed as follows: 
Loose epithelial tissue: Epithelial tissue surrounding ruptured vesicular lesions was 
collected from either the mouth or the feet using sterile forceps and was prepared using 
the SVANODIP® FMDV-Ag Extraction Kit, according to the manufacturer’s instructions. In 
brief, approximately 0.2 g of epithelial tissue was homogenised using the sample 
extraction vial in 1 ml of sample buffer from the SVANODIP® FMDV-Ag LFD kit. The 
homogenate was left to settle for 1 minute and the supernatant added neat to the mobile 
rRT-PCR and Ag-LFD platforms, and processed as previously described prior to rRT-LAMP 
and RT-LAMP-LFD by 1 in 5 dilution in NFW (Waters et al., 2014). 
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Serum: Cattle blood (10 ml) was collected (by veterinarians) from the jugular vein using 
Vacutainer Plus Plastic Serum Tubes (BD, Plymouth, UK). An aliquot was centrifuged using 
an E8 field-based centrifuge (LW Scientific) at 1400 x g for 3 minutes at room 
temperature. Serum was added neat to the mobile rRT-PCR platform and diluted 1 in 5 in 
NFW prior to rRT-LAMP and RT-LAMP-LFD. 
OP fluid: OP fluid was collected using a suitably sized probang cup following OIE guidelines 
(OIE, 2012) (Figure 3.7). OP fluid was added neat to the mobile rRT-PCR platform and 
diluted 1 in 10 in NFW prior to analysis using rRT-LAMP and RT-LAMP-LFD. 
 
 
Figure 3.7 Oesophageal-pharyngeal fluid sampling of a Zebu-cross cow in a Maasai herd 
(Morogoro, Tanzania).  
 
3.3.9 Biosafety procedures in the field 
During field work, a biosafety boundary was established outside of each farm premises, 
to separate livestock-containing areas (considered contaminated) from livestock-free 
areas (considered uncontaminated). This was established to ensure that field work did 
not contribute to the further spread of FMDV. Sample preparation and assay assembly was 
performed inside the contaminated area. Assembled reactions (rRT-LAMP master mix plus 
sample) were surface disinfected with either citric acid (0.2% w/v) or FAM® 30 (1:240) 
prior to transfer to the uncontaminated area where rRT-LAMP on the Genie® II was 
performed. Different personnel were present in these areas to facilitate the transfer of 
samples. Personnel entering the contaminated area donned disposable over-suits, two 
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pairs of gloves and over-shoes, which were surface disinfected as above prior to disposal 
within a bag (along with disposable consumables) for incineration at local laboratory 
facilities. Any non-disposable equipment which was used in the contaminated area (e.g. 
probang cup, forceps, scissors and boots) was suitably surface disinfected prior to transfer 
back to the uncontaminated area. Following each test, and between farms, the Genie® II 
was surface disinfected (as above) and sprayed with DNAZap™ DNA Degradation Solutions 
(Thermo Fisher Scientific). At the end of field work the Genie® II and non-disposable 
equipment was surface disinfected (as above) prior to fumigation with formaldehyde (10 
mg/m3) at 30°C (relative humidity > 70 for > 60 minutes). 
 
3.3.10 Statistical analysis 
Cohen’s Kappa statistic (κ) and the proportion of observed agreement (Aobs) were used to 
measure the agreement between diagnostic tests. All statistical tests were performed in 
the statistical package R (R Core Team, 2014). Cohen’s Kappa statistic (κ) was interpreted 
as published in Landis and Koch (1977).  
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3.4 Results 
3.4.1 Laboratory evaluation of rRT-LAMP and RT-LAMP-LFD 
Initial determination of assay performance: 
During initial optimisation of rRT-LAMP/RT-LAMP-LFD, it was evident that lyophilisation 
of ISO-004 reactions resulted in a reduction of analytical sensitivity (Appendix 1b). 
Consequently, all further evaluation was carried out using the ISO-001 master mix. 
Lyophilised rRT-LAMP/RT-LAMP-LFD ISO-001 reagents maintained equivalent analytical 
sensitivity to their wet counterparts (Chapter 2.4.1) using both an artificial RNA standard 
(101 copies/µl) and RNA extracted from FMDV a cell culture isolate, with the time to 
positivity (TP) consistently reduced for lyophilised reagents (Figure 3.8). 
 
Figure 3.8 Analytical sensitivity of molecular assay formats using (A) an RNA standard and 
(B) dilution series of FMDV RNA. (●) reference real-time reverse transcription (rRT)-PCR; 
(▲) real-time reverse transcription loop-mediated isothermal amplification (rRT-LAMP) 
(wet); (▲) rRT-LAMP (lyophilised). The grey shaded area for the reference rRT-PCR, 
represents cycle threshold values over the diagnostic cut-off threshold of CT < 32 (Shaw 
et al., 2007). Points represent the mean of two replicates (with error bars representing 
range). Half-shading: one replicate positive and the other negative. For RT-LAMP 
combined with lateral-flow detection (RT-LAMP-LFD), the presence of two blue lines 
signifies a positive result (control and test line); the presence of a single band signifies a 
negative result (control line).  
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Determination of the diagnostic window of detection: 
For determination of the rRT-LAMP clinical detection window, FMDV RNA was detected in 
serum from one to four days post-challenge. For OP fluid, FMDV RNA was detected from 
one day post-challenge onwards, until cattle reached their experimental end-point 
(lesions present on three feet) (Figure 3.9). These clinical samples were also used to 
determine how the use of simple sample preparation procedures developed in Chapter 2 
affected the diagnostic window for detection. By diluting sera 1 in 5 in NFW, high 
agreement with the reference rRT-PCR (using extracted RNA) was achieved, with FMDV 
RNA detected in 17/19 FMDV-positive samples (κ = 0.791, p < 0.001, Aobs = 0.895). For OP 
fluid, 1 in 10 dilutions enabled FMDV RNA to be detected in 19/21 FMDV-positive samples, 
again displaying high agreement with the reference rRT-PCR (using extracted RNA) (κ = 
0.741, p = 0.005, Aobs = 0.905). The four discordant samples (serum = 2; OP fluid = 2) 
displayed high reference rRT-PCR CT values (Figure 3.9). For both sample types, the TP 
values were consistently higher when using simple sample preparation methods 
comparatively to extracted nucleic acid (Figure 3.9).  
 
Figure 3.9 Determination of the clinical detection window for real-time reverse 
transcription loop-mediated isothermal amplification (rRT-LAMP) (wet) (B), compared 
against the reference real-time reverse transcription PCR (rRT-PCR) (A). Samples were 
either used following RNA extraction or dilution in nuclease-free water (NFW). For serum 
samples: (●) rRT-PCR (extracted nucleic acid); (●) rRT-LAMP (extracted nucleic acid); (●) 
rRT-LAMP (1 in 5 NFW dilution). For OP fluid samples: (■) rRT-PCR (extracted nucleic 
acid); (■) rRT-LAMP (extracted nucleic acid); (■) rRT-LAMP (1 in 10 NFW dilution). Points 
represent the mean of the four animals (each with two replicates); half-shaded points 
represent points with a mix of positive and negative results. Bars represent standard 
deviation. Samples were collected up to day six days post challenge, when cattle reached 
their experimental end-point (lesions present on three feet). A diagnostic cut-off of CT < 
32 (Shaw et al., 2007) was used to distinguish between rRT-PCR positive and negatives. 
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FMDV RNA was detected in all archival epithelial samples following nucleic acid extraction 
(data not shown). When epithelial suspensions were added to lyophilised ISO-001 rRT-
LAMP and RT-LAMP-LFD following 1 in 5 dilution in NFW, positive amplification was 
observed for all FMDV serotypes evaluated (Table 3.2). 
 
Table 3.2 Results for lyophilised rRT-LAMP evaluation on clinical epithelial samples 
Serotype Sample rRT-LAMP*  (Ta) RT-LAMP-LFD 
Asia 1 TUR/2/2013 10.24 (88.86) Positive 
A IRN/24/2012 8.54 (88.84) Positive 
 TUR/7/2013 11.09 (88.89) Positive 
 TUR/4/2013 10.54 (89.21) Positive 
SAT 1 TAN/50/2012 16.54 (89.41) Positive 
SAT 2 TAN/14/2012 11.24 (89.29) Positive 
 BOT/15/2012 12.39 (89.11) Positive 
N/A Negative epithelium No Tp (No Ta) Negative 
(SAT) Southern African Territories; (NWZ) North West Zimbabwe; (rRT-PCR) real-time reverse 
transcription PCR; (rRT-LAMP): real-time reverse transcription loop-mediated isothermal 
amplification; (Ta) Anneal temperature; (TP) time to positivity; (RT-LAMP-LFD) RT-LAMP combined 
with lateral-flow detection; (Ag-LFD) Antigen-detection lateral-flow device. *Reagents used in a 
lyophilised format. All samples were epithelial suspensions. 
 
3.4.2 Evaluation of rRT-LAMP on FMDV surveillance samples 
For evaluation of rRT-LAMP on archival FMDV surveillance samples, RNA was extracted 
from 246 longitudinal field study samples (cattle = 158; buffalo = 88). High agreement 
was present between rRT-LAMP (wet) and the reference rRT-PCR (κ = 0.900, p < 0.001, 
Aobs = 0.956) in the presence of an rRT-PCR diagnostic cut-off (CT < 32; Shaw et al., 2007). 
However, when comparing rRT-LAMP to rRT-PCR (no diagnostic cut-off), agreement was 
reduced (κ = 0.714, p < 0.001, Aobs = 0.861), with false negative rRT-LAMP samples 
consistently having high rRT-PCR CT values (between 30.68 and 49.55) (Figure 3.10). 
Similar results were evident for buffalo OP fluid and serum samples, with high agreement 
present when a diagnostic cut-off was employed in rRT-PCR (κ = 0.930, p < 0.001, Aobs = 
0.966) comparatively to rRT-PCR with no diagnostic cut-off (κ = 0.697, p < 0.001, Aobs = 
0.863) (Figure 3.11). As such, rRT-LAMP assay performance was comparable to rRT-PCR 
considering a diagnostic cut-off, however was subject to reductions in analytical 
sensitivity if used in its absence. 
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Figure 3.10 Evaluation of rRT-LAMP as a laboratory surveillance tool. Graph shows the 
concordance between the reference real-time reverse transcription PCR (rRT-PCR) and 
real-time reverse transcription loop-mediated isothermal amplification (rRT-LAMP). 
Evaluation was performed over: () 158 oesophageal-pharyngeal fluid samples collected 
from cattle; () 50 oesophageal-pharyngeal fluid samples collected from buffalo; (◯) 38 
serum samples collected from buffalo. The grey shaded area highlights reference rRT-PCR 
CT values over the FMDV diagnostic threshold of CT < 32 (Shaw et al., 2007). Each point 
represents the mean of two replicates. 
 
3.4.3 Evaluation of rRT-LAMP and RT-LAMP-LFD in endemic laboratory settings 
Fourteen archival epithelial tissue suspensions, representing four FMDV serotypes and 
nine locations across Tanzania, were used to compare the performance of POCTs on 
clinical samples within a local laboratory setting in an FMD endemic region (Table 3.3). 
Complete agreement was evident between RT-LAMP and RT-LAMP-LFD assay results (using 
1 in 5 dilutions of epithelial tissue suspensions in NFW), which were both in high 
agreement with rRT-PCR results using the Enigma® FL (κ = 0.759, p = 0.033, Aobs = 0.929) 
(Table 3.3). Ag-LFDs showed reduced sensitivity, with three rRT-LAMP/RT-LAMP-LFD 
FMDV-positive samples called as negative (Table 3.3). 
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Table 3.3 Epithelial tissue suspensions used for low-resource laboratory evaluation 
Serotype Location 
(region) 
Enigma® FL* 
rRT-PCR 
rRT-LAMP*  (Ta) RT-LAMP-LFD Ag-LFD 
O Musoma Rural  25.00 8.50  (88.81) Positive Weak positive 
 Tabora 32.00 12.75  (88.82) Positive Negative 
 Tabora 25.00 8.75 (88.60) Positive Negative 
 Mara 26.00 8.75 (89.00) Positive Strong positive 
 Njombe 23.00 9.00 (89.20) Positive Weak positive 
 Kilimanjaro 31.00 10.00 (88.76) Positive Weak positive 
 Mtwara 23.00 14.00 (88.86) Positive Weak positive 
A Kagera No CT 9.00  (89.12) Positive Weak positive 
SAT 1 Dar es Salaam 28.00 15.00  (89.31) Positive Negative 
 Morogoro 27.00 8.50  (89.10) Positive Weak positive 
SAT 2 Morogoro 27.00 10.00 (88.90) Positive Weak positive 
Un-typed Unknown 32.00 10.00 (88.46) Positive Positive 
 Kilimanjaro No CT No Tp (No Ta) Negative Negative 
 Kilimanjaro No CT No Tp (No Ta) Negative Negative 
(Enigma® FL) Enigma® Field Laboratory; (rRT-PCR) real-time reverse transcription PCR; (rRT-LAMP) real-
time reverse transcription loop-mediated isothermal amplification; (Ta) Anneal temperature; (RT-LAMP-
LFD) RT-LAMP combined with lateral-flow detection; (Ag-LFD) Antigen-detection lateral-flow device. 
*Reagents used in a lyophilised format. 
 
3.4.4 Field evaluation of rRT-LAMP and RT-LAMP-LFD reagents 
The Genie® II and rRT-LAMP / RT-LAMP-LFD protocols devised in the laboratory were 
trialled on 145 samples, from 60 cattle, across 10 farms in East Africa (five cattle sampled 
on two occasions) (Figure 3.11 and 3.12).  
 
Figure 3.11 Characteristic foot-and-mouth disease lesions observed in cattle. (A) un-
ruptured lesion in the interdigital cleft with vesicular fluid present in the blister (1 day 
post onset of clinical signs); (B) ruptured dental pad lesions (2 days post onset of clinical 
signs); (C) healing lesions on the dental pad and gum (8-10 days post onset of clinical 
signs); (D) ruptured lesion in the interdigital cleft (2 days post onset of clinical signs); (E) 
tongue epithelium sloughed off after lesion rupture (3 days post onset of clinical signs); 
(F) un-ruptured lesions on the teats (1 day post onset of clinical signs). 
 
 
 
 
 
 
A 
D 
B 
E 
C 
F 
Chapter 3 
 
85 
 
 
Figure 3.12 Epidemiological tracing of foot-and-mouth disease (FMD) outbreaks in 
Serengeti Area, Tanzania (October 2014). Points represent the location of the small-
holder farms; green shading represents national parks; red shading represents 
regions/counties. The dates given indicate the estimated time since the start of clinical 
signs. 
 
For the 16 cattle 1-7 days since onset of clinical signs, rRT-LAMP identified FMDV RNA in 
13/14 epithelial, 11/14 OP fluid and 11/16 sera samples.  Of the ten cattle 8-14 days post 
onset of clinical signs, rRT-LAMP identified FMDV RNA in 8/9 epithelial, 6/9 OP fluid and 
1/10 sera samples. Of the 27 clinically recovered cattle (15+ days post onset of clinical 
signs, based on recent clinical history and aging of the oldest lesion), rRT-LAMP identified 
FMDV RNA in 14/27 OP fluid samples, while all serum samples were negative. Of the 12 
clinically normal cattle sampled (with no recent clinical history of FMDV infection), all OP 
fluid and sera samples were negative in rRT-LAMP (Appendix 3b). High agreement was 
evident between rRT-LAMP and RT-LAMP-LFD for all sample types: sera (κ = 0.837, p < 
0.001, Aobs = 0.947), OP fluid (κ = 0.852, p < 0.001, Aobs = 0.926) and epithelial samples (κ 
= 0.646, p = 0.123, Aobs = 0.957). All test results were consistent with clinical observations 
(Figure 3.13 and 3.14). 
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Figure 3.13 In situ (a) real-time reverse transcription loop-mediated isothermal 
amplification (rRT-LAMP) and (b) RT-LAMP combined with lateral-flow detection (RT-
LAMP-LFD) results for 145 samples. Cattle were either acutely infected with foot-and-
mouth disease (FMD), displayed healing FMD lesions, were clinically recovered from FMD 
or were clinically asymptomatic (with no recent clinical history of FMD). (OP fluid) 
oesophageal-pharyngeal fluid; (black) positive result; (white) negative result; (NT) not 
tested; (Ta) anneal temperature, amplification was evident however the Ta was outside 
of the accepted range. Each column represents one animal; rows represent sample type. 
For some animals more than one epithelial sample was tested, grey squares represent a 
mix of positive and negative results. a-eThe five animals sampled on two occasions, six 
days apart. The onset of clinical signs was estimated based on the aging of the oldest 
lesion and known clinical history of FMD. *Potential mis-aged lesion. 
* 
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Samples that were positive in rRT-LAMP but negative in RT-LAMP-LFD (n = 6) were 
consistently associated with high rRT-LAMP TP values (Appendix 3b). Two samples were 
positive in RT-LAMP-LFD but negative in rRT-LAMP. One of these (an epithelial sample) 
displayed rRT-LAMP amplification, however the Ta value was out of the accepted 
temperature range by 0.18°C (Ta = 89.68).  
 
Figure 3.14 In situ real-time reverse transcription loop-mediated isothermal 
amplification (rRT-LAMP) results for the 145 East African samples. Time to positivity (TP) 
is indicated for rRT-LAMP (average across two replicates). (CH) clinical history of FMD, 
for instance animal had signs of FMD one to two months previously; (NCS) no clinical signs 
or recent history of FMD. 1Amplification was evident however the anneal temperature (Ta) 
was outside of the accepted range (Ta = 89.68); 
2Lesion material collected was not a 
sufficient amount for processing. 
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During POCT evaluation, there was no access to a laboratory-based rRT-PCR machine, 
therefore comparison against the reference rRT-PCR was performed as previously 
described (Madi et al., 2012) using an Enigma® FL. High agreement was present between 
molecular tests across the 34 samples tested (13 epithelium; 17 OP fluid; 4 sera): rRT-
LAMP and rRT-PCR (κ = 0.635, p < 0.001, Aobs = 0.853) and RT-LAMP-LFD and rRT-PCR (κ = 
0.781, p < 0.001, Aobs = 0.912) (Figure 3.15).  
 
Figure 3.15 Comparison between real-time reverse transcription PCR (rRT-PCR) (Enigma® 
Field Laboratory [FL]) and real-time reverse transcription loop-mediated isothermal 
amplification (rRT-LAMP) (Genie® II) on field samples tested in situ within Tanzania 
(Serengeti District and Morogoro). Colour is representative of sample type, (grey) 
epithelial tissue suspensions [n = 13]; (blue) oesophageal-pharyngeal fluid [n = 17]; (red) 
serum [n = 4]. Samples were added neat to the rRT-PCR and diluted in nuclease-free 
water prior to analysis in rRT-LAMP.  
 
In addition, 23 epithelial samples were assayed using Ag-LFDs, with only slight agreement 
evident between both rRT-LAMP and Ag-LFD (κ = 0.008, p = 0.486, Aobs = 0.522) and RT-
LAMP-LFD and Ag-LFD results (κ = 0.095, p = 0.332, Aobs = 0.565). Out of 12 rRT-PCR 
positive epithelial samples, five were negative by Ag-LFD (Appendix 3b).  
Four clinical samples (two epithelial and two vesicular fluid) from two of the acutely 
infected cattle tested (tag numbers 7804 and 7805) in the Serengeti District, Tanzania 
were also shipped to WRLFMD for characterisation. All four samples were confirmed 
positive for FMDV using rRT-PCR and were typed as serotype SAT 1 by antigen capture 
enzyme-linked immunosorbent assays (Ferris and Dawson, 1988) (data not shown). 
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3.5 Discussion 
Robust and rapid diagnosis of FMD is essential for the effective implementation of disease 
monitoring, control and eradication strategies. However, previous publications which 
highlight RT-LAMP as a potential POCT-ready solution describe reagents and protocols 
unsuitable for field deployment or use in low-resource laboratories (Dukes et al., 2006; 
Shao et al., 2010; Yamazaki et al., 2013; Waters et al., 2014). This chapter describes the 
development, evaluation and deployment of lyophilised RT-LAMP reagents and protocols 
suitable for decentralised detection of FMDV. 
Lyophilisation of ISO-001 RT-LAMP reagents had no negative impact on assay performance, 
with both rRT-LAMP and RT-LAMP-LFD maintaining comparable analytical sensitivity to 
their equivalent wet formats. Furthermore, the TP for lyophilised reagents was 
consistently lower (improved) than the wet formats, providing further support for the 30 
minute incubation time as discussed in Chapter 2. When assessing RT-LAMP as a laboratory 
surveillance tool, and consistent with the results detailed in Chapter 2, RT-LAMP assay 
performance was comparable to the diagnostic rRT-PCR when considering a diagnostic 
cut-off value (Shaw et al., 2007) and using extracted nucleic acid, however was subject 
to reductions in analytical sensitivity if used in the absence of these. Although cut-off 
values are often implemented in rRT-PCR to mitigate against false-positive results, 
duplicate samples that fall within the borderline range (CT: 32-50) also require careful 
monitoring for low levels of FMDV (Shaw et al., 2007).  
Validation of RT-LAMP assays in low-resource laboratory settings highlighted their 
potential to improve the diagnostic capacity within low-to-middle income countries 
(LMICs). At present, laboratories within these settings are often constrained by limited 
laboratory capacity (skilled personnel and availability of technologies/consumables), 
cumbersome procurement systems and poor transport links (that affect maintenance of 
the cold chain). The provision of lyophilised reagents within disposable consumables, in 
addition to simple reporting procedures, helps to address these issues by (i) negating the 
need to order reagents and consumables from multiple suppliers, (ii) simplifying reagent 
storage requirements and (iii) minimising user intervention, thus opening up sensitive 
molecular technologies to unskilled staff. Furthermore, the use of portable platforms, 
such as the Genie® II, can be mains or battery powered, thereby removing the 
requirement for a continual mains power supply which can be unreliable in low-resource 
laboratories. As such, since the evaluation of rRT-LAMP in SUA, a Genie® II and lyophilised 
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reagents have been purchased by the laboratory, who are trialling rRT-LAMP for routine 
FMDV detection. 
When deployed for field validation, both RT-LAMP assay formats generated results 
consistent with clinical observations and Enigma FL® rRT-PCR results, enabling FMDV RNA 
to be detected across the FMD clinical window from acute infection, to delayed viral 
clearance (after field evaluation, Enigma Diagnostics Ltd. liquidated, therefore the 
Enigma® FL was not taken forward for further evaluation). In total, samples from 66 cattle 
across 12 endemic field settings within East Africa were tested. The early detection of 
FMDV was further substantiated by data obtained from samples collected from 
experimentally infected animals, where FMD-positive results were generated from serum 
and OP fluid collected at the onset of clinical signs.  
During both laboratory and field trials (and consistent with data in Chapter 2), the use of 
simple sample preparation procedures led to small reductions in sensitivity. 
Consequently, although simple sample preparation procedures enable rapid confirmation 
of FMD-positives in the field using RT-LAMP, confirmation of FMD-negatives remains a 
challenge and is an area where future improvements could be targeted. However, in all 
these studies, molecular assays consistently outperformed Ag-LFDs, displaying higher 
analytical sensitivity (even in the absence of RNA extraction) and compatibility with a 
greater number of clinical sample types. Ag-LFDs do however remain useful for 
confirmation of FMD positive animals during the acute stage of clinical infection (using 
epithelial samples) and were consistent with molecular assay results under these 
circumstances. 
Field validation highlighted a number of important factors to consider for future protocol 
design specific to the use of rRT-LAMP and RT-LAMP-LFD in situ. For example, appropriate 
sample collection is required to ensure (i) sufficient amount of material is available for 
processing and (ii) samples collected are not contaminated with soil (e.g. foot epithelium) 
or blood/bolus/rumen fluid (OP fluid) and (iii) serum samples are collected and processed 
appropriately to prevent haemolysis. Although LAMP is consistently reported to show 
increased tolerance to inhibitors compared to PCR (Poon et al., 2006; Waters et al., 
2014), high levels of contaminants in samples may increase false-negative (reaction 
inhibition) or false-positive results (non-specific amplification). Furthermore, although 
this chapter demonstrated the suitability of epithelium, serum and OP fluid for FMD 
diagnosis, in order to extend the diagnostic window of detection (increase the time points 
in which FMD can be detected), alternative sample types (e.g. mouth / nasal swabs) may 
be suitable when epithelial material cannot be collected.  
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The requirement to open RT-LAMP-LFD reactions post-amplification for end-point analysis 
leads to a high cross-contamination risk, especially where unskilled hands are involved. A 
prototype closed RT-LAMP-LFD system, the AMPlite®, has recently been developed by The 
Animal and Plant Health Agency (APHA, Addlestone, UK) to minimise this risk (see 
Appendix 4 for preliminary validation). However further validation and commercialisation 
of this prototype device is required. 
In conclusion, this chapter presents the development and evaluation of lyophilised FMDV-
specific rRT-LAMP and RT-LAMP-LFD assays. Both assays were highly compatible with field 
use, with robust chemistry conditions negating the requirement for RNA extraction. 
Furthermore, rRT-LAMP and RT-LAMP-LFD offer advantages over current POCT assays by 
being applicable for use with a larger number of sample types (Ag-LFDs are compatible 
with epithelium and vesicular fluid only), thus increasing the temporal diagnostic window 
of detection Consequently, RT-LAMP provides a realistic solution for simple and rapid 
confirmation of FMD in field settings and pan-FMDV surveillance in LMICs. Therefore, this 
chapter demonstrates an important transition for FMDV-specific molecular assays into 
formats suitable for decentralised deployment.  
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CHAPTER 4 
 
Direct detection and characterisation of foot-
and-mouth disease viruses in East Africa using 
a portable real-time PCR platform 
 
 
 
Elements of this chapter have been published in the following peer-reviewed article: 
Howson, E.L.A., Armson, B., Lyons, N.A., Chepkwony, E., Kasanga, C.J., Kandusi, S., 
Ndusilo, N., Yamazaki, W., Gizaw, D., Cleaveland, S., Lembo, T., Rauh, R., Nelson, W.M., 
Wood, B.A., Mioulet, V., King, D.P and Fowler, V.L. (2017d). Direct detection and 
characterisation of foot-and-mouth disease virus in East Africa using a field-ready real-
time PCR platform. Transbound Emerg Dis. doi: 10.1111/tbed.12684 [Epub ahead of 
print]. 
 
Results from this chapter have been presented at: 
North American PRRS Symposium 2016, Chicago, USA. Poster presentation: Progress in the 
development of real‐time RT-PCR assays for detection of foot‐and‐mouth disease. 
North American PRRS Symposium 2015, Chicago, USA. Poster presentation: Mobile rRT-
PCR for rapid diagnosis of foot-and-mouth disease. 
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4.1 Summary 
The requirement for accurate and rapid diagnosis during foot-and-mouth disease (FMD) 
outbreaks, and the need to establish laboratory testing capacity in FMD-endemic 
countries for the detection and characterisation of FMD virus (FMDV), has motivated the 
development of simple diagnostic platforms and assays to support local decision making. 
Despite this, these platforms and assays largely remain in the research and development 
phase (with the exception of lateral-flow devices for antigen detection) and are largely 
restricted to pan-FMDV diagnosis. Using a commercially available portable thermocycler, 
the T-CORTM 8, this chapter describes the laboratory and field evaluation of a 
commercially available, lyophilised pan-FMDV real-time RT-PCR (rRT-PCR) assay and a 
recently developed lyophilised FMDV-typing assay (East Africa-specific for serotypes: O, 
A, Southern African Territories [SAT] 1 and 2). Laboratory evaluation showed that the 
analytical sensitivity of the lyophilised pan-FMDV and typing rRT-PCR assays were 
comparable to their laboratory-based equivalents. Furthermore, the FMDV-typing rRT-
PCR produced serotyping data for 33 of 36 FMDV reference samples, with no cross-
reactivity between serotypes detected. Both lyophilised rRT-PCR assays were able to 
accurately detect FMDV RNA across a large diagnostic clinical window of detection by 
being compatible with a range of clinical sample types, including epithelial tissue 
suspensions, serum, oesophageal-pharyngeal (OP) fluid and oral swabs, both with and 
without the use of nucleic acid extraction. When deployed in low-resource laboratory and 
field settings in Tanzania, Kenya and Ethiopia, the lyophilised pan-FMDV rRT-PCR was 
used to diagnose 144 samples collected from 78 cattle either clinical, convalescent or 
FMDV-negative). Field results were consistent with clinical observations and a reference 
laboratory-based rRT-PCR. During field evaluation, the FMDV-typing assay identified the 
serotype of all 24 FMDV-positive samples with a pan-FMDV CT value of less than 29, rapidly 
confirming active outbreaks of both serotypes O and A. Throughout field evaluation, no 
false-positives were evident in either lyophilised assay for clinically normal animals. 
These data support the use of portable rRT-PCR platforms in non-specialised, resource-
limited settings for simple, highly sensitive and rapid detection and/or characterisation 
of FMDV. 
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4.2 Introduction 
The high sample throughput and analytical sensitivity associated with real-time reverse 
transcription PCR (rRT-PCR) have resulted in the technique being adopted by numerous 
diagnostic laboratories as a principal tool for the detection of veterinary pathogens (OIE, 
2012). For instance, during the UK 2007 foot-and-mouth disease (FMD) outbreak, of 3246 
clinical samples submitted to the UK National Reference Laboratory for FMD (The Pirbright 
Institute [TPI]), 99.1% were assayed using rRT-PCR, while only 21.8% were analysed by 
the “gold-standard” virus isolation assay (Reid et al., 2009). However, the requirement 
for dedicated laboratory facilities, extensive equipment (nucleic acid extraction methods 
and thermocyclers) and highly trained personnel, impacts on the feasibility of using rRT-
PCR in resource-limited settings and non-specialised facilities. The development of simple 
assays for FMD virus (FMDV) detection, monitoring and characterisation therefore remains 
an ongoing research effort. 
As discussed in Chapter 1, there has been progress to transition rRT-PCR into formats 
suitable for use in decentralised settings (Belák et al., 2010), with numerous publications 
detailing portable rRT-PCR platforms for FMDV detection (Donaldson et al., 2001; 
Callahan et al., 2002; Hearps et al., 2002; King et al., 2008; Paixão et al., 2008; Madi et 
al., 2012; Ambagala et al., 2016; Goller et al., 2017). Furthermore, lyophilised pan-FMDV 
rRT-PCR assay kits are now available for a number of these platforms, increasing the 
compatibility with low-resource laboratory and field settings (Boyle et al., 2004). 
However, current assay formats and platforms are limited by low sample throughput, the 
requirement for RNA extraction (and thus methods and equipment to perform this) or are 
commercially unavailable. Chapter 2 introduced a newly developed, commercially 
available, lyophilised pan-FMDV rRT-PCR assay (TC-9092-064; Tetracore Inc., MD, USA) 
which showed compatibility with crude sample preparation procedures, such as dilution 
of sample in nuclease-fee water (NFW). Additionally, this assay displayed diagnostic 
performance above that of alternative isothermal solutions. When combined with the T-
CORTM 8 (Tetracore Inc.), a commercially available, portable, battery-powered 
thermocycler (Almassian et al., 2013), this rRT-PCR assay offer a realistic possibility for 
decentralised FMD diagnosis, however further development and evaluation is required.  
To date, evaluation of portable rRT-PCR platforms has only been performed using pan-
FMDV assay formats. However, in order for effective FMD control mechanisms to be 
implemented (for instance selection of appropriate vaccine strains) it is important to fully 
understand the epidemiological context of the disease, including accurate identification 
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of the particular serotypes present (Sumption et al., 2012). As such, there have been 
efforts to design serotype-specific FMDV rRT-PCR assays. By targeting variable capsid-
coding regions of the FMDV genome, which display high sequence variability even within 
FMDV serotypes, assays can be regionally tailored to detect specific topotypes/strains 
(Giridharan et al., 2005; Ahmed et al., 2012; Reid et al., 2014; Jamal and Belsham, 2015; 
Bachanek-Bankowska et al., 2016; Knowles et al., 2016). The transfer of these FMDV-
typing rRT-PCR assays onto portable platforms could further strengthen the diagnostic 
capacity of resource-limited laboratories by offering a simple solution for rapid and 
improved FMDV characterisation. 
This chapter evaluates the performance of a commercially available lyophilised pan-FMDV 
rRT-PCR assay, and a recently lyophilised East Africa-specific typing assay (Bachanek-
Bankowska et al., 2016), both performed on a commercially available portable 
thermocycler. In order to maximise the diagnostic clinical window of detection (points at 
which FMDV RNA can be detected following infection), it was important to evaluate these 
assays on a number of different sample types (epithelial tissue suspensions, serum, 
oesophageal-pharyngeal [OP] fluid). This chapter also evaluated the use of swabs in 
scenarios where it was not possible to collect epithelial material from ruptured lesions. 
Evaluation was performed within laboratory (UK, Kenya and Tanzania) and East African 
field settings (Kenya, Tanzania and Ethiopia), providing an approach that can both detect 
and type FMDV in situ using molecular methods.   
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4.3 Materials and Methods 
4.3.1 Ethics statement 
Clinical samples used in this chapter for laboratory evaluation were either archival 
samples generated in previous in vivo studies approved by The Pirbright Institute (TPI) 
Ethical Review Committee under the Animal Scientific Procedures Act (ASPA), or 
comprised of samples submitted by endemic countries to the to the Food and Agricultural 
Organization (FAO) World Reference Laboratory for FMD (WRLFMD) at TPI. Negative 
bovine epithelium was obtained from a UK abattoir as previously described (Chapter 
2.3.1).  
Field sampling in Tanzania was conducted as part of an ongoing research project under 
the Wellcome Trust Intermediate Fellowship (WT104017MA), which aligned with the 
standards set in the ASPA guidelines. Sampling in Kenya was carried out as part of a 
training programme run by The European Commission for the Control of Foot-and-Mouth 
Disease (EuFMD), with permission from the Kenyan Director of Veterinary Services. In 
Ethiopia, field sampling was carried out as part of The World Organisation for Animal 
Health (OIE) twinning project “Strengthening the capacity of foot-and-mouth disease 
diagnosis and surveillance in Ethiopia and East Africa”.  
 
4.3.2 Laboratory-based reference real-time reverse transcription PCRs 
Reference pan-FMDV assay: The one-step rRT-PCR, used as the reference test, was 
performed as stated previously (Chapter 2.3.2). At TPI, rRT-PCR was performed on a 
bench top real-time PCR machine (Stratagene Mx3005PTM: Agilent Technologies, CA, USA) 
using nucleic acid extracted using the MagMAX™-96 Viral RNA Isolation Kit (Applied 
Biosystems®, Thermo Fisher Scientific, MA, USA) following an automated procedure on a 
KingFisher™ Flex (Thermo Fisher Scientific). RNA was extracted from 50 µl sample and 
eluted in a final volume of 90 µl MagMAX™ elution buffer (Thermo Fisher Scientific).  
In East African laboratories, RNA was extracted using the QIAamp® Viral RNA Mini Kit 
(Qiagen, Hilden, Germany). RNA was extracted from 140 µl of sample and eluted in a final 
volume of 60 µl QIAamp® buffer AVE (Qiagen). rRT-PCR reactions were performed on 
either a PikoReal™ Real-Time PCR System (Thermo Fisher Scientific) (Foot-and-Mouth 
Disease Laboratory, Kenya) or Applied Biosystems® 7500 fast thermal cycler (Applied 
Biosystems®) (Sokoine University of Agriculture, Tanzania). It was not possible to 
benchmark in Ethiopia as there was no access to a laboratory-based rRT-PCR machine. 
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For all rRT-PCR assays, positive reactions were defined as those which gave a detectable 
cycle threshold (CT) value. 
Reference typing assay: The East-Africa specific typing rRT-PCR assay was performed as 
previously described (Bachanek-Bankowska et al., 2016). Reactions were performed in 
duplicate using extracted nucleic acid (MagMAX™-96 Viral RNA Isolation Kit / KingFisher™ 
Flex) on a bench-top thermocycler (Stratagene Mx3005PTM). This assay was selected as 
the primers designed by Bachanek-Bankowska et al. (2016) were tailored to detect FMD 
viruses currently circulating in East Africa, the setting for field evaluation in this chapter.  
 
4.3.3 Lyophilised real-time reverse transcription PCRs 
Pan-FMDV assay (lyophilised): Pan-FMDV rRT-PCR was performed in duplicate using 
lyophilised T-CORTM 8 (#2) reagents with inhibition control (TC-9092-064, Tetracore Inc., 
MD, USA) as stated previously (T-CORTM 8 [#2]: Chapter 2.3.3). Reactions were performed 
in duplicate on the T-CORTM 8 (Tetracore Inc.). 
Typing assay (lyophilised): The East Africa-specific typing rRT-PCR (Tetracore Inc.) was 
performed using the same chemistry, thermal cycling conditions and parameters as the 
lyophilised pan-FMDV rRT-PCR (T-CORTM 8 [#2] reagents), with primers and probes as 
previously published in Bachanek-Bankowska et al. (2016). Probes for each serotype were 
modified for multiplex detection using the following fluorescence channels: O (Dragonfly 
Orange™ [DFO]), A (6-fluorescein amidite [FAM]), Southern African Territories (SAT) 1 
(Cy®5) and SAT 2 (Texas Red® [TxR]). Reactions were performed in duplicate using the T-
CORTM 8. 
 
4.3.4 Laboratory evaluation of lyophilised rRT-PCR reagents 
Initial determination of assay performance: 
Analytical sensitivity (limit of detection [LOD]) was determined using FMDV RNA extracted 
from four separate decimal dilution series (10-1 to 10-8), each consisting of an FMDV cell 
culture isolate diluted in negative bovine epithelial tissue suspensions (10% [w/v] in M25 
phosphate buffer: 35 mM Na2HPO4, 5.7 mM KH2PO4, pH 7.6). The four cell culture isolates 
selected represented the serotypes currently circulating in East Africa and those targeted 
by the FMDV-typing assay: O/TAN/39/2012 (topotype East Africa-2); A/TAN/6/2013 
(topotype AFRICA, lineage G-I); SAT 1/KEN/72/2010 (topotype I [North West Zimbabwe]); 
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SAT 2/KEN/2/2008 (topotype IV). RNA extraction was performed using the MagMAX™-96 
Viral RNA Isolation Kit / KingFisher™ Flex (as described above in 4.3.2) 
Diagnostic sensitivity of the pan-FMDV reagents had been previously evaluated and is 
described in Chapter 2.4.2. For the typing assay, diagnostic sensitivity was assessed using 
RNA extracted from 36 samples (serotypes O, A, SAT 1 and SAT 2) originating from East 
Africa (Samples from Tanzania and Kenya included in Appendix 5). These samples had 
been previously characterised by WRLFMD using antigen capture enzyme-linked 
immunosorbent assays (Ferris and Dawson, 1988) and sequencing of the VP1 region 
(Knowles and Samuel, 2003). The diagnostic specificity of the typing assay was 
determined using RNA extracted from original epithelial tissue suspensions of the 
following vesicular disease viruses: swine vesicular disease virus (UKG/24/1972; 
UKG/50/1972; UKG/51/1972; UKG/68/1972), vesicular stomatitis Indiana virus (VSIV) and 
vesicular stomatitis New Jersey virus (VSNJV). 
 
Comparison of thermocyclers: 
To ensure that neither the reagents nor the thermocycler used affected the performance 
of assays, RNA was extracted from a dilution series of cell culture isolate FMDV 
O/UAE/2/2003 in negative bovine epithelium (as previously described in Chapter 2.3.6). 
The extracted RNA was used as template in the reference and lyophilised pan-FMDV rRT-
PCRs, performed both on a benchtop (Stratagene Mx3005PTM) and portable (T-CORTM 8) 
thermocycler. 
 
Determination of the diagnostic window for detection: 
The diagnostic window of detection (time points post-infection when FMDV RNA can be 
detected within clinical samples) was determined using RNA extracted from unvaccinated 
intradermolingual needle inoculated cattle, challenged with FMDV isolate A/TAI/17/2016 
(topotype ASIA, lineage Sea-97). Archival samples comprised of serum (n = 11) and mouth 
swabs (n = 11) taken daily from two animals from the day of challenge, and epithelium (n 
= 4) and OP fluid (n = 2) collected from the same animals post-mortem (carried out on 
the day of culling). These samples were also used to further evaluate the simple sample 
preparation procedures (dilution of samples in NFW) developed in Chapter 2 (Chapter 
2.3.7) on clinical samples. 
Chapter 4 
 
100 
 
4.3.5 Field evaluation of lyophilised rRT-PCR reagents 
Field work was carried out in FMD endemic settings, which were selected on the basis of 
existing collaborations with investigators working on the epidemiology of FMD. Samples 
were collected opportunistically from locations where a local animal health worker or 
farmer reported the presence (or recent presence) of clinical signs consistent with FMDV 
infection. Samples (n = 144) from 78 individual cattle over 13 farms across East Africa 
were analysed in situ. The number of samples collected was the maximum amount that 
could be logistically collected in terms of livestock availability and the working time 
frame. This comprised of 13 cattle from two small holdings in Kericho County (Kenya, 
June 2016), 16 cattle from two small holdings in Nakuru County (Kenya, June 2016), 43 
cattle from seven small holdings in Morogoro Rural and Mvomero Districts (Morogoro 
Region, Tanzania, September 2016) and six cattle from two small holdings in Adama 
(Ethiopia, October, 2016) (Figure 4.1, Appendix 6). The samples collected (n = 9) and rRT-
PCR reactions performed in Ethiopia were by carried out by Dr Veronica Fowler (TPI). 
 
Figure 4.1 Sampling locations in East Africa. Blue points represent the location of each 
small holder; green shading represents national parks; red shading represents counties. 
Field sampling locations are representative of FMDV pool 4. 
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Samples were collected from cattle at different stages of infection (acute, convalescent 
and recovered) and included one or more of the following sample types per animal: 
serum, swab, OP fluid and mouth/foot epithelium (Appendix 6). For each animal, the 
time since the start of clinical signs was estimated based on aging of the oldest lesion 
(using FAO guidelines [DEFRA, 2005]) and known clinical history (provided by livestock 
owners and veterinary officers). Cattle from the same herds that had no history or clinical 
signs of FMD at the time of the visit were also opportunistically sampled (n = 12). Samples 
were collected and processed as follows: 
Loose epithelial tissue: Epithelial tissue of ruptured vesicular lesions from either the 
mouth or the feet was prepared using the SVANODIP® FMDV-Ag Extraction Kit and 
SVANODIP® FMDV-Ag LFD kit (Boehringer Ingelheim, Bracknell, UK) as previously described 
(Chapter 3.3.8). Epithelial samples from the feet (interdigital space/coronary band) were 
briefly washed in sterile water prior to processing to remove soil contaminants. The 
homogenate was left to settle for one minute, and then the supernatant was removed 
and diluted 1 in 10 in NFW prior to analysis using lyophilised rRT-PCR. 
Swabs: When collection of epithelial material was not possible (e.g. no loose epithelium 
present), the surface of ruptured lesions in the mouth or on the feet (interdigital 
space/coronary band) were swabbed (GenoTube Livestock: Thermo Fisher Scientific) 
(Figure 4.2). The feet were cleaned in sterile water (as above) prior to swabbing to 
remove soil contaminants. Swabs were agitated by hand in 1 ml NFW, which was then 
used directly in analysis using lyophilised rRT-PCR. 
 
Figure 4.2 Lesion swab sampling of two cattle displaying clinical signs characteristic of 
foot-and-mouth disease (Nakuru, Kenya). Swabs were taken in these instances due to the 
absence of any loose epithelial material on the lesion sites: (A) ruptured lesion on the 
gum; (B) ruptured and healing lesion on the dental pad. 
 
  
A B 
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OP fluid: OP fluid was collected using a suitably sized probang cup following the guidelines 
within the diagnostic manuals of the OIE (2012) and diluted 1 in 10 in NFW prior to analysis 
using lyophilised rRT-PCR. 
Serum: Blood (10 ml) was collected (by veterinarians) from either the jugular or tail vein 
using Vacutainer® Plus Plastic Serum Tubes (BD, Plymouth, UK), or similar. Samples were 
transported back to a local laboratory and centrifuged at 3000 x g for 10 minutes. Serum 
was removed and diluted 1 in 10 in NFW prior to analysis. 
 
4.3.6 Biosafety procedures in the field 
During field work, a biosafety boundary was established and biosafety procedures 
followed as previously stated in Chapter 3 (3.3.9). Between runs and farms the T-CORTM 
8 was surface disinfected (with either citric acid [0.2% w/v] of FAM® 30 [1:240]) and 
sprayed with DNAZap™ PCR DNA Degradation Solutions (Thermo Fisher Scientific). At the 
end of field work the T-CORTM 8 was surface disinfected (as above) prior to fumigation 
with formaldehyde (10 mg/m3) at 30°C (relative humidity > 70 for > 60 minutes). Samples 
for concordance testing were added to MagMAX™-96 Viral RNA lysis buffer within the 
contaminated area, surface disinfected (as above) for transfer to the uncontaminated 
area and transported (double-contained) to appropriate local laboratory facilities on ice. 
 
4.3.7 Statistical analysis 
Cohen's Kappa statistic (κ) and the proportion of observed agreement (Aobs) were used to 
measure the agreement between diagnostic tests. Statistical analyses were performed 
using R (R Core Team, 2014). 
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4.4 Results 
4.4.1 Laboratory evaluation of lyophilised rRT-PCR reagents 
Initial determination of assay performance: 
The analytical sensitivity of the lyophilised pan-FMDV reagents, performed on the T-CORTM 
8, was equivalent to the reference rRT-PCR across the four serotypes tested (both 
consistently detected down to 10-6 for each serotype) (Figure 4.3). The internal control 
was positive in all lyophilised pan-FMDV assays. For the typing assay, analytical sensitivity 
was reduced in comparison to the pan-FMDV reagents, with detection of serotypes A and 
SAT 1 showing a one log10 reduction, and detection of O and SAT 2 displaying a two log10 
reduction in LOD (Figure 4.3).  
 
Figure 4.3 Analytical sensitivity of lyophilised reagents in comparison to the reference 
real-time reverse transcription PCR (rRT-PCR). RNA was extracted from four separate 
dilution series of foot-and-mouth disease virus (FMDV) cell culture isolates: 
O/TAN/39/2012; A/TAN/6/2013; Southern African Territories [SAT] 1/KEN/72/2010; SAT 
2/KEN/2/2008. (●) reference rRT-PCR performed on a benchtop thermocycler; (●) pan-
FMDV lyophilised reagents performed on the T-CORTM 8; (■) typing lyophilised reagents 
performed on the T-CORTM 8. Points represent the mean of two replicates; half-shaded 
points represent that of the replicates, one was positive and the other negative; error 
bars indicate the range. 
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Using the same four FMDV isolates, lyophilised typing reagents (multiplex format) were 
compared to their wet equivalents (singleplex format) (Bachanek-Bankowska et al., 2016) 
(Figure 4.4). The analytical sensitivity was comparable across all four serotypes, with all 
disagreements limited to one of the two replicates (Figure 4.4). 
 
Figure 4.4 Analytical sensitivity of lyophilised East Africa-specific typing reagents in 
comparison to the reference typing real-time reverse transcription PCR (rRT-PCR). Assays 
were performed on RNA extracted from four dilution series of foot-and-mouth disease 
virus (FMDV) cell culture isolates: O/TAN/39/2012; A/TAN/6/2013; Southern African 
Territories [SAT] 1/KEN 72/2010; SAT 2/KEN/2/2008). (■) reference typing rRT-PCR 
performed on a benchtop thermocycler (Bachanek-Bankowska et al., 2016); (■) 
lyophilised typing reagents performed on the T-CORTM 8. Points represent the mean of 
two replicates; half-shaded points represent that of the identical replicates, one was 
positive and the other negative. The error bars indicate the range. 
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Diagnostic sensitivity of the lyophilised pan-FMDV assay was assessed in Chapter 2 across 
43 FMDV-positive samples (previously diagnosed by the WRLFMD) (Chapter 2.4.1), with 
100% concordance evident with the reference rRT-PCR. Diagnostic sensitivity of the 
lyophilised serotype-specific assay was assessed using 36 FMDV-positive clinical field 
samples (previously diagnosed by the WRLFMD), originating from East Africa and six 
epithelial tissue suspension samples representing viruses that cause similar characteristic 
lesions to FMDV. These included swine vesicular disease virus (SVDV: UKG/24/1972; 
UKG/50/1972; UKG/51/1972; UKG/68/1972) and vesicular stomatitis virus (VSV: Indiana 
1 [VSIV]; New Jersey [VSNJV]). Of the FMDV-positive samples, the serotype-specific typing 
assay detected 7/8 serotype A, 9/10 serotype O, 7/7 serotype SAT 1 and 10/11 serotype 
SAT 2 samples (Appendix 5). The three samples for which no serotype was detected 
generated high CT values on the reference rRT-PCR (values of 35.64, 27.18 and 30.65) 
(Figure 4.5) and lyophilised pan-FMDV rRT-PCR (values of 35.50, 29.85 and 32.15). No 
cross-reactivity among serotypes was observed for any of the clinical samples tested, and 
the serotype-specific assay yielded negative results against SVDV, VSNJV and VSIV isolates 
(Appendix 5). 
 
Figure 4.5 Comparison between lyophilised typing reagents and pan-FMDV (foot-and-
mouth disease virus) real-time reverse transcription PCR (rRT-PCR). Diagnostic sensitivity 
was assessed using RNA extracted from a panel of 36 FMDV-positive clinical field samples 
from East Africa. (A) Comparison against the reference rRT-PCR; (B) Comparison against 
lyophilised rRT-PCR. The colour of points indicates serotype: (blue) A; (red) O; (yellow) 
Southern African Territories (SAT) 1; (purple) SAT 2. For both graphs, points represent 
the mean of two replicates.  
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Comparison of thermocyclers: 
Neither the pan-FMDV reagents (reference rRT-PCR or lyophilised rRT-PCR) nor the 
platform used (Stratagene Mx3005PTM or T-CORTM 8) affected analytical sensitivity. Both 
reagents consistently detected down to 10-5 of an FMDV RNA dilution series using both 
platforms (Figure 4.6). The internal control was detected in all lyophilised pan-FMDV 
assays, on both thermocyclers. 
 
Figure 4.6 Comparison between real-time reverse transcription PCR (rRT-PCR) reagents 
and thermocycling platforms. The comparison was performed using a dilution series of 
foot-and-mouth disease virus (FMDV) RNA (isolate O/UAE/2/2003). (A) Reactions 
performed on a bench-top thermocycler (Stratagene Mx3005PTM); (B) Reactions performed 
on the T-CORTM 8. (●) reference rRT-PCR; (●) pan-FMDV lyophilised rRT-PCR. Points 
represent the mean of two replicates (bars indicate range); half-shaded points represent 
that of the identical replicates, one was positive and the other negative. 
 
Determination of the diagnostic window for detection: 
For determination of the clinical detection window (for the lyophilised pan-FMDV 
reagents), FMDV RNA was detected in serum from one to four days post-challenge, mouth 
swabs from two days post-challenge onwards and in all epithelium and OP fluid samples 
collected post-mortem when RNA extraction was performed (Figure 4.7). Using the same 
reagents, the use of simple sample preparation procedures (using 1 in 10 dilutions of un-
extracted clinical samples in NFW) enabled FMDV RNA to be detected in 26/28 FMDV-
positive samples (defined using the reference rRT-PCR with extracted RNA). The two 
discordant samples (false-negatives) had CT values of 35.3 (serum four days post-
challenge) and 29.0 (OP fluid taken post-mortem) when using extracted RNA in the 
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lyophilised pan-FMDV rRT-PCR (Figure 4.7). In comparison, when using simple sample 
preparation procedures (1 in 10 dilution in NFW) for analysis with the reference rRT-PCR, 
FMDV RNA was detected in only 19/28 FMDV-positive samples (data not shown).  
 
Figure 4.7 Determination of the clinical detection window for lyophilised pan-FMDV (foot-
and-mouth disease virus) real-time reverse transcription PCR reagents. Assays performed 
on extracted RNA: (●) serum; (■) mouth swabs; (▲) foot epithelium; (▼) mouth 
epithelium; (♦) oesophageal-pharyngeal (OP) fluid. Assays performed on samples diluted 
1 in 10 in nuclease-free water: (●) serum; (■) mouth swabs; (▲) foot epithelium; (▼) 
mouth epithelium; (♦) OP fluid. Points represent the mean of two animals, each with two 
replicates; half-shaded points represent that of the identical replicates, one was positive 
and the other negative; error bars indicate the standard deviation. (PM) samples collected 
post-mortem (animals were culled at either 5 or 6 days post challenge). 
 
4.4.2 Field evaluation of lyophilised rRT-PCR reagents 
An initial comparison of T-CORTM 8 reagents was performed to ascertain whether the T-
CORTM 8 (#1) reagents were also outperformed by the newer T-CORTM 8 (#2) in field 
settings (evident in laboratory settings in Chapter 2.4.2). This evaluation was performed 
in Kenya, across 41 samples (epithelium [n = 6]; serum [n = 24]; lesion swab [n = 10]; OP 
fluid [n= 1]) (Figure 4.8). For FMDV detection, 40/41 samples were in agreement between 
the two sets of reagents (T-CORTM 8 [#1] reagents did not detect FMDV RNA in one serum 
sample from a cow with acute FMD infection). For T-CORTM 8 (#2) reagents, the internal 
control was amplified in all samples. For T-CORTM 8 (#1) reagents, five FMDV-positive 
epithelial samples had negative internal control results (in these samples FMDV RNA 
detection displayed low CT values between 16.0 and 19.7). As such, all further analysis in 
the field was performed using T-CORTM 8 (#2). 
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Figure 4.8 Comparison between T-CORTM 8 (#1) and (#2) real-time reverse transcription 
PCR (rRT-PCR) reagents in field settings using simple sample preparation methods (1 in 
10 dilution in nuclease-free water). Squares represent the mean of two replicates: (black) 
both positive; (grey) one replicate was positive; (white) both negative. rRT-PCR reactions 
were multiplexed for detection of foot-and-mouth disease virus (FMDV) RNA and an 
exogenous internal control (IC). Each column represents one sample, numbers in grey 
indicate the approximate age of the oldest lesion; (NCS) no clinical signs. 
 
The T-CORTM 8 and the rRT-PCR protocols (using T-CORTM 8 [#2] reagents) developed in 
the laboratory were then taken forward for subsequent field testing, over 144 samples 
from 78 cattle across 13 farms in East Africa (Figure 4.9). 
  
Figure 4.9 Setting up the T-CORTM 8 real-time reverse transcription PCR in field settings 
(two small-holdings in Kenya). 
 
Using the pan-FMDV lyophilised rRT-PCR reagents in combination with the T-CORTM 8, 
FMDV RNA was identified in 5/5 epithelial, 1/1 swab and 3/3 serum samples collected 
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from cattle 1-3 days post initial FMDV infection. Of the cattle 4-7 days post FMDV 
infection, FMDV RNA was identified in 13/14 epithelial, 15/19 swab, 3/4 OP fluid and 
3/29 serum samples collected. Of the cattle where initial FMDV infection occurred 8+ 
days previously (based on recent clinical history and aging of the oldest lesion), FMDV 
RNA was identified in 3/12 OP fluid samples, while all sera (n = 25) and swab (n = 10) 
samples were negative. FMDV was not detected in any OP fluid (n = 8), mouth swab (n = 
2) or sera (n = 12) samples collected from the 12 clinically normal cattle (Figure 4.10, 
Appendix 6). The internal control was amplified in 143/144 samples (The negative result 
was derived from a FMDV-positive lesion swab). 
 
Figure 4.10 In situ real-time reverse transcription PCR (rRT-PCR) results for 144 East 
African samples using lyophilised rRT-PCR reagents (T-CORTM 8). Samples were collected 
from cattle displaying clinical signs of foot-and-mouth disease (FMD), from cattle with a 
clinical history (CH) of FMD in the last two months, and cattle with no clinical signs or 
recent clinical history within the last two months (NCS). Each point represents the mean 
CT for a single sample (tested in duplicate) on the pan-FMD virus rRT-PCR using simple 
sample preparation procedures (1 in 10 dilution in nuclease-free water); half-shaded 
points indicate that out of the replicates, one was positive and the other negative 
(samples that share the same CT will only appear as a single point with individual CT values 
presented within Appendix 6). Positive samples were then tested using the lyophilised 
typing assay, the colour represents the serotype detected: (blue) A; (red) O; (grey) 
serotype not detected.  
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Samples considered positive by the lyophilised pan-FMDV assay (n = 46), in addition to a 
selection of samples from cattle considered clinically normal (n = 7), were subsequently 
characterised using the lyophilised typing assay (using 1 in 10 dilutions in NFW for sample 
preparation), which has been developed to detect all known FMDV strains relevant to this 
region (Bachanek-Bankowska et al., 2016). Of these, 24 were identified as either A or O 
(Figure 4.11). No amplification was present for samples collected from clinically normal 
cattle (Figure 4.10, Appendix 6). FMDV-positive samples where the serotype was not 
detected (n = 22) had pan-FMDV CT values of > 29 (using lyophilised reagents) (Figure 
4.10, Appendix 6). 
 
Figure 4.11 Epidemiological tracing of foot-and-mouth disease (FMD) outbreaks in East 
Africa. Red shading represents regions/counties. (A) Kericho/Nakuru Area, Kenya (June 
2016); (B) Morogoro Area, Tanzania (September 2016). Points represent the small-holders 
sampled: (white) samples negative for FMD; (grey) positive for FMD but serotype could 
not be detected; (red) positive for FMD, serotype O; (blue) positive for FMD, serotype A. 
The dates given indicate the estimated time since the start of clinical signs; (NCS) no 
clinical signs. 
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For comparison, 99 of the samples tested using the lyophilised pan-FMDV rRT-PCR (using 
the T-CORTM 8 with dilution in NFW for sample preparation) were also tested using the 
reference rRT-PCR (using extracted RNA) within local laboratory settings in East Africa. 
High agreement was apparent (κ = 0.864, p < 0.001, Aobs = 0.936) between pan-FMDV 
assays in terms of positive and negative test results (Figure 4.12), with all discordant 
results between tests having CT values of > 36 (Appendix 6), which is at the threshold of 
the analytical sensitivity for both tests. 
 
Figure 4.12 Comparison between real-time reverse transcription PCR (rRT-PCR) field and 
laboratory results. Field assays were performed using lyophilised pan-FMDV (foot-and-
mouth disease virus) rRT-PCR (using dilution in nuclease-free water for sample 
preparation) and laboratory assays were performed using the reference rRT-PCR 
performed in local laboratories (using extracted RNA). Points represent the mean of two 
replicates. 
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4.5 Discussion 
Throughout the ongoing research effort to develop point-of-care tests for the diagnosis 
of FMD, a number of publications have detailed the transfer of FMDV-specific rRT-PCR 
assays onto portable detection platforms (Hearps et al., 2002; Paixão et al., 2008; Madi 
et al., 2012; Howson et al., 2015;). However, current assays are either not commercially 
available or are suitable for research purposes only (i.e. not diagnostic use). This chapter 
evaluates the performance of commercially available, lyophilised FMDV-specific assays, 
in combination with a commercially available portable thermocycler, in laboratory and 
decentralised settings within East Africa (low-resource laboratory and field settings). Such 
tests have the potential to contribute valuable epidemiological information to support 
country-level and regional control programs, such as the Progressive Control Pathway for 
FMD (Sumption et al., 2012). 
As previously discussed in Chapter 3, the provision of reagents in a lyophilised kit format 
simplifies reagent storage by negating the requirement for a cold chain, whilst minimising 
the requirement for skilled personnel and multiple pipetting stages by streamlining assay 
set up (assays only require the addition of a re-suspension buffer and the test sample). 
The lyophilised pan-FMDV reagents, in combination with the T-CORTM 8, maintained 
comparable diagnostic performance to the reference rRT-PCR when evaluated with 
extracted RNA. Furthermore, these reagents were able to detect FMDV RNA from multiple 
clinical sample types, in the presence or absence of nucleic acid extraction, as early as 
one day post-infection. Consequently, they offer a potential solution for molecular-based 
diagnosis in field settings. 
Although T-CORTM 8 (#1) and (#2) reagents displayed comparable sensitivity for FMDV 
detection in the field, in concordance with Chapter 2, amplification of the internal 
control was consistently improved using T-CORTM 8 (#2) reagents. Due to the requirement 
to confirm that FMDV-negative reactions contain an undetectable amount of FMDV RNA 
as opposed to being a result of amplification inhibition, T-CORTM 8 (#2) reagents were 
selected for further evaluation. Throughout field validation of the T-CORTM 8 in East 
Africa, these pan-FMDV lyophilised reagents generated results consistent with clinical 
observations, with FMDV detected in samples from the early onset of infection through to 
delayed viral clearance. Results were gained in less than 1.5 hours from sample 
collection. Furthermore, high concordance was evident between results gained in the 
field (T-CORTM 8 rRT-PCR using dilution of samples in NFW) and local East African 
laboratories (reference rRT-PCR using RNA extraction), with any disagreements 
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associated with samples that had CT values above the diagnostic threshold of CT < 32 
(Shaw et al., 2007).  
Results in this chapter demonstrated that when epithelial material could not be collected 
from ruptured lesions, swabbing the surface of the lesions was sufficient for detecting 
the presence of FMDV, extending the diagnostic window of detection from that shown in 
Chapter 3 (increasing the time points in which FMD can be detected). This is important 
as during outbreaks of FMD and disease surveillance, it is unlikely that all animals would 
be examined during the acute clinical phase (where epithelial samples are most 
appropriate). 
Although the provision of simple FMDV positive/negative results is sufficient for the 
confirmation of FMD during outbreaks, the value of this information is limited in countries 
where FMD is endemic. In these situations, it is beneficial to characterise circulating FMDV 
outbreaks in order to make tailored control programs, including vaccination-based 
strategies, a realistic possibility (Namatovu et al., 2013). In support of this, this chapter 
evaluated a lyophilised version of a published East Africa-typing specific assay (Bachanek-
Bankowska et al., 2016). Lyophilisation and multiplexing of the assay had limited effect 
on the analytical sensitivity of the FMDV typing assay, however the sensitivity of these 
reagents was reduced in comparison to the pan-FMDV rRT-PCR assays.  
In field settings, the lyophilised typing assay was able to characterise FMDV present in 
four different sample types, collected from seven small holdings (three in Kenya, three 
in Tanzania and one in Ethiopia), where cattle presented two to seven day old FMD 
lesions. Samples which were unable to be typed (n = 22) were all considered as weak 
positives by the lyophilised pan-FMDV rRT-PCR (CT > 29) and therefore at the threshold at 
which characterisation information can be routinely obtained by sequencing. The typing 
assay performance in field settings is consistent with the ability to obtain characterisation 
data within laboratory settings. Two serotypes were detected during the period of testing 
(O and A), leading to the first reported characterisation of FMDV in field-based settings 
using molecular methods. Furthermore, the preliminary FMD surveillance data collected 
revealed interesting epidemiological patterns, for example in June 2016, two separate 
FMD outbreaks were evident in the Kericho and Nakuru areas of Kenya, with FMDV O and 
A serotypes detected 120 km apart. 
In conclusion, this chapter describes the laboratory and field evaluation of lyophilised 
FMDV-specific rRT-PCR assays in combination with a portable thermocycler. In addition 
to providing a means to rapidly confirm cases of FMD on or close to the farm during 
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outbreaks, these technologies could potentially provide a route for low-resource 
laboratories to establish robust field/laboratory testing capacity, thereby providing 
support to programmes that monitor and control FMD. The simplicity of the T-CORTM 8 to 
operate, combined with robust lyophilised reagents, high sensitivity and compatibility 
with simple sample preparation methods, demonstrate an important transition for FMDV-
specific rRT-PCR assays into formats suitable for use in decentralised, resource-limited 
settings.  
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CHAPTER 5 
 
Using sequence data to predict the 
performance of real-time PCR assays 
 
 
 
Results from this chapter have been presented at: 
EuFMD Research Group Open Session 2016, Cascais, Portugal. Oral presentation: GoPrime: 
In silico evaluation of real-time PCR primers and probes for detection of foot-and-mouth 
disease virus. 
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5.1 Summary 
Real-time PCR (rPCR) has become a widely accepted diagnostic tool for the detection and 
quantification of nucleic acid. In order for these assays to achieve high sensitivity and 
specificity, primer/probe-template complementarity is essential, however mismatches 
are often unavoidable and can result in false-negative results and errors in quantifying 
target sequences. Consequently, primer and probe sequences require continual 
evaluation to ensure they remain fit for purpose (especially when considering RNA viruses 
with a high mutation rate). The effect of mismatches on rPCR has been widely studied, 
however data has only currently been used to advise on primer design. Following further 
investigation into primer/probe-template mismatches, this chapter describes the use of 
experimental data for predicting the performance of rPCR assays. Empirical data 
generated to investigate the effects of different primer/probe-template mismatches, 
using foot-and-mouth disease virus (FMDV) as a model, demonstrated that their effects 
on rPCR cycle threshold (CT) and limit of detection (LOD) followed a consistent pattern in 
terms of mismatch type and position. For example, the most deleterious mismatches 
occurred at the 3ʹ-end of primers (a single G-A mismatch in the final nucleotide resulted 
in a change in CT of 11.57), with a maximum of two mismatches being tolerated in this 
region before amplification was completely inhibited. For the probe, single mismatches 
at the 5ʹ-end had almost no effect on CT, with single mismatches throughout the rest of 
the probe impacting rPCR CT by 1.63 - 3.38 (four or more mismatches across the probe 
inhibited rPCR). A linear model was used to calculate the effect of different mismatches 
on the CT and LOD of reactions, results of which became the parameters of GoPrime: a 
mathematical model designed to predict the performance of rPCR primers and probes 
across multiple sequence data. Evaluation of GoPrime was performed using a set of 
experimental rPCR data, using DNA oligonucleotides designed to vary in the primer/probe 
target regions as template (n = 97). GoPrime on average predicted the impact of 
mismatches on CT to be 3.15 (SD 2.23) away from the observed value, and impact of 
mismatches on LOD to be 1.58 (SD 0.76) away from the observed value. GoPrime was also 
applicable to other areas of the FMDV genome, with predictions for the likely targets of 
a FMDV-typing assay consistent with published experimental data. These data support the 
use of mathematical models for rapidly predicting the performance of rPCR primers and 
probes in silico. 
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5.2 Introduction 
Real-time PCR (rPCR) has become an essential tool in molecular biology and is routinely 
used for detection, quantification and differentiation of nucleic acids in both research 
and diagnostic settings (Mackay et al., 2002; Espy et al., 2006). Central to the  specificity 
and sensitivity of rPCR assays are the primers and probes, with amplification affected by 
factors such as primer/probe-template complementarity and the presence of secondary 
structures (e.g. primer dimers) (Cha and Thilly, 1992). However, designing primers and 
probes with full sequence complementarity to all of the required targets can be 
problematic. For instance, when considering RNA viruses such as foot-and-mouth disease 
virus (FMDV), the high mutation rate (in the range of 10-3 to 10-5 per nucleotide site, per 
genome replication [Domingo et al., 1985; Drake and Holland, 1999]), can result in fully 
conserved regions being too short to accommodate primer/probe sets. This is especially 
true when designing assays to target the more varied genomic regions for serotype/strain 
differentiation (Bachanek-Bankowska et al., 2016). Consequently, primer/probe-
template mismatches are often unavoidable and a compromise approach that 
accommodates sequence mismatches is often adopted to design diagnostic tests. 
The effects of mismatches on PCR amplification have been well studied and quantified 
for both primers (Kwok et al., 1990; Huang et al., 1992; Christopherson et al., 1997; Klein 
et al., 2001; Smith et al., 2002; Whiley and Sloots, 2005; Yao et al., 2006; Bru et al., 
2008; Boyle et al., 2009; Süß et al., 2009; Klungthong et al., 2010; Stadhouders et al., 
2010) and probes (Süß et al., 2009; Klungthong et al., 2010). For instance, primer-
template mismatches in the 3ʹ-end region of the primer (defined in this chapter as the 
last 4 nucleotides) have been shown to have a larger effect on PCR amplification than 
those located towards the 5ʹ-end, due to disruption of the DNA polymerase active site 
(Kwok et al., 1990; Whiley and Sloots, 2005; Bru et al., 2008; Süß et al., 2009; 
Stadhouders et al., 2010). Furthermore for rPCR probes, mismatches in the centre have 
been shown to destabilise probe annealing, thereby having a larger impact on amplicon 
detection than mismatches located at the 5ʹ-end (Süß et al., 2009). 
Primer/probe-template mismatches can be especially problematic when considering the 
use of rPCR for diagnostic purposes. By impacting rPCR amplification, mismatches can 
alter the cycle threshold (CT) at which targets are detected, leading to errors in nucleic 
acid quantification. For instance, a single internally-located mismatch can result in up to 
a 1,000-fold underestimation of initial copy number (Bru et al., 2008). Notably, 
mismatches at the 3ʹ-end of primers have been shown to produce effects ranging from a 
Chapter 5 
 
118 
 
two-fold underestimation of initial copy number to complete prevention of amplification, 
thus leading to false-negative results (Stadhouders et al., 2010).  
These effects of mismatches result in the requirement for continual evaluation of primer 
and probe sequences. In addition to laborious manual laboratory-based screening, 
primer/probe validation traditionally occurs though Basic Local Alignment Search Tool 
(BLAST) searches against publically available sequences (Altschul et al., 1990), with tools 
now developed to automate the process (Dyer et al., 2008; Lemmon and Gardner, 2008). 
However, despite numerous studies into the effects of mismatches, no primer evaluation 
programs to date have been developed using experimental data, with target sequences 
only reported as putative hits or misses. With rPCR assays requiring different performance 
criteria depending upon their use, the provision of binary predictions is limited. For 
example, high specificity is paramount for assays used to differentiate between diseases, 
high sensitivity is required for assays used to confirm negative results, and an awareness 
of cross-reactivity is important for assays that distinguish between closely related 
sequences, such as FMDV serotypes (Bachanek-Bankowska et al., 2016). As such, the 
availability of a quantitative primer/probe validation program could support rPCR 
evaluation by giving researchers and diagnosticians the ability to rapidly predict whether 
assays are fit for purpose. 
This chapter describes the effects of different primer/probe-template mismatches on CT 
and limit of detection (LOD), and the presentation of a primer/probe evaluation program 
(GoPrime), in order to ascertain to what extent the effect of mismatches in rPCR can be 
predicted. 
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5.3 Materials and Methods 
5.3.1 The effects of primer/probe-template mismatches 
To study the effects of primer/probe-template mismatches on CT and LOD, rPCR was 
performed using DNA oligonucleotide targets, which had been designed to vary in the 
primer/probe binding regions. 
Linear DNA oligonucleotides templates of 109 bp (Sigma-Aldrich, Munich, Germany) were 
designed around the target region for a published assay (Callahan et al. 2002): a 
conserved region of the FMDV genome (3Dpol-coding region). Ninety templates were 
ordered, each designed to evaluate the effect of different variations in the primer/probe 
binding regions (Table 5.1). For example, variations across the length of the primer/probe 
target regions were designed to evaluate the effect of position, with different bases 
substituted to investigate the effects of mismatch type and mismatch quantity. Sequences 
were based on O/UKG/35/2001 (accession number KR265074, nucleotides 7862-7970). In 
addition, a template with full primer/probe-template complementarity was ordered as 
used as the reference template (R) in all rPCR reactions. 
 
 
Table 5.1 Linear DNA oligonucleotide templates for real-time PCR targets (5ʹ-3ʹ) 
 Forward primer target Probe target Reverse primer target 
R ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
1 ACTGGGTTTTACAAACCTGTGG TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
2 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC CCCGTGGCAGGACTCGC 
3 ACTGGGTTTTACAAACCTGTGG TCCTTTGCACGCCGTGGGAC CCCGTGGCAGGACTCGC 
4 ACTGGGTTTTACAAACCTGTGC TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
5 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC GCCGTGGCAGGACTCGC 
6 ACTGGGTTTTACAAACCTGTGC TCCTTTGCACGCCGTGGGAC GCCGTGGCAGGACTCGC 
7 ACTGGGTTTTACAAACCTATAA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
8 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TTCATGGCAGGACTCGC 
9 ACTGGGTTTTACAAACCTATAA TCCTTTGCACGCCGTGGGAC TTCATGGCAGGACTCGC 
10 ACTGGGTTTTACAAACCTTTTA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
11 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TACTTGGCAGGACTCGC 
12 ACTGGGTTTTACAAACCTTTTA TCCTTTGCACGCCGTGGGAC TACTTGGCAGGACTCGC 
13 ACTGGATTCTACGAACTTGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
14 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTAGCGGGACTTGC 
15 ACTGGATTCTACGAACTTGTGA TCCTTTGCACGCCGTGGGAC TCCGTAGCGGGACTTGC 
16 ACTGGTTTGTACCAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
17 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCCGGACTAGC 
18 ACTGGTTTGTACCAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCCGGACTAGC 
19 ATTAGATTCTGCGAACTTGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
20 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTAGCGGGGCTTGT 
21 ATTAGATTCTGCGAACTTGTGA TCCTTTGCACGCCGTGGGAC TCCGTAGCGGGGCTTGT 
22 AATTGTTTGTCCCAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
23 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCCGGCCTAGA 
24 AATTGTTTGTCCCAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCCGGCCTAGA 
25 AATAGTTTCTCCGAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
26 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCGGGCCTTGA 
27 AATAGTTTCTCCGAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCGGGCCTTGA 
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R ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
28 ACTGGTTTCTACGAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
29 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCGGGACTTGC 
30 ACTGGTTTCTACGAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCGGGACTTGC 
31 ACTGGTTTTTACGAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCGGGACTTGC 
32 ACTGGTTTTTACAAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCAGGACTTGC 
33 ACTGGTTTTTACGAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCAGGACTCGC 
34 ACTGGTTTTTACAAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
35 ACTGGGTTTTACAAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCAGGACTCGC 
36 ACTGGTTTCTACGAACATGTGA TCCTTTGCACGCCGTGGGAC CCCGTGGCAGGACTCGC 
37 ACTGGTTTCTACGAACATGTGA TCCTTTGCACGCCGTGGGAC GCCGTGGCAGGACTCGC 
38 ACTGGTTTCTACGAACATGTGA TCCTTTGCACGCCGTGGGAC TTCGTGGCAGGACTCGC 
39 ACTGGTTTCTACGAACATGTGA TCCTTTGCACGCCGTGGGAC TACGTGGCAGGACTCGC 
40 ACTGGTTTTTACAAACATGTGA TCCTTTGCACGCCGTGGGAC CCCGTGGCAGGACTCGC 
41 ACTGGTTTTTACAAACATGTGA TCCTTTGCACGCCGTGGGAC GCCGTGGCAGGACTCGC 
42 ACTGGGTTTTACAAACCTGAGG TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
43 ACTGGGTTTTACAAACCTGCGG TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
44 ACTGGGTTTTACAAACCTGAGC TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
45 ACTGGGTTTTACAAACCTGTTG TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
46 ACTGGGTTTTACAAACCTGTAG TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
47 ACTGGGTTTTACAAACCTGTTC TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
48 ACTGGGTTTTACAAACCTGGAA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
49 ACTGGGTTTTACAAACCTGCAA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
50 ACTGGGTTTTACAAACCTGGTA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
51 ACTGGGTTTTACAAACCTTTGG TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
52 ACTGGGTTTTACAAACCTATGG TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
53 ACTGGGTTTTACAAACCTTTGC TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
54 ACTGGGTTTTACAAACCTGTAA TCCTTTGCACGCCGTGGGAC TTCGTGGCAGGACTCGC 
55 ACTGGGTTTTACAAACCTGTTA TCCTTTGCACGCCGTGGGAC TACGTGGCAGGACTCGC 
56 ACTGGGTTTTACAAACCTGTAA TCCTTTGCACGCCGTGGGAC TACGTGGCAGGACTCGC 
57 ACTGGGTTTTACAAACCTATTA TCCTTTGCACGCCGTGGGAC TCTGTGGCAGGACTCGC 
58 ACTGGGTTTTACAAACCTATTA TCCTTTGCACGCCGTGGGAC TCAGTGGCAGGACTCGC 
59 ACTGGGTTTTACAAACCTATTA TCCTTTGCACGCCGTGGGAC CCCGTGGCAGGACTCGC 
60 ACTGGGTTTTACAAACCTATTA TCCTTTGCACGCCGTGGGAC GCCGTGGCAGGACTCGC 
61 ACTGGGTTTTACAAACCTGTGA TCCTTGGCGCACAGCGGTAC TCCGTGGCAGGACTCGC 
62 ACTGGGTTTTACAAACCTGTGA TCCTTGGCGCACCGCGGTAC TCCGTGGCAGGACTCGC 
63 ACTGGGTTTTACAAACCTGTGA TCCTTGGCACACCGCGGTAC TCCGTGGCAGGACTCGC 
64 ACTGGGTTTTACAAACCTGTGA TCCTTGGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
65 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
66 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACACCGTGGGAC TCCGTGGCAGGACTCGC 
67 ACTGGGTTTTACAAACCTGTGA CCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
68 ACTGGGTTTTACAAACCTGTGA GCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
69 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAT TCCGTGGCAGGACTCGC 
70 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAA TCCGTGGCAGGACTCGC 
71 ACTGGGTTTTACAAACCTGTGA GGCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
72 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGCT TCCGTGGCAGGACTCGC 
73 ACTGGGTTTTACAAACCTGTGA CCATTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
74 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGTAT TCCGTGGCAGGACTCGC 
75 ACTGGGTTTTACAAACCTGTGA TTCGTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
76 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGTGGC TCCGTGGCAGGACTCGC 
77 ACTGGGTTTTACAAACCTGTGA CCCTTTGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
78 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACACCGCGGGAT TCCGTGGCAGGACTCGC 
79 ACTGGGTTTTACAAACCTGTGA CACTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
80 ACTGGGTTTTACAAACCTGTGG TCCTTGGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
81 ACTGGGTTTTACAAACCTGTGG TCCTTTGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
82 ACTGGGTTTTACAAACCTGTGC TCCTTTGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
83 ACTGGGTTTTACAAACCTTTGG TCCTTTGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
84 ACTGGGTTTTACAAACCTGTGG CCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
85 ACTGGGTTTTACAAACCTGTGG TCCTTTGCACGCCGTGGGAT TCCGTGGCAGGACTCGC 
86 ACTGGTTTTTACAAACATGTGA TCCTTTGCACACCGCGGGAC TCCGTTGCAGGACTTGC 
87 ACTGGTTTTTACAAACATGTGA TCCTTTGCACACCGCGGGAC TCCGTGGCAGGACTCGC 
88 ACTGGGTTTTACAAACATGTGA TCCTTTGCACACCGTGGGAC TCCGTTGCAGGACTCGC 
89 ACTGGGTTTTACAAACATGTGA CCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
90 ACTGGGTTTTACAAACATGTGA TCCTTTGCACGCCGTGGGAT TCCGTGGCAGGACTCGC 
The primer/probe target sequences of the 90 DNA templates (109 base pairs in length) in 5ʹ-3ʹ orientation. 
Non-target regions between the primer/probe targets were identical to O/UKG/35/2001 (accession number 
KR265074: nucleotides 7862-7970). Black sequences represent the reference template (R); grey sequences 
represent the varying DNA templates, red underlined based depict primer/probe-template mismatch sites. 
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Real-time PCR: 
rPCR reactions were performed using two Taq-based rPCR kits: 
ExciteTM UF 2x Master Mix (ExciteTM UF) (Quantig Ltd., Camberley, UK), a Taq-based rPCR 
kit, was selected as it required minimal reaction set-up, increasing the likelihood of assay 
variation being attributed to target sequence differences rather than human error. 
Reactions were performed in a total of 20 µl, containing: 5 µl template, 10 µl 2x master 
mix, 50 nM ROX reference dye, primers and probes as previously described (Callahan et 
al. 2002) and made up to volume with nuclease-free water (NFW). Thermal cycling 
conditions were 95°C for 3 minutes, followed by 50 cycles of 95°C for 5 seconds and 60°C 
for 20 seconds.  
SuperScript™ III Platinum™ One-Step qRT-PCR Kit (SSIIITM) (Thermo Fisher Scientific, MA, 
USA) was chosen as it is a commonly used Taq-based kit (routinely used within the Food 
and Agricultural Organization (FAO) World Reference Laboratory for Foot-and-Mouth 
Disease [WRLFMD]), it was used for the reference real-time reverse transcription PCR 
(rRT-PCR) in Chapters 2 to 4, and it is compatible with both RNA and DNA templates 
(Appendix 7b). Reagents, parameters and thermal cycling conditions were as reported in 
Shaw et al. (2007), with the addition of 50 nM ROX reference dye per reaction and 
omission of the reverse transcription (RT) step. Primers and probes were as previously 
published (Callahan et al., 2002).  
All rPCR reactions were performed on an ABI ViiATM 7 Real-Time PCR system thermocycler 
(Thermo Fisher Scientific). The CT was called automatically using ViiA™ 7 Software and 
positive reactions were defined as those that gave a detectable CT. Initial rPCR reactions 
were performed in duplicate using 106 copies of template. Where CT values were 
detected, further rPCR reactions were performed in duplicate across a log10 dilution series 
of template (106-100 copies/reaction) in 0.1 µg/µl carrier RNA (Ambion®, Thermo Fisher 
Scientific). The effect of mismatches on rPCR were determined by calculating the change 
in CT (ΔCT) and change in LOD (ΔLOD) between the reference and varying oligonucleotide 
DNA templates. 
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5.3.2 Development of GoPrime 
In order to ascertain the effect of each primer/probe-template mismatch type on ΔCT and 
ΔLOD, linear model analysis was performed. Linear model variables were selected based 
on statistical analysis (to ascertain which primer/probe-template mismatch locations 
were statistically different from one another) and previously published data (Table 5.2). 
 
Table 5.2 Statistical analyses to determine linear model variables 
Comparison Templates [mismatch]  Tukey test p-value Result 
3ʹ-end of 
primers 
A: 45-47 (nt 1 and 2) 
B: 42-44 (nt 1 and 3) 
C: 51-53 (nt 1 and 4) 
A-B: p < 0.001 
A-C: p = 0.083   
B-C: p = 0.307     
No significant difference present 
between bases 3 and 4 (grouped together 
in the linear model). Previously published 
in Stadhouders et al. (2010). 
3ʹ-end of 
probe 
A: 72 (nt 1 and 2) 
B: 74 (nt 1 and 3) 
C: 76 (nt 2 and 4) 
A-B: p = 0.997  
A-C: p = 0.569 
B-C: p = 0.612 
No significant difference present 
between probe nt 1 – 4 (grouped together 
in the linear model). 
5ʹ-end of 
probe 
A: 71 (nt 20 and 19) 
B: 73 (nt 20 and 18) 
C: 75 (nt 19 and 17) 
A-B: p = 0.598 
A-C: p = 0.862 
B-C: p = 0.300 
No significant difference present 
between probe nt 20-17 (grouped 
together in the linear model). 
Regions of 
probe 
A: 65 (middle of probe) 
B: 72,74,76 (3ʹ-end) 
C: 71,73,75,79 (5ʹ-end) 
A-B: p = 0.021  
A-C: p = 0.001 
B-C: p < 0.001 
Significant differences between 
mismatches in the middle, 3ʹ-end and 5ʹ-
end of the probe (treated separately in 
the linear model). 
One way analysis of variance (ANOVA) tests (with post-hoc Tukey tests), were used to determine which 
primer/probe-template mismatch positions gave statistically different changes in cycle threshold. (nt): 
nucleotide. Template numbers refer to the oligonucleotide sequence in Table 5.1. 
 
Linear model analysis (Chambers, 1992) was performed in R (R Core Team, 2014), using 
the variables stated in Table 5.3 and all quantitative data collected (90 templates, across 
106 – 100 copies of template, using both Taq-based kits, to analyse the average effects of 
mismatches). The results of the linear model were used to parameterise GoPrime: a 
mathematical model for predicting the effects of mismatches on rPCR. GoPrime was built 
in collaboration with Dr Richard Orton (The University of Glasgow), who translated the 
primer/probe mismatch rules and CT penalties into computer code written in the Java 
programming language.  
Table 5.3 Variables included in linear model analysis 
  Mismatch type Variable 
Primers 
(forward or reverse) 
Percentage mismatch (forward and reverse combined) 
Type 1 mismatch at the 3ʹ-end (nucleotide 1) 
Type 2 mismatch at the 3ʹ-end (nucleotide 1) 
Type 1 mismatch at the 3ʹ-end (nucleotide 2) 
Type 2 mismatch at the 3ʹ-end (nucleotide 2) 
Type 1 mismatch at the 3ʹ-end (nucleotides 3-4) 
Type 2 mismatch at the 3ʹ-end (nucleotides 3-4) 
Probe 
Percentage mismatch 
3ʹ-end mismatch (final four nucleotides) 
5ʹ-end mismatch (final four nucleotides) 
Mismatches were grouped as one of two types: (type 1) purine-pyrimidine mismatch (G-T or C-A nucleotide 
base pairing, leading to a minor conformational change in the primer/probe-template duplex); (type 2) 
purine-purine or pyrimidine-pyrimidine mismatch (G-A, A-A, G-G, C-T, T-T or C-C nucleotide base pairing, 
leading to a major conformational change in the primer/probe-template duplex). 
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5.3.3 Evaluating GoPrime as a predictor of rPCR performance 
Artificial variations within the FMDV 3Dpol-coding region: 
Initial evaluation of GoPrime was performed by comparing the ΔCT and ΔLOD evident from 
experimental rPCR results using both the ExciteTM UF and SSIIITM protocols (Chapter 5.3.1) 
(differences between the results for the reference template and each of the 90 varying 
DNA templates) against the predicted results from GoPrime.  
 
Naturally occurring sequence variations within the FMDV 3Dpol-coding region: 
A search was performed using the National Centre for Biotechnology Information (NCBI) 
nucleotide database (NCBI, 2017) in order to find FMDV sequences that had naturally 
occurring variations in the Callahan et al. (2002) target region (Table 5.4). Seven linear 
DNA oligonucleotides of 109 bp were ordered to include these differences in the 
primer/probe target regions. These were then used as template in rPCR, using both the 
ExciteTM UF and SSIIITM protocols (Chapter 5.3.1), with results compared to predictions 
from GoPrime. 
 
Alternative target sites within the FMDV genome: 
In order to ascertain how transferable GoPrime was to other areas of the FMDV genome, 
GoPrime was used to analyse four FMDV-typing assays designed to target VP1/2A-coding 
regions (Bachanek-Bankowska et al., 2016). The four sets of primers and probes (specific 
for either serotype A, O, Southern African Territories [SAT] 1 or SAT 2 field viruses 
circulating in East Africa) were evaluated against the 66 VP1/2A-coding sequences used 
Table 5.4 Linear DNA templates representing naturally occurring FMDV field isolates 
for testing GoPrime predictions (5ʹ-3ʹ) 
R 
Forward primer target Probe target Reverse primer target 
ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
JX040500 ACTGGGTTTTACAAACCTATGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
KC440884 ACTGGATTTTATAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
AY593802 ACTGGGTTTTACAAACCTGTGA TCCTTCGCACGCCGTGGGAC TCTGTGGCAGGGCTCGC 
KC440883 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCTGTGGCGGGACTCGC 
AY593812 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCAGTGGCAGGACTCGC 
KF112882 ACTGGGTTTTACAAACCTGTGA CCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
HM191257 ACTGGGTTTTACAAACCTGTGA TCCTTCGCACGCCGTGGGAC TCTGTGGCAGGACTCGC 
The primer/probe binding regions of the seven DNA oligonucleotides ordered to test the program (109 base 
pairs in length, with regions between primers consistent with the sequences for each accession number.  
Black sequences represent the reference template (R); grey sequences represent the varying DNA 
templates, with red underlined based depicting primer/probe-template mismatch sites. FMDV serotypes 
were as follows: JX040500 (O); KC440884 (Southern African Territories 2); AY593802 (A); KC440883 (O); 
AY593812 (O); KF112882 (O); HM191257 (O). 
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in initial laboratory-based evaluation (A = 15; O = 20; SAT 1 = 19; SAT 2 = 12) (unpublished 
sequences from The Pirbright Institute). The published experimental results (Bachanek-
Bankowska et al., 2016) and GoPrime predictions for the likely targets of each assay were 
then compared and displayed using GoPrimeTree. The serotype O primers (Bachanek-
Bankowska et al., 2016) were also evaluated against 24 viruses from outside of East Africa 
(sequences from GenBank) (Table 5.5), again with results displayed in GoPrimeTree. 
 
 
 
 
 
 
 
 
 
 
 
5.3.4 Statistical and phylogenetic analysis 
All statistical analyses were performed using R (R Core Team, 2014). The root-mean-
square deviation (RMSD) was used to measure the differences between the predicted ΔCT 
values and the ΔCT values actually observed. Phylogenetic trees were produced from 
sequence alignments in Mega (version 7.0.21) (Kumar et al., 2016) using the neighbour-
joining method (Saitou and Nei, 1987) and viewed in FigTree (version 1.4.3) (Rambaut, 
2016). 
 
 
 
Table 5.5 Foot-and-mouth disease virus isolates used to test GoPrime 
Accession Number (NCBI) Isolate Location Year 
KJ825809.1 O/IND/250(541)/2013 India 2013 
KF694743.1 O/S13KOR/2002 South Korea 2002 
JX947858.1 O/UKG/91dpc UK 2001 
KF112880.1 O/MYA/5/2009 Myanmar 2009 
JF749851.1 O/IRN/073/2001 Iran 2001 
JX040499.1 O/TUR/8/2011 Turkey 2011 
JX570650.1 O/BFS/1860/B2.6D.V UK 1967 
JX570643.1 O/BFS/1860/A2.32D.P UK 1967 
HQ632770.1 O/MAY/1/2004 Malaysia 2004 
GU384683.1 O/PAK/45/2008 Pakistan 2008 
FJ175666.1 O/Israel 07-6387 Israel 2007 
AY686687.1 O/ES/2001 China* 2001 
FJ542369.1 O/UKG/2000/2001 UK 2001 
EF552694.1 O/UKG/4998/2001 UK 2001 
EF552688.1 O/UKG/3952/2001 UK 2001 
AY593832.1 O/UK2001-FB UK 2001 
AY593826.1 O/o2brescia Italy 1947 
AF511039.1 O/Akesu/58 China 1958 
EF175732.1 O/CHA/WFL China Unknown 
DQ404175.1 O/UKG/173/2001 UK 2001 
DQ404159.1 O/UKG/14603/2001 UK 2001 
AF026168.2 O/TAW/Chu-Pei Taiwan 1997 
AY317098.1 O/HKN/2002 Hong Kong 2002 
AJ539136.1 O/TAW/2/99 Taiwan 1999 
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5.4 Results 
5.4.1 The effects of primer/probe-template mismatches on rPCR 
The effects of primer-template mismatches: 
Primer-template mismatches instigated a wide variety of effects on rPCR amplification. 
Single mismatches at the 3ʹ-end of the primer (using both rPCR kits) had the most 
detrimental effect on CT (ΔCT of between 6.44 and 11.57), with the impact of mismatches 
declining further toward the 5ʹ-end (Figure 5.1).  
 
Figure 5.1 The effects of 3ʹ-end primer-template mismatches on real-time PCR (rPCR) 
cycle threshold (CT). Results represent the effects of mismatches on cycle threshold (ΔCT) 
derived from linear model analysis, across two rPCR kits (ExciteTM UF 2x Master and 
SuperScript™ III Platinum™ One-Step qRT-PCR Kit) and a dilution series of template (106 – 
100 copies/reaction). (nt) nucleotide. (white) type 1 mismatch: purine-pyrimidine 
mismatch (G-T or C-A nucleotide base pairing, leading to a minor conformational change 
in the primer/probe-template duplex); (grey) type 2 mismatch: purine-purine or 
pyrimidine-pyrimidine mismatch (G-A, A-A, G-G, C-T, T-T or C-C nucleotide base pairing, 
leading to a major conformational change in the primer/probe-template duplex). 
 
Furthermore, the type of mismatch was shown to be important. For instance, at the 3ʹ-
end of the reverse primer, a C-A mismatch (type 1) resulted in an average effect of ΔCT 
of 8.59, whereas a G-A mismatch (type 2) in the same location resulted in an average 
effect of ΔCT of 11.57 (Figure 5.2A). Up to two mismatches in the 3ʹ-end of the primer 
could be tolerated (Figure 5.2B; Figure 5.2C) before amplification did not occur, however 
a minimum of 104 copies of template per reaction were required in these circumstances. 
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Figure 5.2 The effects of primer-template mismatches on real-time PCR (rPCR) cycle 
threshold (CT). (A) single mismatches at the 3ʹ-end; (B) and (C) multiple mismatches at 
the 3ʹ-end; (D) effect of primer-template percentage complementary. Results represent 
the average increase in cycle threshold (ΔCT) from the reference template across two 
rPCR kits (ExciteTM UF 2x Master and SuperScript™ III Platinum™ One-Step qRT-PCR Kit) 
and a dilution series of template (106 – 100 copies/reaction). The limit of detection (LOD) 
for each template is defined as the lowest dilution where all replicates were positive 
(displayed in grey text). Error bars represent the standard deviation. (F) forward primer; 
(R) reverse primer; (nt) nucleotide.  
 
When studying the effect of primer/probe-template percentage complementary across 
the total length of the primers (Figure 5.2D), a minimum of 82.05% primer-template 
match between the forward and reverse primers (combined) was required for 
amplification to occur. However, at this percentage, mismatches impacted upon amplicon 
detection by a ΔCT of 19.31 with a LOD of 10
6 copies per reaction. 
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The effects of probe-template mismatches: 
Single mismatches at the 5ʹ-end of the site recognised by the TaqMan probe had very little 
effect on CT (ΔCT of 0.06 – 0.15), whereas single mismatches at the 3ʹ-end impacted 
amplicon detection by a ΔCT of 2.87 - 3.38 (Figure 5.3A). When studying the effect of the 
mismatches across the length of the probe, a minimum of 85% probe-template 
complementarity was required in order for effective detection to occur, impacting upon 
rPCR ΔCT by 6.57 with a LOD of 10
4 (Figure 5.3B). 
 
Figure 5.3 The effects of probe-template mismatches on real-time PCR (rPCR) cycle 
threshold. (A) single mismatches at the 3ʹ-end or 5ʹ-end; (B) effect of probe-template 
percentage complementary. Results represent the average increase in cycle threshold 
(CT) from a perfectly matched template, across two rPCR kits (Excite
TM UF 2x Master and 
SuperScript™ III Platinum™ One-Step qRT-PCR Kit) and a dilution series of template (106 – 
100 copies/reaction). The limit of detection (LOD) for each template is defined as the 
lowest dilution where all replicates were positive (displayed in grey text). Error bars 
represent the standard deviation. (P) probe; (nt) nucleotide; percentages represent 
probe-template complementarity. 
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The effect of primer/probe-template mismatches across template copy number: 
Template titrations were used to evaluate how the initial template copy number affected 
rPCR amplification in the presence of primer/probe-template mismatches (Figure 5.4). 
Analysis included all targets with positive CT values for three or more dilution points 
(44/90 templates). Linear regression (analysis of the slope) showed that no significant 
difference was evident between templates (F-value = 1.227, p = 0.162), therefore 
mismatches instigate a similar ΔCT and ΔLOD irrespective of the template copy number. 
 
Figure 5.4 The effect of primer/probe-template mismatches across different copy 
numbers of template. Results are shown for the ExciteTM UF 2x Master Mix, and display a 
subset of the oligonucleotides tested (Table 5.1). (A): () perfect match; () template 
1; () template 2; () template 4; () template 5. (B): () perfect match; () template 
66; () template 65; () template 64; () template 35; () template 34. (C): () 
perfect match; () template 69; () template 70; () template 67; () template 68. 
Points represent the mean of two replicates; half-shaded points represent when one 
duplicate was positive and the other negative; error bars represent standard deviation; 
(ΔCT) change in cycle threshold. 
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5.4.2 Development of GoPrime 
Using linear model analysis, the average effect of each primer/probe-template mismatch 
type was determined, accounting for both single and multiple mismatches in the primer 
and probe binding regions, by implementing additive and dampening effects where 
necessary (Table 5.6).  
 
Results from the linear model were used to parameterise GoPrime (freely available 
through https://github.com/rjorton/GoPrime [Orton, 2017]). To use GoPrime, users 
input their primer/probe sequences (5ʹ - 3ʹ [fasta format]) and a file of sequences to be 
analysed (5ʹ - 3ʹ [fasta format]). GoPrime first analyses the template, in both orientations, 
for possible forward and reverse primer targets (Figure 5.7). This is done based on the 
minimum requirements for primer-template complementarity, which were defined during 
data analysis as the lowest dilution of template which produced positive CT values in all 
replicates (Table 5.7).  
 
Table 5.6 The effect of mismatches calculated from linear model analysis 
Factor Mismatch type  ΔCT SE t value p value 
Primer 
% mismatch (forward/reverse combined)* 0.86 0.03 31.75 < 0.001 
nt 1 mismatch (type 1) 1.64 0.23 7.15 < 0.001 
2x nt 1 mismatch (type 1) 5.07 0.75 6.76 < 0.001 
nt 1 mismatch (type 2) 4.01 0.33 12.18 < 0.001 
2x nt 1 mismatch (type 2) 8.90 1.14 7.80 < 0.001 
nt 2 mismatch (type 1) 1.19 0.37 3.23 0.002 
2x nt mismatch (type 1) 3.51 0.70 5.03 < 0.001 
nt 2 mismatch (type 2) 3.64 0.36 10.11 < 0.001 
2x nt 2 mismatch (type 2) 6.31 0.97 6.51 < 0.001 
nt 3-4 mismatch (type 1) 1.03 0.33 3.07 0.001 
2x nt 3-4  mismatch (type 2) 1.76 0.86 0.20 0.839 
nt 3-4 mismatch (type 1) 2.91 0.31 9.32 < 0.001 
2x nt 3-4 mismatch (type 2) 4.86 2.69 1.80 0.072 
Probe 
% mismatch 0.35 0.02 8.51 < 0.001 
3ʹ-end mismatch (nucleotides 1-4) 0.41 0.20 2.01 0.044 
5ʹ-end mismatch (nucleotides 1-4) -1.05 0.19 -5.55 < 0.001 
(nt) nucleotide; (ΔCT) change in cycle threshold; (SE) standard error. For multiple mismatches, the linear 
model was able to calculate the effect of having the same type of mutation in both the primers (2x), if 
two mismatches were present but different the linear model calculated the additive/dampening effect: 
two 3ʹ-end primer mismatches (ΔCT: -0.27 [2dp]); two probe 3ʹ-end mismatches (CT: -0.84 [2dp]); one 
primer and one probe mismatch (ΔCT: +0.43 [2dp]). Mismatches were grouped as one of two types: (type 
1) purine-pyrimidine mismatch (G-T; C-A: minor conformational change in the primer/probe-template 
duplex); (type 2) purine-purine or pyrimidine-pyrimidine mismatch (G-A; A-A; G-G; C-T; T-T; C-C: major 
conformational change in the primer/probe-template duplex). *If a type nt 1 mismatch was present, the 
percentage mismatch ΔCT would be calculated and additional nt 1 mismatch ΔCT penalty added. ΔCT, SE 
and t value given to 2 decimal places. 
Table 5.7 Minimum primer/probe-template complementarity required for amplification 
Factor Minimum requirements for real-time PCR amplification 
Primer 3ʹ-end 
Maximum of two mismatches in the 3ʹ-ends (either in one primer, or between the 
primers). 
Primer percentage A minimum of 82.05% match is required (combined % for the pair) 
Probe percentage A minimum of 85.00% match is required 
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Once possible forward and reverse primer targets are identified, they are evaluated as 
possible primer pairs (Figure 5.5). Potential probe targets (optional) are then identified 
between the primer pairs, searching again in both orientations based on the probe-
template mismatch limits determined during data analysis (Table 5.7).  
 
Figure 5.5 GoPrime flow diagram. GoPrime examines sets of primer sequences (optionally 
including a probe sequence), searches the target genome sequences for potential 
matches, then predicts the effect of any primers/probe-template mismatches present on 
real-time PCR cycle threshold and limit of detection.  
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Once a potentially suitable primer/probe set has been identified, GoPrime uses the 
results of the linear model to predict whether amplification is likely to occur and the 
effect of any mismatches present on ΔCT and ΔLOD, implementing additive/dampening 
effects of multiple mismatches where necessary. GoPrime provides the outputs as two 
separate text files. Firstly, a simple analysis, which provides each sequence name against 
the predicted ΔCT and ΔLOD, number of mismatches present and the likely amplicon 
length. The second analysis provides more detail, including the position and orientation 
of each likely primer/probe target and the type of any mismatches present (Figure 5.5). 
As an optional extra, users can display their results using GoPrimeTree. In order to use 
this, users input the simple output of GoPrime (text file) in addition to a phylogenetic 
tree (nexus format). GoPrimeTree colour codes the sequences according to the predicted 
ΔCT, via annotation of the nexus tree file, so that the predicted targets and effect of the 
primer/probe-template mismatches can be easily visualised across multiple sequence 
data (Figure 5.6). 
 
Figure 5.6 GoPrimeTree flow diagram. GoPrimeTree takes the simple output of GoPrime 
and combines it with a phylogenetic tree, colour coding each sequence according to 
whether it is likely to be detected and the predicted changes in cycle threshold. 
Note, within this chapter GoPrime was parametrised using the experimental results 
detailed, preliminary analysis of alternative parameters was also carried out by adding 
published data to the model (Süß et al., 2009; Stadhouders et al., 2010) (Appendix 7a). 
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5.4.3 Evaluating GoPrime as a predictor of rPCR performance 
Artificial variations within the FMDV 3Dpol-coding region: 
Initial evaluation of GoPrime, comparing the experimental and predicted rPCR results for 
the 90 varying DNA templates (Table 5.1), showed that on average GoPrime predicted the 
ΔCT of reactions 3.32 (SD 2.26; RMSD 4.02) and ΔLOD of reactions 1.65 (SD 0.74) away 
from the observed result (Figure 5.7). Out of the 90 DNA templates, concordance was 
evident between GoPrime and the observed rPCR results for 80 templates in terms of 
whether the target was detected (70 positive; 10 negative). Disagreements were limited 
to the upper thresholds of rPCR reactions and GoPrime. For example, the five targets 
which were detected in experimental rPCR but predicted as negative in GoPrime, 106 
copies were required for detection to occur (average ExciteTM UF ΔCT of 21.00; SSIII
TM ΔCT 
of 15.14). For the five targets that were predicted to amplify but produced negative 
experimental results, a large ΔCT was predicted (average ΔCT: 13.28; range 11.07-15.49).  
 
Figure 5.7 Evaluating GoPrime as a predictor of real-time PCR (rPCR) performance using 
artificial sequence variations. (A) observed change in cycle threshold for ExciteTM UF 2x 
Master Mix; (B) observed change in cycle threshold for SuperScript™ III Platinum™ One-
Step qRT-PCR Kit. For the observed change in cycle threshold, points represent the 
average across all dilutions (106-100) of starting template. 
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Naturally occurring sequence variations within the FMDV 3Dpol-coding region: 
Evaluation of GoPrime using the seven DNA oligonucleotide templates containing 
sequence variations, observed in naturally occurring FMDV isolates in the Callahan et al. 
(2002) target region (Table 5.9), showed that GoPrime on average predicted the ΔCT of 
reactions 1.41 (SD 0.79; range 0.20-2.68; RMSD 1.61) away from the observed result 
(Figure 5.8A; 5.8B; 5.9). GoPrime on average predicted the ΔLOD of reactions 0.70 (SD 
0.39; range 0.06-1.41) away from the observed result (Figure 5.8C; 5.8D; 5.9).  
 
Figure 5.8 Evaluating GoPrime as a predictor of real-time PCR (rPCR) performance using 
naturally occurring sequence variations. (A) observed change in cycle threshold for 
ExciteTM UF 2x Master Mix; (B) observed change in cycle threshold for SuperScript™ III 
Platinum™ One-Step qRT-PCR Kit; (C) observed change in limit of detection for ExciteTM 
UF 2x Master Mix; (D) observed change in limit of detection for SuperScript™ III Platinum™ 
One-Step qRT-PCR Kit. For the observed results, points represent the average change in 
cycle threshold or limit of detection across all dilutions (106-100) of starting template. 
A B 
C D 
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Figure 5.9 Evaluating GoPrime as a predictor of real-time PCR (rPCR) performance using 
natural sequence variations across different starting quantities of template (106-100). 
Each graph represents a different target accession number: (A) JX040500; (B) KC440884; 
(C) AY593802; (D) KC440883; (E) AY593812; (F) KF112882; (G) HM191257. The black line 
represents the observed cycle threshold (CT) values for each template using the Excite
TM 
UF 2x Master Mix. The grey dashed line represents the predicted CT based on the observed 
values for the perfect match template plus any ΔCT predicted. 
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Alternative target sites within the FMDV genome: 
Although GoPrime can only be currently used to evaluate rPCR and two-step rRT-PCR 
assays (in which RT and PCR stages are separate and mismatches persist through to cDNA), 
GoPrime was able to identify the likely targets for four FMDV-typing assays (East Africa 
specific for serotypes A, O, SAT 1 and SAT 2). The targets identified were consistent with 
previously published results (Bachanek-Bankowska et al., 2016) (Figure 5.10). 
 
Figure 5.10 Using GoPrime and GoPrimeTree to predict the likely targets of foot-and-
mouth disease virus (FMDV)-typing PCR assays (Bachanek-Bankowska et al., 2016) (n = 
66). Four primer/probe sets were tested: (A) serotype A; (B) serotype O; (C) serotype 
Southern African Territories (SAT) 1; (D) serotype SAT 2. For the colour scheme: () 
perfect primer/probe-template match; () cycle threshold affected by up to a CT of 5; 
() cycle threshold affected by up to a CT of 10; () sequence predicted not to amplify. 
A B 
C D 
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GoPrime also distinguished between similar targets for the O primer/probe set (East 
Africa-specific) (Bachanek-Bankowska et al., 2016) when challenged with 24 serotype O 
viruses from outside of East Africa (Figure 5.11). 
 
Figure 5.11 Using GoPrime and GoPrimeTree to predict the specificity of foot-and-mouth 
disease virus (FMDV)-typing PCR assays. Serotype O primers (Bachanek-Bankowska et al., 
2016) were evaluated against 20 East African FMDVs (as published in Bachanek-Bankowska 
et al., 2016) and 24 serotype O sequences from GenBank. For the colour scheme: () 
perfect primer/probe-template match; () cycle threshold affected by up to a CT of 5; 
() cycle threshold affected by up to a CT of 10; () cycle threshold affected by up to a 
CT of 15; () sequence predicted not to amplify. 
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5.5 Discussion 
Primer/probe-template mismatches are often unavoidable in rPCR, leading to the 
requirement for continual monitoring of primers/probes against available sequence data, 
to ensure that assays remain fit for purpose. Consequently, the ability to quantitatively 
evaluate the performance of rPCR primers and probes in silico could aid researchers and 
diagnosticians by rapidly predicting the effects of mismatches present on rPCR 
amplification, which is not possible using current methods.  
Consistent with previous publications, mismatches in the 3ʹ-end of primers had a more 
detrimental effect on rPCR amplification than those located towards the 5ʹ-end, due to 
disruption of the DNA polymerase active site (Kwok et al., 1990; Whiley and Sloots, 2005; 
Bru et al., 2008; Süß et al., 2009; Stadhouders et al., 2010). The effect of single 
mismatches within the 3ʹ-end region displayed a consistent pattern, related to both 
nucleotide position and mismatch type. Furthermore, amplification was evident for 
reactions with multiple mismatches at the 3ʹ-end, which has not been previously reported 
(Stadhouders et al., 2010), however a minimum of 104 template copies was required for 
amplification to occur. As previously published by Süß et al., (2009), the amount of 
starting template did not significantly impact the ΔCT evident from primer-template 
mismatches. This is likely due to mismatches having the largest impact upon amplification 
in the first few rPCR cycles (Nogva and Rudi, 2004), as primers (and therefore mismatches) 
are incorporated into target sequences for subsequent cycles (Süß et al., 2009).  
The effect of probe-template mismatches also displayed a consistent pattern in terms of 
their position within the probe. For example, mismatches in the centre of the probe were 
shown to impact rPCR more than those at the 5ʹ-end, due to destabilising probe-template 
annealing (Süß et al., 2009). Single mismatches at the 5ʹ-end had a minimal effect on the 
CT of reactions. This has been previously documented (Süß et al., 2009), and is likely due 
to these mismatches having minimal impact on the 5ʹ nuclease activity of Taq DNA 
polymerase. Again, the amount of starting template did not significantly alter the ΔCT 
evident for probe-template mismatches. This concurs with a previous study which showed 
the efficiency of mismatched probes to remain constant throughout rPCR reactions (Süß 
et al., 2009).  
Although the experimental data gained in this study was specific to the rPCR conditions 
and primer/probe sequences evaluated, consistent patterns in the effects of mismatches 
enabled the creation of GoPrime, which was parameterised using experimental 
observations. When used to predict the effects of mismatches within the same FMDV 
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genomic region used to develop the program, GoPrime was on average able to predict the 
ΔCT 3.15 away from the observed experimental value (n = 97). However, GoPrime was 
also applicable over a broader genomic context, and was able to predict the likely targets 
of four FMDV-typing assays which target alternative regions of the FMDV genome. 
Furthermore, with rPCR assays requiring different performance criteria depending upon 
their use, the ability of GoPrime to quantitatively predict the effect of primer/probe-
template mismatches on both CT and LOD could help diagnosticians accurately assess 
whether rPCR assays are fit for their intended use. For instance, some rPCR assays might 
give positive results in spite of mismatches when high viral loads are present (such as in 
acute stages of disease), but generate a false-negative in the presence of lower viral loads 
(such as in oesophageal-pharyngeal fluid or environmental samples).  
In addition to rPCR, GoPrime can be used to predict the ΔCT and ΔLOD for mismatches 
present in two-step rRT-PCR as the use of Oligo(dT) or random hexamers for the RT stage 
results in primer/probe-template mismatches persisting though to cDNA. However, 
GoPrime’s use is limited for one-step rRT-PCR where gene-specific primers are used in 
both the RT and rPCR stages (one primer is incorporated into cDNA). Preliminary analysis 
was performed on the effect of primer/probe-template mismatches in one-step rRT-PCR 
and is detailed in Appendix 7b. However, further analysis of the effects of mismatches on 
one-step rRT-PCR is required before it can be added as a function for GoPrime. For 
example, different rRT-PCR kits have previously been shown to differ in their tolerance 
to mismatches (Stadhouders et al., 2010).  
In conclusion, this chapter describes the development of GoPrime: a freely available 
primer evaluation program which predicts the likely performance of primer/probe sets 
across multiple sequence data. Experimental data suggested that mismatch impacts 
follow a consistent pattern, enabling GoPrime to be parametrised from experimental 
observations. Within this chapter, GoPrime was only validated against primers and probes 
targeting FMDV, a further research avenue would be to challenge GoPrime with 
alternative targets, to ascertain the prediction accuracy in these circumstances. By 
providing a novel quantitative approach to primer/probe evaluation, GoPrime offers 
increased flexibility to the user by not only predicting the likely targets of primer/probe 
sets but also estimating the effects of any mismatches present on CT and LOD in silico, 
thereby enabling selection of the most appropriate primer/probe combination given the 
research question and diagnostic sample.  
 
Chapter 6 
 
139 
 
CHAPTER 6 
 
Discussion and future directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
140 
 
6.1 Thesis summary 
Accurate and rapid diagnostic tests are an essential component of surveillance programs 
to control and eradicate disease. As such, efforts have been made in the development 
and deployment of point-of-care tests (POCTs) in order to accelerate diagnostic 
confirmation and provide flexibility in disease control. For example, within the veterinary 
field, POCTs have proven effective during the final stages of rinderpest eradication 
(Brüning et al., 1999), are planned for use in the first stages of Peste des Petits Ruminants 
eradication in West Africa (OIE/FAO, 2015) and have been proposed as a way to empower 
field workers to participate in rabies disease surveillance (Markotter et al. 2009; Halliday 
et al. 2012; Cleaveland et al., 2014). 
The current diagnostic strategy for foot-and-mouth disease (FMD) is centred almost 
exclusively around dedicated laboratories. However, the utility and practicality of 
laboratory-based tests, especially during the period of time when scaling-up activities are 
required in emergency outbreak situations, and when considering routine diagnostics in 
resource-poor settings, can be limited by factors including (i) logistically complicated 
sample transportation to centralised facilities, (ii) requirement for diagnostic 
infrastructure and (iii) the need for highly trained personnel. POCTs offer a promising 
solution to this problem as they are developed for use within decentralised settings, such 
as at the pen-side and in low-resource laboratories.  
 
6.1.1 Drivers for the development of point-or-care tests 
The ability to detect FMD virus (FMDV) in challenging environments presents multiple 
opportunities for FMD diagnostics. For example, the use of POCTs during FMD outbreaks 
in normally disease free countries could help to improve the readiness of crisis 
management by increasing the efficiency of local control and surveillance measures. 
Within these scenarios, POCTs could be used to rapidly confirm the presence of disease, 
for rapid reporting and decision making, in advance of confirmation and further 
characterisation within laboratory settings (Figure 6.1). This in turn could enable 
evidence-based support for culling of livestock, as opposed to using methods such as 
“slaughter on suspicion” which were implemented during the UK 2001 FMD outbreak 
(Anderson, 2002). Furthermore, POCT could be useful in outbreak scenarios where the 
transport of samples to centralised facilities is logistically difficult. As such, the 
development of simple and portable diagnostic devices has been recommended within 
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independent reports that have followed recent FMD outbreaks (Anderson, 2002; Anon, 
2002a; 2002b). 
 
Figure 6.1 World Reference Laboratory for Foot-and-Mouth Disease (WRLFMD) 
contingency plan for UK outbreaks. Black arrows symbolise the current contingency plan 
(WRLFMD, 2016a), grey arrows symbolise how point-of-care tests could be implemented 
into current contingency plans, in providing a tool to accelerate diagnostic confirmation 
and help gain rapid control. 
 
POCTs also have the potential to immediately improve the diagnostic capacity within low-
to-middle income countries (LMICs) with endemic FMD infection. Laboratories within 
these regions are motivated to participate in FMDV surveillance, however are often 
constrained by poor infrastructure, resulting in an inability to diagnose FMD adequately 
(Vosloo et al., 2002; Paton et al., 2009). For example, within the Eastern Africa Regional 
Laboratory Network (EARLN), a network created for the exchange of scientific knowledge 
related to the control of FMD, only 3 out of 13 FMD diagnostic laboratories routinely use 
molecular-based assays, with no laboratory established for the systematic 
characterisation of FMD outbreaks (Namatovu et al., 2013). This, in combination with the 
logistical challenges associated with transporting samples from the field to appropriate 
laboratories, results in the majority of FMD outbreaks in East Africa remaining unrecorded 
(Vosloo et al., 2002). For example, although samples from these countries can be 
submitted for free characterisation (up to 50 samples per year) at the World Reference 
Laboratory for Foot-and-Mouth Disease (WRLFMD, The Pirbright Institute, UK), no samples 
from Tanzania or Kenya have been received in the last two years (WRLFMD, 2016b). 
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These missed opportunities to detect and characterise circulating FMDV serotypes hinder 
LMICs advancements along the Progressive Control Pathway for FMD (PCP-FMD), a global 
strategy led by the World Organisation for Animal Health (OIE) and Food and Agriculture 
Organization of the United Nations (FAO) to assist and facilitate countries where FMD is 
still endemic to progressively reduce its impact. With total FMD control unlikely for East 
Africa in the near future, due to factors such as poor infrastructure, social 
customs/attitudes and highly complex epidemiology (Vosloo et al., 2002; Ayebazibwe et 
al., 2010b; Maree et al., 2014), a progressive approach for FMD control is required, with 
surveillance necessary at all stages (Sumption et al., 2012) (Figure 6.7). Therefore, 
increasing diagnostic capacity is now considered a priority of the EARLN, especially in 
regard to molecular capabilities (Namatovu et al., 2013). 
 
Figure 6.2 Progressive Control Pathway for Foot-and-Mouth Disease (PCP-FMD). Adapted 
from Sumption et al. (2012). 
 
The availability of simple-to-use, portable devices, such as the T-CORTM 8 (Tetracore Inc., 
MA, USA) and Genie® II (OptiGene Ltd., Horsham, UK), offer a simple solution for 
molecular diagnostics, regardless of the setting. However, in order to transition such 
platforms into use, resolutions are required to fill significant gaps that limit the use of 
POCTs. These include strategies to (i) overcome sample preparation bottlenecks, (ii) 
ensure confidence in POCT diagnostic performance, (iii) stabilise reagents, (iv) streamline 
assay protocols, (v) guarantee quality control, (vi) evaluate if assays are fit for purpose 
and (vii) transition assays into current diagnostic strategies. The overarching aim of this 
thesis was therefore to create an end-to-end molecular toolbox for the detection and 
characterisation of FMDV in challenging environments, such in the field or low-resource 
laboratories (Figure 6.3). Through the development of solutions for the limiting factors 
listed above, this thesis provides robust evidence that simple POCTs can be successfully 
deployed for the rapid detection and characterisation of FMDV in decentralised settings.  
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6.2 Overcoming sample preparation bottlenecks 
Technologies for POCTs have existed for a number of years, however one major 
bottleneck that remained was the development of sample preparation techniques suitable 
for use in low-resource settings (Dineva et al., 2007). Although a number of simple sample 
preparation methods have been published (Waters et al., 2014), limited attempts have 
been made to combine these techniques with FMDV-specific POCTs. This thesis addressed 
this through the first multiway comparison of 11 sample preparation methods across seven 
assay formats, concluding that reverse transcription loop-mediated isothermal 
amplification (RT-LAMP) and real-time reverse transcription PCR (rRT-PCR) can be 
performed in the absence of RNA extraction, with reliable performance achieved using 
the dilution of samples in nuclease-free water (NFW) (Howson et al., 2017b).  
Importantly, results demonstrate that the dilution of serum, epithelial suspensions, 
mouth/feet swabs and oesophageal-pharyngeal fluid (OP fluid) in NFW enables FMDV RNA 
to be detected across a large diagnostic window, with pan-FMDV diagnosis of cattle 
possible in the clinical, as well as convalescent stages of FMD infection (including the 
capability to detect FMDV in OP fluid two months after initial infection) (Howson et al., 
2017c; 2017d). Furthermore, these methods permit in situ characterisation, with FMDV 
serotype able to be determined from all above sample types, in cattle two to seven days 
post initial infection (using FMDV-positive samples with a pan-FMDV rRT-PCR cycle 
threshold [CT] value of less than 29) (Howson et al., 2017d). 
In addition to sample preparation bottlenecks, over the last few years, a large emphasis 
has been placed on the development of non-invasive sampling procedures, such as the 
use of rope chews for collection of oral fluids (Mouchantat et al., 2014) and aerosols (Ryan 
et al., 2009; Waters et al., 2014). Initial investigation into use of FTA® cards for “non-
invasive” sampling and low-cost transportation has also been performed (Muthukrishnan 
et al., 2008), however the technique published still requires wiping of FTA® cards across 
open mouth lesions. Building upon these studies, this thesis demonstrated that it was 
possible to detect FMDV RNA in saliva collected non-invasively onto FTA® cards by simply 
wiping them across the chin and lips of cattle. This promising finding should be 
investigated further to determine the clinical detection window for this approach.  
Combined, these efforts can be used to reduce the sample preparation bottleneck, and 
future work should be aimed at transitioning these methods to other important 
susceptible species, especially those in which clinical signs are more discrete and 
therefore more challenging to detect. 
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6.3 Ensuring confidence in diagnostic performance 
A further inhibitor, with regard to the use of POCTs, is scepticism over whether 
decentralised tests can produce comparable results to traditional laboratory-based 
diagnostics. For example, the antigen-detection lateral-flow device (Ag-LFD), which is 
one of the most recognised POCT platforms, is widely published to have reduced 
analytical sensitivity comparatively to molecular methods (Metwally et al., 2010).  
Consequently, misconceptions can arise over the performance of POCTs in general.  
Data in this thesis challenges this scepticism, revealing that the transition of laboratory-
based assays into POCT-formats does not negatively impact upon assay performance. For 
instance, pan-FMDV POCT rRT-PCR displays equivalent sensitivity to the reference rRT-
PCR, and even in the absence of RNA extraction is comparable to the reference rRT-PCR 
in the presence of a diagnostic cut-off (Shaw et al., 2007). Although comparable to their 
laboratory based-equivalents, POCT RT-LAMP and FMDV-typing rRT-PCR assays are 
comparable to the reference rRT-PCR only when considering a diagnostic cut-off value 
and using extracted RNA (Howson et al., 2017c; 2017d). Further work is therefore 
required in order to understand whether comparable diagnostic cut-offs for POCTs are 
required, or whether cut-off values are useful only for laboratory settings.  
In light of this, RT-LAMP and FMDV-typing rRT-PCR POCTs are most likely to be used for 
confirmation and characterisation of acutely infected animals in cases where rapid 
diagnosis is required (Figure 6.4). Conversely, pan-FMDV POCT rRT-PCR is able to report 
a CT value in weaker samples, and is therefore suitable both for confirmation of negative 
samples and detection of FMDV across the diagnostic window from pre-clinically infected 
through to convalescent animals (Figure 6.4).  
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Figure 6.4 The proposed use of point-of-care tests across the foot-and-mouth disease 
(FMD) diagnostic window. (red) sera; (black) vesicular epithelium; (green) oesophageal-
pharyngeal fluid; (purple) mouth/foot swabs. The dotted x-axis line represents the 
incubation period, which is dependent upon: infectious dose, viral strain, animal species 
and host determinants. Based on data from Alexandersen et al. (2003a) and King et al. 
(2012). (rRT-PCR) real-time reverse transcription PCR; (rRT-LAMP) real-time reverse 
transcription loop-mediated isothermal amplification (grey shaded area represents cycle 
threshold [CT] values over the diagnostic cut-off [Shaw et al., 2007]); (Ag-LFD) antigen-
detection lateral-flow device (suitable for use with epithelium and vesicular fluid only). 
 
6.4 Stabilisation of reagents 
Assays for use in decentralised settings must be able to incorporate reagents compatible 
with the environmental conditions found in the countries of deployment. However, the 
majority of previously published FMDV-specific assays utilise wet reagents, containing 
temperature sensitive enzymes. These present a challenge for long term storage in 
disease-free countries (contingency planning) or use in endemically infected countries 
where electricity supply can be unreliable and erratic (absence of a reliable cold chain).  
This thesis addressed this through robust evaluations of lyophilised reagents for (i) pan-
FMDV RT-LAMP assays, (ii) a commercially available lyophilised pan-FMDV rRT-PCR assay, 
and (iii) an East Africa-specific FMDV-typing rRT-PCR assay. Significantly, results indicate 
that reagent lyophilisation does not negatively impact upon assay performance, even 
when used in high-ambient temperature settings, with all lyophilised assays displaying 
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comparable analytical sensitivity to their wet equivalents (Howson et al., 2017c; 2017d). 
 
Importantly, field-work highlighted a number of additional benefits associated with the 
lyophilisation of reagents. For instance, lyophilisation helps to simplify transportation 
requirements, as reagents do not require any form of a cold chain. This ultimately reduces 
shipping costs (Table 6.1), without altering the integrity and performance of the reagents. 
In light of this, lyophilisation of reagents should not only be considered for other FMD 
diagnostic methods, but also beyond to other disease surveillance programs.  
Table 6.1 Price of shipping molecular kits to East Africa 
Origin Destination Kit format Requirements Shipping time Shipping cost* 
OptiGene Ltd., UK SUA, Tanzania RT-LAMP wet -80°C ice bricks Three days GB £ 189 
OptiGene Ltd., UK SUA, Tanzania RT-LAMP dry None Three days GB £ 114 
Tetracore Ltd., USA SUA, Tanzania rRT-PCR wet Dry ice Four days GB £ 816 
Tetracore Ltd., USA SUA, Tanzania rRT-PCR dry None Four days GB £ 248 
*Prices quoted from DHL (https://www.dhl.com) on 17/07/2017 
 
6.5 Streamlining assay protocols 
In order to successfully utilise POCTs in decentralised settings, assays must be in the 
format of a “ready-to-use kit” and utilise protocols suitable for use in challenging 
environments. Previously, the only reported evaluations of FMDV-specific POCTs in field-
settings were limited to rRT-RPA, which required an RNA extraction step (Abd El Wahed 
et al., 2013), and Ag-LFDs during the UK 2007 FMDV outbreak (Ryan et al., 2008). 
Building upon these initial studies, molecular assays in this thesis were modified to utilise 
simple field-ready protocols (outlined in Appendix 8) (Figure 6.5). In addition, while the 
majority of molecular tests ideally require (i) dedicated spaces for reagent preparation, 
RNA extraction and template addition, (ii) uninterrupted mains power for cold-storage of 
reagents and powering of platforms and (iii) skilled laboratory staff for assay assembly 
and result analysis, the POCTs developed and evaluated in this thesis alleviate these 
constraints by:  
1. Negating complex sample preparation as RNA extraction is not necessary. 
2. Streamlining assay set-up by reducing the pipetting stages. 
3. Minimising the potential for cross-contamination by using closed systems such 
as real-time detection or the AMPlite® (Appendix 4). 
4. Using battery powered platforms (which can be charged using car batteries), 
removing the need for reliable mains power.  
5. Using platforms that automatically analyse and report results. 
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Importantly, in these formats, assays were able to (i) rapidly detect FMDV in the field and 
low-resource laboratories (30 minutes for rRT-LAMP and 80 minutes for rRT-PCR) and (ii) 
identify FMDV serotype for the first time in situ (Howson et al., 2017c; 2017d).  
Furthermore, preliminary evaluation of the AMPlite® (APHA, Addlestone, UK), concluded 
RT-LAMP combined with automated lateral-flow detection (RT-LAMP-LFD) can be reduced 
to a single pipetting stage without compromising assay performance (Appendix 4).  
 
Figure 6.5 Point-of-care test workflow for use in challenging settings. (rRT-PCR) real-
time reverse transcription PCR; (rRT-LAMP) real-time reverse transcription loop-mediated 
isothermal amplification; (RT-LAMP-LFD) reverse transcription loop-mediated isothermal 
amplification with lateral-flow detection; (RB) resuspension buffer; (NFW) nuclease-free 
water; (OP fluid) oesophageal-pharyngeal fluid. *optional field centrifuge. 
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By streamlining protocols, a generic diagnostic approach becomes achievable whereby 
one method can be used for the detection of multiple diseases. For instance, knowledge 
gained during the lifespan of project has enabled Tetracore to develop a number of 
additional POCTs to differentiate between a panel of vesicular diseases (Appendix 9). 
Opportunity exists for similar expansion of the Genie® II, as this platform is already being 
used for screening in customs settings (OptiGene Ltd., 2017); supplementation of new 
assays (including the availability of lyophilised core regents where users add their own 
primers) would not be logistically challenging should new emerging threats arise. 
 
6.6 Guaranteeing quality control 
Quality control of POCTs is often thought of as a complex issue, as performing assays 
outside of recognised quality assurance systems (such as ISO/IEC 17025), may give rise to 
concerns regarding test confidence and result acceptance. Consequently, although many 
FMDV-specific POCTs are published in peer-reviewed journals, none yet appear in the OIE 
Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (OIE, 2012), with the 
exception of Ag-LFDs. This thesis has begun to address this through (i) designing molecular 
assays that contain inbuilt quality checks, and (ii) providing initial validation data for 
POCT use.  
Notably, data presented in this thesis demonstrates that the addition of an exogenous 
internal control into rRT-PCR (T-CORTM 8 [#2]) and RT-LAMP-LFD (AMPlite®), does not 
impact upon analytical sensitivity and would reliably report false-negative reactions if 
subject to inhibition (Howson et al., 2017d). Furthermore, the addition of an anneal curve 
to rRT-LAMP, which reports an amplicon specific anneal temperature, ensures that non-
specific amplification, and consequent false-positive results, are highlighted (Howson et 
al., 2017c). Importantly, using these inbuilt controls during field work, out of 145 samples 
(from 60 cattle over 10 farms in 2 countries) analysed using RT-LAMP and 144 samples 
(from 78 cattle over 13 farms in 3 countries) analysed using rRT-PCR, no false-positives 
were detected and results were consistent with clinical observations and the reference 
rRT-PCR. Notably, all assays tested display 100% specificity when challenged with 
alternative vesicular disease viruses. 
As a result, it would be a worthwhile exercise to generate further validation data, in order 
to produce a dossier for consideration of inclusion of these tests in the OIE Manual of 
Diagnostic Tests and Vaccines for Terrestrial Animals (OIE, 2012). Indeed, such an exercise 
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would enhance initial efforts that have already been pursued within this area. For 
example, as part of an EU funded project (RAPIDIA-FIELD, 2017), small validation 
exercises have been performed on RT-LAMP and cartridge based rRT-PCR (Enigma® Mini 
Laboratory: Enigma® Diagnostics, Porton Down, UK), with high consensus in results 
reported between a number of European and African laboratories (Goller et al., 2017).  
 
6.7 Evaluating if assays are fit for purpose 
Although molecular-based assays are well accepted for the diagnosis of FMD, the high 
mutation rate associated with RNA viruses can result in primer/probe-template 
mismatches often being unavoidable. Assays therefore require continual evaluation to 
ensure they remain fit for purpose. Data generated in this thesis revealed that the effects 
of primer/probe-template mismatches on real-time PCR (rPCR) CT and limit of detection 
(LOD) follow a consistent pattern. These experimental results were used to parameterise 
the mathematical model behind GoPrime, a freely-available (Orton, 2017), novel 
primer/probe validation program which is able to predict the performance of PCR-based 
assays in silico. 
When screening 97 templates against the Callahan et al. (2002) primers and probe 
sequences, GoPrime was on average able to predict the effect of mismatches on CT to be 
3.15 away from the observed experimental value, and accurately predicted the targets 
of four previously published FMDV-typing assays (Bachanek-Bankowska et al., 2016) across 
66 sequences. With an increasing number of rRT-PCR publications for detection of FMDV, 
in addition to the continual increase in sequence data available online, GoPrime has the 
potential to rapidly evaluate whether primer and probe sequences are fit for purpose with 
sufficient coverage to detect circulating FMDV strains. 
 
6.8 Transitioning assays into current diagnostic strategies 
Transitioning of POCTs into current diagnostic strategies needs to be considered to 
determine how these assays could work in parallel with, or replace, existing 
methodologies, as without proper management, decentralisation of testing could put 
further stress on veterinary systems. In foreseeing this problem, POCT protocols for 
human diagnostics have been integrated into contingency plans, such as the World Health 
Organization (WHO) recommendations on the use of rapid testing for human influenza 
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diagnosis (WHO, 2005). In order to follow in the footsteps of such strategies, and achieve 
recognition for the simple molecular POCT protocols developed within this thesis 
(Appendix 8), it would be an advisable exercise to carry further assay validation by 
following the “Principles and Methods for Validation of Diagnostic Assays for Infectious 
Diseases” as recommended by the OIE (OIE, 2012 [Chapter 1.1.4/5]). 
By deploying POCTs into diagnostic strategies, the implementation of data sharing and 
storage procedures are also necessitated, to ensure instant reporting and monitoring of 
results. Some of the newer POCT platforms, such as the T-CORTM 8 and Genie® III, are 
equipped with data transmission capacity, enabling real-time reporting to laboratories. 
Furthermore, with programs such as EpiCollect now freely-available (which utilises mobile 
phones for data entry), results can easily be collated in internet databases for centralised 
analysis (Aanensen et al., 2009). For example, EpiCollect has now been utilised in 
preliminary trials with Kenyan Maasai farmers to monitor diseases of veterinary 
importance (FAO, 2010). The advent of the “Internet of Things” (IoT), an interconnection 
of physical devices with network infrastructure to enable collection and exchange of data 
(Xia et al., 2012), may further revolutionise decentralised testing. By connecting POCT 
through internet-based software, which is a current initiative of Toshiba for the Genie® 
III, real-time data exchange and analysis can be automated, negating the requirement for 
manual report preparation. 
 
6.9 Future research directions 
The development of a molecular toolbox, suitable for decentralised detection of FMDV, 
has inevitably raised a number of new questions and opened up directions for future 
research. In particular, there are two main areas which require further investigation. 
 
6.9.1 Application of point-of-care tests to answer FMD research questions 
Recent data have suggested that FMD outbreaks occur as continuous repeating patterns 
of alternating serotypes, driven by livestock movements and livestock contact networks 
(Casey-Bryars, 2016). If true, this suggests that infection cycles may be predictable, in 
terms of temporal and spatial patterns of serotypic dominance, opening up possibilities 
and opportunities for disease control. For example, although vaccination is cited as an 
existing FMD control strategy for East Africa (Hunter, 1998; Rweyemamu and Astudillo, 
2002), the ability to predict waves of serotypic dominance would improve the 
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effectiveness of  vaccination strategies (Vosloo et al., 2002; Mumford, 2007). However, 
further investigation of this hypothesis is difficult considering the current diagnostic 
capacity in East Africa (Namatovu et al., 2013). The lyophilised FMDV-typing assay and T-
CORTM 8 offer a new avenue to investigate this hypothesis, as FMDV serotype can be 
determined in under two hours (from sample collection to result calling) in either 
laboratory or field-settings. Furthermore, with the communities of East Africa having 
previously shown effective engagement with disease control programmes, such as rabies 
control in northern Tanzania (Cleaveland et al., 2003) and Rinderpest eradiation 
throughout East Africa (Mariner et al., 2012), such enthusiasm could enable such 
hypothesis testing and FMD surveillance to be performed. 
 
6.9.2 Extending GoPrime to alternate molecular assays 
The current version of GoPrime allows researchers to quantitatively evaluate the 
performance of rPCR primers and probes in silico across multiple sequence data. 
However, parameterisation of GoPrime should be extended to include other molecular 
assays, such LAMP. The complex primer requirements for LAMP result in primer-template 
mismatches often being unavoidable, as four to six primers are necessary to target six to 
eight sequence regions (Notomi et al. 2000; Nagamine et al. 2002). Very limited work has 
been conducted into investigating the effects of these mismatches (Wang, 2016), and 
further research is necessary. Therefore, the study conducted in Chapter 5 should be 
expanded, firstly to ascertain the effects of each mismatch type on LAMP performance, 
and secondly to include and evaluate this as a function of GoPrime. Furthermore, GoPrime 
has been designed for rPCR in such a way to accommodate any primers, probes and 
targets, regardless of the pathogen, however validation within this thesis has been limited 
to primers and probes which target FMDV. Consequently, a further research avenue would 
be to challenge GoPrime with alternative targets, to ascertain the prediction accuracy in 
these circumstances. 
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6.10  Concluding remarks 
Overall, this thesis has demonstrated that sophisticated molecular assays can be 
simplified into formats which can be used easily and quickly by unskilled staff, with the 
potential to be rolled out immediately into FMDV outbreak scenarios, or within endemic 
FMD settings where there is often a high turnover of staff.  
Predictions indicate that the POCT market will increase in value to US$ 38.2 billion by 
2024 (researchandmarkets.com, 2017), demonstrating a real commitment of investors 
and stakeholders towards implementation of these technologies. Even within the duration 
of this project, technologies have advanced so rapidly that prototype devices, which 
combine automated sample collection, are beginning to appear on the horizon (Regen et 
al., 2008; Figure 6.6). With continuous investment and progression being made within the 
field of POCTs, it is only a matter of time before decentralised detection of FMDV becomes 
a practical reality. 
 
Figure 6.6 The future of point-of-care tests. The Tantei, developed by the Food and 
Environment Research Agency (FERA), is a fully automated prototype designed for 
detection of plant pathogens. The platform performs automated air sampling, nucleic 
acid extraction, loop-mediated isothermal amplification (using lyophilised regents), 
result interpretation and transmission of results without operator intervention, enabling 
real-time, remote pathogen surveillance. 
 
 
Appendix 
 
154 
 
Appendices 
Appendix 1 
Optimisation of isothermal reactions 
1a) Optimisation of reverse transcription loop-mediated isothermal amplification using 
wet reagent formats (Chapter 2): 
 
Figure 7.1 Optimisation of reverse transcription loop-mediated isothermal amplification 
(RT-LAMP) conditions for wet reagents. (A) Primer concentration comparison for ISO-001 
real-time RT-LAMP (rRT-LAMP) (internal primers [µM]: loop primers [µM]: external primers 
[µM]): (●) 2 : 1: 0.2; (▲) 1.6 : 0.8 : 0.2; (■) 1.2 : 0.6 : 0.2; (◆) 0.8 : 0.4 : 0.2. (B) Addition 
of Avian Myeloblastosis Virus (AMV) reverse transcriptase for ISO-001 rRT-LAMP: (■) rRT-
LAMP plus 2 U AMV; (■) rRT-LAMP with no AMV. (C) Reaction time for ISO-001 and ISO-004 
reagents: (●) reference real-time RT-PCR (rRT-PCR); (■) ISO-001 rRT-LAMP performed for 
60 minutes; (▲) ISO-004 rRT-LAMP performed for 60 minutes. The table presents results 
for RT-LAMP with end-point lateral-flow detection (RT-LAMP-LFD). All points represent 
the mean of two replicates (bars display the range), half-shaded points indicate where 
one replicate was positive and the other negative. 
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1b) Optimisation of reverse transcription loop-mediated isothermal amplification using 
lyophilised reagent formats (Chapter 3): 
 
Figure 7.2 Selection of reverse transcription loop-mediated isothermal amplification (RT-
LAMP) lyophilised reagents. A comparison was performed between wet and lyophilised 
reagents for real-time RT-LAMP (rRT-LAMP) and RT-LAMP combined with lateral-flow 
detection (RT-LAMP-LFD) using a dilution series of RNA extracted from a FMDV cell culture 
isolate (Chapter 2.3.6). Grey shaded area represent cycle threshold (CT) values over the 
diagnostic cut-off threshold of CT < 32 (Shaw et al., 2007). All points represent the mean 
of two replicates (bars display the range): (■) ISO-001 in a wet format; (■) ISO-001 in a 
lyophilised format; (▲) ISO-004 in a wet format; (▲) ISO-004 in a lyophilised format. For 
RT-LAMP-LFD (table): (+) both duplicates positive; (+/-) one duplicate positive; (-) both 
duplicates negative. 
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Appendix 2 
Comparison of sample preparation methodologies 
 
Figure 7.3 Comparison of sample preparation methods for the reference real-time 
reverse transcription PCR (rRT-PCR). Performed on a bench top real-time PCR machine 
(Stratagene Mx3005PTM). Grey shaded area represent cycle threshold (CT) values over the 
diagnostic cut-off threshold of CT < 32 (Shaw et al., 2007). A total of 11 sample 
preparation methods were trialled: nine simple preparation techniques, compared to 
automated robotic extraction and the use of neat samples. Extraction from antigen-
detection lateral-flow devices (Ag-LFDs) was trialled for epithelial suspensions only. All 
points represent the mean of two replicates; half shaded points represent when one 
replicate was positive and the other negative. 
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Figure 7.4 Comparison of sample preparation methods for real-time reverse transcription 
loop-mediated isothermal amplification (rRT-LAMP) (wet reagents). Performed on a 
Genie® II. A total of 11 sample preparation methods were trialled: nine simple preparation 
techniques, compared to automated robotic extraction and the use of neat samples. 
Extraction from antigen-detection lateral-flow devices (Ag-LFDs) was trialled for 
epithelial suspensions only. All points represent the mean of two replicates; half shaded 
points represent when one replicate was positive and the other negative. 
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Figure 7.5 Comparison of sample preparation methods for real-time reverse transcription 
recombinase polymerase amplification (rRT-RPA). Performed using the TwistAmp® exo RT 
kit, on a Genie® II. A total of 11 sample preparation methods were trialled: nine simple 
preparation techniques, compared to automated robotic extraction and the use of neat 
samples. Extraction from antigen-detection lateral-flow devices (Ag-LFDs) was trialled for 
epithelial suspensions only. All points represent the mean of two replicates; half shaded 
points represent when one replicate was positive and the other negative. 
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Figure 7.6 Comparison of sample preparation methods for T-CORTM 8 (#1) real-time 
reverse transcription PCR (rRT-PCR). Performed on a T-CORTM 8. A total of 11 sample 
preparation methods were trialled: nine simple preparation techniques, compared to 
automated robotic extraction and the use of neat samples. Extraction from antigen-
detection lateral-flow devices (Ag-LFDs) was trialled for epithelial suspensions only. All 
points represent the mean of two replicates; half shaded points represent when one 
replicate was positive and the other negative. 
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Figure 7.7 Comparison of sample preparation methods for T-CORTM 8 (#2) real-time 
reverse transcription PCR (rRT-PCR). Performed on a T-CORTM 8. A total of 11 sample 
preparation methods were trialled: nine simple preparation techniques, compared to 
automated robotic extraction and the use of neat samples. Extraction from Ag-LFDs 
(antigen-detection lateral-flow devices) was trialled for epithelial suspensions only. All 
points represent the mean of two replicates; half shaded points represent when one 
replicate was positive and the other negative. 
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Appendix 3 
Samples for evaluation of isothermal reactions 
Appendix 3a: Samples used to evaluate reverse transcription loop-mediated isothermal 
amplification (RT-LAMP) performance in laboratory settings 
 
 
 
 
 
Table 7.1 Samples used to evaluate RT-LAMP 
Purpose Sample type Sample/s 
Comparison of RT-LAMP 
master mixes 
Cell culture isolate (dilution series in 10% 
[w/v] bovine epithelial tissue suspension) 
O/UAE/2/2003 
Evaluation of lyophilised 
reagents on clinical samples 
Archival field epithelial tissue suspensions 
Asia 1/TUR/2/2013 
A/IRN/24/2012 
A/TUR/7/2013 
A/TUR/4/2013 
Sat 1/TAN/50/2012 
SAT 2/TAN/14/2012 
SAT 2/BOT/15/2012 
Evaluation of sample 
preparation methodologies 
Experimental bovine sera (n = 19) and 
oesophageal-pharyngeal fluid samples (n = 21) 
from cattle challenged with FMDV 
O/UKG/34/2001 
Evaluation of rRT-LAMP as a 
laboratory surveillance tool 
Field samples (OP fluid) collected from cattle 
between September 2011 and November 2013 
(n = 158) 
Representing serotypes 
O, A, SAT 1 and SAT 2 
Experimental samples (serum = 38; OP fluid = 
50) from buffalo challenged directly with 
three FMDV isolates 
KNP/196/91/1 (SAT 1) 
KNP/19/89/2 (SAT 2) 
KNP/1/08/3 (SAT 3) 
Evaluation of rRT-LAMP and 
RT-LAMP-LFD in endemic 
laboratory settings 
Archival field epithelial tissue suspensions 
O/Musoma Rural 
O/Tabora 
O/Tabora 
O/Mara 
O/Njombe 
O/Kilimanjaro 
O/Ntwara 
A/Kagera 
SAT 1/Dar es Salaam 
SAT 1/Morogoro 
SAT 2/Morogoro 
GD/Unknown 
NVD/Kilimanjaro 
NVD/Kilimanjaro 
Evaluation of the AMPlite® 
Cell culture isolate (dilution series in 10% 
[w/v] bovine epithelial tissue suspension) 
O/UAE/2/2003 
(RT-LAMP) reverse transcription loop-mediated isothermal amplification; (rRT-LAMP) real-time RT-LAMP; 
(RT-LAMP-LFD) RT-LAMP with molecular lateral-flow detection; (FMDV) foot-and-mouth disease virus; (SAT) 
Southern African Territories; (OP fluid) oesophageal-pharyngeal fluid.  
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Appendix 3b. Table 7.2 Clinical samples used to evaluate RT-LAMP in field settings 
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Appendix 4 
Preliminary evaluation of the AMPlite® 
Field validation of reverse transcription loop-mediated isothermal amplification using 
molecular lateral-flow detection (RT-LAMP-LFD) highlighted a number of important 
factors for consideration in future assay design, including the requirement to minimise 
cross-contamination. Consequently, in order to reduce the number of pipetting stages 
required in the field and minimise the opportunities/risk for cross-contamination between 
assays, preliminary trials were performed on the AMPlite®, which is a prototype closed 
RT-LAMP-LFD system developed by The Animal and Plant Health Agency (APHA, 
Addlestone, UK).  
RT-LAMP-LFD reactions were performed in a total reaction mix of 50 µl, containing 
labelled primers, ISO-001 master mix (wet) and reverse transcriptase at equivalent final 
concentrations as previously stated (Chapter 2.3.4). In addition, reactions contained a 
proprietary internal control (IC) (104 copies) and detecting primers (0.4 µM internal 
primers: 0.04 µM external primers: 0.2 µM loop primers labelled with digoxigenin 
[forward] and biotin [reverse]). Reactions were incubated in the AMPlite® heat block for 
30 minutes at 65°C. Once the incubation has completed, the AMPlite® automatically 
dispensed the reaction onto the LFD (Figure 7.8): a positive result was signified by the 
presence of three lines (test, RT-LAMP IC and LFD read lines), a negative result was 
indicated by the presence of the IC and LFD read lines only.  
 
 
Figure 7.8 AMPlite® device and heat block. Reaction mixture was added to the AMPlite® 
sample well (a). Upon closing of the lid, the reaction was dispensed into the reaction 
chamber (b), and device inserted into the AMPlite® heat block (c). Following incubation, 
the heat block automatically releases lateral-flow device (LFD) running buffer (d) through 
reaction chamber, dispensing the reaction onto the LFD (e). (R) LFD read line; (C) internal 
control line; (+) test-line. 
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The analytical sensitivity of the AMPlite®, established using RNA extracted from a FMDV 
cell culture isolate (as described in Chapter 2.3.6), was maintained in comparison to RT-
LAMP-LFD (Table 7.3). 
 
Table 7.3 Analytical sensitivity of the AMPlite® comparatively to RT-LAMP-LFD 
 10-fold dilution series of FMDV (O/UAE/2/2003) RNA  
 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 
Reference  
rRT-PCR 
15.61 18.89 22.02 25.62 29.09 32.08 36.66 No CT 
RT-LAMP-LFD 
 
        
AMPlite® 
 
        
(rRT-PCR) real-time reverse transcription PCR; (RT-LAMP-LFD) RT-LAMP combined with molecular lateral-
flow detection. For RT-LAMP-LFD, the upper band represents the LFD control line, and lower band the test 
line. For the AMPlite®, the upper band represents the LFD read control, middle the internal control and 
lower band the test line. In samples with high amounts of FMDV, the control lines are often feint due to 
reagent competition. 
 
During field work in Kenya (Chapter 3.3.8) preliminary trials were performed using two 
lyophilised RT-LAMP-LFD pellets (Chapter 3.3.3), re-suspended with 30 µl of re-suspension 
buffer, 10 µl sample and made up to 50 µl total volume with NFW. The heat block was 
powered through a vehicle auxiliary, using a 200 W inverter. 100% concordance between 
rRT-LAMP, RT-LAMP-LFD and the AMPlite® was present across the three samples (serum = 
1; epithelium = 2) tested (data not shown). 
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Appendix 5 
Laboratory evaluation of lyophilised real-time reverse 
transcription PCR 
Table 7.4 Clinical samples for evaluation of rRT-PCR in laboratory settings 
Serotype WRLFMD sample 
ID 
Topotype Lineage Location Year Type Reference 
rRT-PCR 
Lyophilised 
rRT-PCR 
Typing 
rRT-PCR 
O HKN/12/2015 CATHAY unnamed Hong Kong 2015 OS 28.26 28.70 N/A 
 IRN/26/2015 ME-SA PanAsia-2BAL-09 Iran 2015 OS 28.67 27.75 N/A 
 KUW/1/2016 ME-SA PanAsia-2BAL-09 Kuwait 2016 OS 16.86 18.35 N/A 
 KUW/4/2016 ME-SA PanAsia-2BAL-09 Kuwait 2016 OS 14.06 15.75 N/A 
 PAK/30/2015 ME-SA PanAsia-2BAL-09 Pakistan 2015 OS 21.20 19.60 N/A 
 PAK/32/2015 ME-SA PanAsia-2BAL-09 Pakistan 2015 OS 21.30 20.80 N/A 
 PAK/34/2015 ME-SA PanAsia-2BAL-09 Pakistan 2015 OS 20.70 20.55 N/A 
 PAT/4/2015 ME-SA PanAsia Palestine 2015 OS 27.90 28.30 N/A 
 TAN/5/2009 EA-2 unnamed Tanzania 2012 OS 23.82 24.10 23.75 
 TAN/39/2012 EA-2 unnamed Tanzania 2012 OS 24.03 27.45 25.95 
 TAN/3/2014 EA-2 unnamed Tanzania 2014 OS 26.68 29.15 27.80 
 TAN/6/2014 EA-2 unnamed Tanzania 2014 OS 26.57 28.75 28.95 
 KEN/10/2009 EA-2 unnamed Kenya 2009 OS 27.18 29.85 No CT 
 KEN/146/2010 EA-2 unnamed Kenya 2010 OS 16.87 19.10 18.95 
 KEN/151/2010 EA-2 unnamed Kenya 2010 OS 20.54 23.70 28.35 
 KEN/152/2010 EA-2 unnamed Kenya 2010 OS 20.15 21.90 25.65 
 KEN/154/2010 EA-2 unnamed Kenya 2010 OS 25.33 24.50 26.20 
 KEN/15/2011 EA-2 unnamed Kenya 2011 OS 19.61 21.90 22.45 
A IRN/21/2015 ASIA G-VII Iran 2015 OS 27.39 26.80 N/A 
 IRN/24/2015 ASIA Iran-05SIS-10 Iran 2015 OS 21.68 19.85 N/A 
 SAU/8/2015 ASIA G-VII Saudi Arabia 2015 OS 26.78 25.30 N/A 
 PAK/31/2015 ASIA Iran-05FAR-11 Pakistan 2015 OS 18.63 19.55 N/A 
 PAK/56/2015 ASIA Iran-05FAR-11 Pakistan 2015 OS 22.63 25.80 N/A 
 TAN/42/2009 AFRICA G-I Tanzania 2009 OS 21.79 23.15 23.65 
 TAN/56/2012 AFRICA G-I Tanzania 2012 OS 35.64 35.50 No CT 
 TAN/61/2012 AFRICA G-I Tanzania 2012 OS 26.96 31.35 28.55 
 TAN/70/2012 AFRICA G-I Tanzania 2012 OS 20.36 23.00 23.05 
 TAN/71/2012 AFRICA G-I Tanzania 2012 OS 24.91 27.60 25.75 
 TAN/15/2013 AFRICA G-I Tanzania 2013 OS 15.78 18.85 21.05 
 KEN/28/2008 AFRICA G-I Kenya 2008 OS 30.61 30.45 27.20 
 KEN/22/2009 AFRICA G-I Kenya 2009 OS 28.09 29.10 28.00 
SAT 1 TAN/50/2012 I (NWZ) unnamed Tanzania 2012 OS 25.21 27.10 26.45 
 TAN/23/2013 I (NWZ) unnamed Tanzania 2013 OS 15.87 17.95 20.75 
 TAN/29/2013 I (NWZ) unnamed Tanzania 2013 OS 15.38 17.50 21.85 
 TAN/22/2014 I (NWZ) unnamed Tanzania 2014 OS 17.44 21.75 25.40 
 KEN/26/2008 I (NWZ) unnamed Kenya 2008 OS 16.05 18.35 22.95 
 KEN/9/2009 I (NWZ) unnamed Kenya 2009 OS 23.37 25.25 25.20 
 KEN/12/2009 I (NWZ) unnamed Kenya 2009 OS 24.54 23.80 25.20 
SAT 2 ZIM/9/2015 II unnamed Zimbabwe 2015 OS 25.44 26.05 N/A 
 ZIM/21/2015 II unnamed Zimbabwe 2015 OS 26.16 26.95 N/A 
 TAN/3/2011 IV IV Tanzania 2011 OS 25.08 25.95 24.40 
 TAN/7/2011 IV IV Tanzania 2011 OS 22.63 24.35 24.25 
 TAN/5/2012 IV unnamed Tanzania 2012 OS 20.37 23.30 21.25 
 TAN/10/2012 IV unnamed Tanzania 2012 OS 19.77 22.30 23.35 
 TAN/14/2012 IV unnamed Tanzania 2012 OS 22.44 25.10 22.65 
 TAN/19/2012 IV unnamed Tanzania 2012 OS 25.78 24.75 22.20 
 TAN/64/2012 IV unnamed Tanzania 2012 OS 25.56 26.20 24.80 
 KEN/2/2007 IV unnamed Kenya 2007 OS 30.65 32.15 No CT 
 KEN/12/2011 IV unnamed Kenya 2011 OS 16.74 18.85 19.00 
 KEN/21/2011 IV unnamed Kenya 2011 OS 17.19 19.15 18.45 
 KEN/4/2012 IV unnamed Kenya 2012 OS 25.48 27.70 24.30 
 SUD/7/2014 VII Alx-12 Sudan 2015 OS 35.03 35.90 N/A 
Asia 1 IRN/20/2015 ASIA Sindh-08 Iran 2015 OS 22.37 20.60 N/A 
 PAK/28/2015 ASIA Sindh-08 Pakistan 2015 OF 20.27 22.30 N/A 
 PAK/29/2015 ASIA Sindh-08 Pakistan 2015 OF 18.13 21.1 N/A 
 PAK/33/2015 ASIA Sindh-08 Pakistan 2015 OS 19.31 19.20 N/A 
 PAK/43/2015 ASIA Sindh-08 Pakistan 2015 OS 23.11 22.80 N/A 
SVDV UKG/24/1972 Undefined Undefined UK 1972 CC No CT No CT No CT 
 UKG/50/1972 Undefined Undefined UK 1972 CC No CT No CT No CT 
 UKG/51/1972 Undefined Undefined UK 1972 CC No CT No CT No CT 
 UKG/68/1972 Undefined Undefined UK 1972 CC No CT No CT No CT 
VSIV Colorado/1942 Undefined Undefined USA 1942 CC No CT No CT No CT 
VSNJV Columbia/1964 Undefined Undefined Colombia 1964 CC No CT No CT No CT 
(rRT-PCR) real-time reverse transcription PCR; (OS) original suspension; (OF) original fluid e.g. vesicular fluid; (CC) cell culture; 
(CT) cycle threshold value is the average value across two replicates; (WRLFMD) World Reference Laboratory for Foot-and-
Mouth Disease; (FMDV) foot-and-mouth disease virus; (SAT) Southern African Territories; (SVDV) swine vesicular disease virus; 
(VSIV) vesicular stomatitis Indiana virus; (VSNJV) vesicular stomatitis New Jersey virus.  
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Appendix 6 
Field evaluation of real-time reverse transcription PCR  
Table 7.5 Clinical samples for evaluation of rRT-PCR in field settings 
Animal 
reference 
Location 
Approximate 
lesion age 
Sample 
T-CORTM 8 
pan-FMDV 
T-CORTM 8 
serotype specific Reference 
rRT-PCR A 
(FAM) 
O 
(DFO) 
SAT 1 
(Cy®5) 
SAT 2 
(TxR) 
Cow_1 
Kericho 
County, 
Kenya 
(Farm 1) 
4 days Serum 36.40 No CT No CT No CT No CT No CT 
Cow_2 7 days Serum No CT N/A N/A N/A N/A No CT 
Cow_3 10 days Serum No CT N/A N/A N/A N/A No CT 
Cow_4 6 days Serum No CT N/A N/A N/A N/A No CT 
Cow_5 10 days Serum No CT N/A N/A N/A N/A No CT 
Cow_6 10 days Serum No CT N/A N/A N/A N/A No CT 
Cow_7 7 days Serum No CT N/A N/A N/A N/A No CT 
Cow_8 10 days Serum No CT N/A N/A N/A N/A No CT 
Cow_9 
Kericho 
County, 
Kenya 
(Farm 2) 
5 days 
Epithelium 20.25 21.00 No CT No CT No CT 19.44 
Serum 29.55 27.15 No CT No CT No CT 28.88 
Cow_10 5 days Serum No CT N/A N/A N/A N/A No CT 
Cow_11 3 days 
Epithelium 20.15 22.20 No CT No CT No CT 23.14 
Serum 32.30 30.50 No CT No CT No CT 32.02 
Cow_12 2 days Epithelium 17.80 22.25 No CT No CT No CT 20.17 
Cow_13 4 days Epithelium 19.55 21.70 No CT No CT No CT 17.64 
Cow_14 Nakuru 
County, 
Kenya 
(Farm 3) 
4 days 
Lesion swab 25.40 No CT 26.70 No CT No CT 30.53 
Serum No CT N/A N/A N/A N/A No CT 
Cow_15 4 days Lesion swab 29.80 No CT 32.80 No CT No CT 33.09 
Cow_16 7 days Lesion swab 32.75 No CT 34.40 No CT No CT 40.97 
Cow_17 10 days Lesion swab 39.00* N/A N/A N/A N/A No CT 
Cow_18 
Nakuru 
County, 
Kenya 
(Farm 4) 
7 days 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A No CT 
Cow_19 5 days 
Epithelium 36.2 No CT No CT No CT No CT No CT 
Serum No CT N/A N/A N/A N/A No CT 
Cow_20 8 days 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A No CT 
Cow_21 7 days 
Lesion swab 28.85 No CT No CT No CT No CT 27.17 
Serum No CT N/A N/A N/A N/A No CT 
OP fluid 26.85 No CT 25.25 No CT No CT 26.45 
Cow_22 5 days 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A No CT 
Cow_23 NCS Serum No CT N/A N/A N/A N/A No CT 
Cow_24 10 days Serum No CT N/A N/A N/A N/A No CT 
Cow_25 6 days 
Lesion swab 29.00 No CT No CT No CT No CT 34.90 
Serum No CT N/A N/A N/A N/A No CT 
Cow_26 10 days Serum No CT N/A N/A N/A N/A No CT 
Cow_27 7 days Serum No CT N/A N/A N/A N/A No CT 
Cow_28 NCS Serum No CT N/A N/A N/A N/A No CT 
Cow_29 2 days 
Epithelium 17.35 No CT 16.90 No CT No CT 21.21 
Lesion swab 30.80 No CT No CT No CT No CT 39.14 
Serum 36.90 No CT No CT No CT No CT No CT 
Cow_30 
Morogoro 
Region, 
Tanzania 
(Farm 5) 
ca. 1 month 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A N/A 
Cow_31 ca. 1 month 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A No CT 
Cow_32 ca. 2 weeks 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A N/A 
Cow_33 ca. 1 month 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A N/A 
Cow_34 ca. 2 weeks 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A No CT 
Cow_35 ca. 2 weeks 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A N/A 
Cow_36 ca. 1 month 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A No CT 
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Cow_37 
Morogoro 
Region, 
Tanzania 
(Farm 6) 
ca. 1-2 
months 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid 35.95 No CT No CT No CT No CT 32.66 
Cow_38 
ca. 1-2 
months 
Serum No CT No CT No CT No CT No CT N/A 
OP fluid No CT N/A N/A N/A N/A No CT 
Cow_39 
ca. 1-2 
months 
Serum No CT No CT No CT No CT No CT N/A 
OP fluid No CT N/A N/A N/A N/A No CT 
Cow_40 
ca. 1-2 
months 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT No CT No CT No CT No CT N/A 
Cow_41 
ca. 1-2 
months 
Serum No CT No CT No CT No CT No CT N/A 
OP fluid No CT N/A N/A N/A N/A No CT 
Cow_42 
ca. 1-2 
months 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid 32.65 No CT No CT No CT No CT 30.44 
Cow_43 
ca. 1-2 
months 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A No CT 
Cow_44 
Morogoro 
Region, 
Tanzania 
(Farm 7) 
ca. 2 weeks 
Lesion swab No CT N/A N/A N/A N/A 38.31 
Serum No CT N/A N/A N/A N/A No CT 
Cow_45 5 days 
Epithelium 28.60 No CT 28.25 No CT No CT 20.10 
Lesion swab 32.25 No CT No CT No CT No CT 25.37 
Serum No CT N/A N/A N/A N/A 37.24 
Cow_46 4 days 
Epithelium 26.25 No CT 23.45 No CT No CT 17.05 
Lesion swab 24.75 No CT 22.30 No CT No CT 18.83 
Serum 37.50 No CT No CT No CT No CT 27.57 
Cow_47 4 days 
Epithelium 23.75 No CT 20.20 No CT No CT 18.62 
Lesion swab 23.30 No CT 21.05 No CT No CT 18.67 
Serum No CT N/A N/A N/A N/A 38.03 
Cow_48 2 days 
Epithelium 19.85 No CT 17.95 No CT No CT 17.77 
Serum 35.70 No CT No CT No CT No CT 35.10 
Cow_49 NCS 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_50 NCS 
Mouth swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_51 NCS 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_52 
Morogoro 
Region, 
Tanzania 
(Farm 8) 
ca. 1-2 
months 
Lesion swab No CT No CT No CT No CT No CT No CT 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_53 NCS 
Serum No CT No CT No CT No CT No CT N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_54 NCS 
Serum No CT No CT No CT No CT No CT N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_55 NCS 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_56 NCS 
Mouth swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_57 7 days 
Lesion swab No CT N/A N/A N/A N/A 38.11 
Serum No CT N/A N/A N/A N/A N/A 
Cow_58 NCS 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid No CT N/A N/A N/A N/A N/A 
Cow_59 
Morogoro 
Region, 
Tanzania 
(Farm 9) 
5 days 
Lesion swab 30.55 No CT No CT No CT No CT 23.08 
Serum No CT N/A N/A N/A N/A No CT 
Cow_60 9 days 
Lesion swab 36.00* N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A N/A 
Cow_61 5 days 
Epithelium 24.10 No CT 27.00 No CT No CT 15.24 
Serum No CT N/A N/A N/A N/A No CT 
Cow_62 5 days 
Lesion swab 33.50 No CT No CT No CT No CT 30.83 
Serum No CT N/A N/A N/A N/A No CT 
Cow_63 4 days 
Epithelium 36.30 No CT No CT No CT No CT 34.97 
Lesion swab 34.25 No CT No CT No CT No CT 26.30 
Serum No CT N/A N/A N/A N/A No CT 
Cow_64 7 days 
Lesion swab No CT N/A N/A N/A N/A No CT 
Serum No CT N/A N/A N/A N/A No CT 
Cow_65 
4 days 
Epithelium 27.65 No CT 36.00 No CT No CT 23.10 
Serum No CT N/A N/A N/A N/A No CT 
7 days Epithelium 29.90 No CT 28.05 No CT No CT 22.61 
Cow_66 7 days 
Epithelium 37.50* N/A N/A N/A N/A No CT 
Serum No CT     N/A 
Cow_67 
Morogoro 
Region, 
Tanzania 
(Farm 10) 
NCS Serum No CT N/A N/A N/A N/A N/A 
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Cow_68 
Morogoro 
Region, 
Tanzania 
(Farm 11) 
4 days 
Epithelium 33.85 No CT No CT No CT No CT 31.08 
Lesion swab 29.20 No CT No CT No CT No CT 21.26 
Serum No CT N/A N/A N/A N/A No CT 
Cow_69 4 days 
Epithelium 34.95 No CT No CT No CT No CT 31.48 
Serum No CT N/A N/A N/A N/A No CT 
Cow_70 7 days 
Serum No CT N/A N/A N/A N/A No CT 
OP fluid 35.20 No CT No CT No CT No CT 26.11 
Cow_71 10 days 
Serum No CT N/A N/A N/A N/A No CT 
OP fluid No CT N/A N/A N/A N/A No CT 
Cow_72 4 days 
Epithelium 24.75 No CT 26.05 No CT No CT 16.65 
Serum No CT N/A N/A N/A N/A No CT 
Cow_73 Adama, 
Ethiopia 
(Farm 12) 
2 days Epithelium 22.50 No CT 21.70 No CT No CT N/A 
5 days 
Lesion swab 29.15 No CT 35.00 No CT No CT N/A 
Serum No CT N/A N/A N/A N/A N/A 
OP fluid 29.70 No CT 35.00 No CT No CT N/A 
Cow_74 NCS Serum No CT N/A N/A N/A N/A N/A 
Cow_75 10 days OP fluid 36.40 No CT No CT No CT No CT N/A 
Cow_76 Adama, 
Ethiopia 
(Farm 13) 
6 days Lesion swab 32.05 No CT No CT No CT No CT N/A 
Cow_77 7 days Lesion swab 38.05 No CT No CT No CT No CT N/A 
Cow_78 7 days OP fluid No CT N/A N/A N/A N/A N/A 
All results represent the average cycle threshold (CT) across two real-time reverse transcription PCR (rRT-PCR) replicates. 
*represents replicates where one was positive and the other negative. (NCS) no clinical signs: swabs in these animals were 
taken from the mouth; (N/A) not applicable, test not performed; (OP fluid) oesophageal-pharyngeal fluid; (FMDV) foot-and-
mouth disease virus. Shaded rows represent positive pan-FMDV results, for which the rRT-PCR typing assay was performed 
(blue: positive typing results for serotype A; red: positive typing results for serotype O; grey: did not type). The reference 
rRT-PCR was performed in laboratory settings within East Africa, using extracted RNA (this was not possible in Ethiopia due 
to a lack of facilities). 
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Appendix 7 
Evaluation of GoPrime 
Appendix 7a: The addition of published data into the parameters of GoPrime: 
The effect of primer/probe-template mismatches have previously been quantified and 
published for a number of different targets and Taq-based kits (Süß et al., 2009; 
Stadhouders et al., 2010). In order to ascertain whether the use of alternative parameters 
affected the prediction ability of GoPrime, data from these publications were added to 
the linear model analysis, in addition to the experimental data collected in Chapter 5. 
Results of the linear model were used to update the underlying mathematical model 
behind GoPrime (Table 7.6). 
 
Using these data as the underlying parameters, evaluation of GoPrime was repeated using 
the oligonucleotide templates containing the 90 artificial variations and seven naturally 
occurring variations within the FMDV 3Dpol-coding region. Using the templates containing 
artificial variations, the predictions for GoPrime were slightly improved, with the change 
in cycle threshold (ΔCT) predictions on average being 2.75 away from the observed result 
(SD 1.95; RMSD 3.37) (Figure 7.9A; 7.9B). Similar results were evident using the templates 
containing naturally occurring variations: GoPrime on average predicted the ΔCT of 
reactions 1.33 away from the observed result (SD 1.07; RMSD 1.69) (Figure 7.9C; 7.9D).  
Table 7.6 The effect of different mismatches calculated from linear model analysis 
Factor Mismatch type  ΔCT SE t value p value 
Primer 
% mismatch (forward/reverse combined) 1.00 0.03 -35.39 < 0.001 
nt 1 mismatch (type 1) 2.41 0.24 10.05 < 0.001 
2x nt 1 mismatch (type 1) 6.12 0.82 7.45 < 0.001 
nt 1 mismatch (type 2) 4.87 0.34 14.38 < 0.001 
2x nt 1 mismatch (type 2) 9.94 1.25 7.94 < 0.001 
nt 2 mismatch (type 1) 1.79 0.35 5.17 < 0.001 
2x nt mismatch (type 1) 4.47 0.77 5.85 < 0.001 
nt 2 mismatch (type 2) 3.71 0.37 10.05 < 0.001 
2x nt 2 mismatch (type 2) 7.36 1.06 6.92 < 0.001 
nt 3-4 mismatch (type 1) 0.89 0.37 2.39 0.0172 
2x nt 3-4  mismatch (type 1) 1.68 0.94 0.73 0.468 
nt 3-4 mismatch (type 2) 2.14 0.31 6.88 < 0.001 
2x nt 3-4 mismatch (type 2) 4.16 2.96 1.40 0.161 
Probe 
% mismatch 0.27 0.02 11.91 < 0.001 
3ʹ-end mismatch 0.68 0.43 1.60 0.110 
5ʹ-end mismatch -1.08 0.33 -5.62 < 0.001 
(nt) nucleotide; (ΔCT) change in cycle threshold; (SE) standard error. For multiple mismatches, the linear 
model was able to calculate the effect of having the same mutation in both the primers (2x). Mismatches 
were grouped as one of two types: (type 1) purine-pyrimidine mismatch (G-T; C-A: minor conformational 
change in the primer/probe-template duplex); (type 2) purine-purine or pyrimidine-pyrimidine mismatch 
(G-A; A-A; G-G; C-T; T-T; C-C: major conformational change in the primer/probe-template duplex). *If a 
type nt 1 mismatch was present, the percentage mismatch ΔCT would be calculated and additional nt 1 
mismatch ΔCT penalty added.  ΔCT, SE and t value given to 2 decimal places. 
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Figure 7.9 The addition of published data into GoPrime. GoPrime was evaluated using 
both the templates containing artificial (n = 90) and naturally occurring (n = 7) sequence 
variations. (A) observed change in cycle threshold for ExciteTM UF 2x Master Mix for 
artificial variations; (B) observed change in cycle threshold for SuperScript™ III Platinum™ 
One-Step qRT-PCR Kit for artificial variations; (C) observed change in cycle threshold for 
ExciteTM UF 2x Master Mix for natural variations; (D) observed change in cycle threshold 
for SuperScript™ III Platinum™ One-Step qRT-PCR Kit for natural variations. For the 
observed results, points represent the average change in cycle threshold or limit of 
detection across all dilutions (106-100) of starting template. 
 
 
 
 
A B 
C D 
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Appendix 7b: Impact of primer-template mismatches on one-step real-time reverse 
transcription PCR 
GoPrime, in its current form, was designed to evaluate real-time PCR and two-step real-
time reverse transcription PCR (rRT-PCR) (where mismatches persist through to the 
complementary DNA [cDNA]). To ascertain the effect of mismatches in one-step rRT-PCR, 
in which gene-specific primers are used in both the reverse transcription and rPCR stages, 
linear dsDNA constructs of 178 bp (gBlocks®: Integrated DNA Technologies Inc., IA, USA) 
were designed to contain M13 forward and reverse primer targets (commonly used as a 
cloning site), a T7 promoter and a 109 bp 3Dpol-coding region (containing the Callahan et 
al. [2002] target region [as stated in Chapter 5.3.1]) (Figure 7.10; Table 7.7). 
 
Figure 7.10 Simplified schematic of the double-stranded DNA (dsDNA) constructs. Grey 
regions represent the M13 bacteriophage primer targets; the black arrow represent the 
T7 promoter; the blue region represents the 109 bp 3Dpol-coding region (Table 5.5). 
 
 
Synthetic RNA transcripts (137 bp in length) were produced by in vitro transcription using 
a MEGAshortscriptTM T7 Transcription Kit (InvitrogenTM, Thermo Fisher Scientific, MA, 
USA), followed by DNase digestion using TURBOTM DNase (Ambion®, Thermo Fisher 
Scientific). Transcripts were purified using a MEGAclear™ Transcription Clean-Up Kit 
(Ambion®). Quantification and quality of the RNA transcripts were examined using a 
NanoDrop ND-1000 spectrophotometer at A260 (Thermo Fisher Scientific) and Qubit
® 
Fluorometer with Qubit® RNA HS Assay Kit (InvitrogenTM). A dilution series of the RNA 
standard (106 to 100 copies) was then prepared in 0.1 µg/ml carrier RNA (Ambion®) and 
used as template in rRT-PCR reactions which were performed as previously stated 
Table 7.7 3Dpol-coding regions contained within the DNA constructs (5ʹ-3ʹ) used to prepare RNA 
oligonucleotides  
 Forward primer target Probe target Reverse primer target 
R ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
1 ACTGGGTTTTACAAACCTGTGC TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
2 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC GCCGTGGCAGGACTCGC 
3 ACTGGTTTCTACGAACATGTGA TCCTTTGCACGCCGTGGGAC TCCGTGGCAGGACTCGC 
4 ACTGGGTTTTACAAACCTGTGA TCCTTTGCACGCCGTGGGAC TCCGTTGCGGGACTTGC 
The primer/probe binding regions of the four templates. Regions between the primer/probe sites were 
identical to O/UKG/35/2001 (Accession number KR265074: nucleotides 7862-7970). Black sequences 
represent the reference template (R); grey sequences represent the varying DNA templates, with red 
underlined based depicting primer/probe-template mismatch sites. 
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(Chapter 2.3.2), using a ABI ViiATM 7 Real-Time PCR system and SuperScript™ III Platinum™ 
One-Step qRT-PCR Kit (as described in Chapter 5.3.1). 
Differences were evident between mismatches that occurred in the forward and reverse 
primers. The presence of forward primer-template mismatches resulted in similar change 
in cycle threshold (ΔCT) when used in rPCR and one-step rRT-PCR (Figure 7.11). 
Conversely, when the reverse primer-template mismatches were present, the ΔCT was 
reduced in one-step rRT-PCR comparatively to rPCR (Figure 5.13). This is likely due to the 
Callahan et al. (2002) assay studied utilising the reverse primer for the reverse 
transcription stage, therefore cDNA generated will contain the reverse primer sequence. 
However, further analysis of the effects of these mismatches are required in order to add 
one-step rRT-PCR as a function of GoPrime. 
 
Figure 7.11 The impact of 3ʹ-end mismatches on real-time PCR (rPCR) and one-step real-
time reverse transcription PCR (rRT-PCR). Results show the raw experimental data 
collected, using the SuperScript™ III Platinum™ One-Step qRT-PCR Kit (for rPCR the 
reverse transcription step was omitted). (ΔCT) change in cycle threshold from the 
reference template. White bars represent the ΔCT for rPCR; grey bars represent the ΔCT 
for one-step rRT-PCR. Error bars represent the standard error. Templates 4 and 28 
(Chapter 5, Table 5.1) contained forward primer-template mismatches; templates 5 and 
29 (Chapter 5, Table 5.1) contained reverse primer-template mismatches. 
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Appendix 8 
Protocols for the use of molecular point-of-care tests 
Point-of-care test selection 
Molecular-based point-of-care tests should be selected based on the estimated FMD-status 
of the animal and required results (detection/characterisation), according Figure 1. 
 
Figure 1. Point-of-care test selection chart.  For pan-FMDV diagnosis ( assay be used, 
however alternatives may be better);   For FMDV-typing.  
Sample processing  
Samples should be collected according to Manual of Diagnostic Tests and Vaccines for 
Terrestrial Animals (OIE, 2012), and processed as stated in Table 1. 
 
Table 1 Processing of samples for molecular POCTs Dilution in NFW 
Sample Processing rRT-PCR RT-LAMP 
Epithelium Epithelial tissue should be prepared using a SVANODIP® FMDV-Ag 
Extraction Kit (Boehringer Ingelheim), by homogenising 0.2 g of 
tissue in the sample extraction vial with 1 ml of sample buffer from 
the SVANODIP® FMDV-Ag LFD kit (Boehringer Ingelheim).  
Note. Epithelial samples from the feet (interdigital space/coronary band) 
should be briefly washed in sterile water prior to processing to remove soil 
contaminants. 
1 in 10 1 in 5 
Serum Blood (collected using serum tubes) should be centrifuged either in 
a low-resource laboratory or using a field-based centrifuge 
(minimum 1400 x g for 3 min) at room temperature. Alternatively, 
blood can be left to clot at room temperature for 30 minutes, with 
serum pipetted from the top. 
1 in 10 1 in 5 
Mouth and 
foot swabs 
Once taken, swabs should be agitated by hand in 1 ml NFW, which 
can be used directly in analysis.  
Note. If using foot swabs, the feet should be briefly cleaned in sterile water 
prior to swabbing to remove soil contaminants. 
Neat Neat 
OP fluid Once collected, OP fluid only requires dilution in NFW for 
processing. 
Note. Allow the sample to settle before processing to reduce contaminants. 
1 in 10 1 in 10 
(rRT-PCR) real-time reverse transcription PCR; (RT-LAMP) reverse transcription loop-mediated isothermal amplification; 
(OP fluid) oesophageal-pharyngeal fluid; (NFW) nuclease-free water; (POCT) point-of-care tests. 
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  rRT-PCR using the T-CORTM 8 
Materials supplied Additional materials required 
 T-COR 8TM device 
 AC Adapter 
 Magnetic stirrer 
 T-COR 8TM reactions 
(eight reactions per packet) 
 Resuspension buffer  
(in 1 ml aliquots) 
 T-COR 8TM quick start guide 
 Nuclease-free water 
 Pipettes and tips for 5 µl and 20 µl volumes 
 DNAZap™ DNA Degradation Solutions  
(Thermo Fisher Scientific) 
 
Note: The T-COR 8TM can be powered by battery (one charge is enough for approximately eight runs) or 
through mains power. 
 
Protocol for set-up 
 
 
 
 
 
 
Analysis 
T-COR 8TM software will automatically analyse results and report samples as FMDV-
positive, FMDV-negative or re-test (for instance if the internal control has failed to 
amplify). Results can be easily saved and shared (instructions within the T-COR 8TM quick 
start guide).  
 
Note. The T-CORTM 8 should be surface disinfected between runs to prevent cross-contamination. Ensure to follow 
appropriate biosecurity procedures throughout. 
1) Prepare work surfaces and pipettes using DNAZapTM 
2) Remove reactions from the sealed packet 
3) Add 20 µl of resuspension buffer to each of the pellets  
4) Add 5 µl of the sample to be tested (processed as above)  
5) Close the lid, tap tubes to remove air bubbles and place 
each reaction within the magnetic stirrer for 5 - 10 
seconds  
6) Switch on the T-CORTM 8 using the circular side button 
7) Select [Barcode] under the Guided start-up option 
8) Hold the barcode (on the sealed packet) 3 inches from 
the scanner. This will automatically enter the correct 
thermocycling conditions for each reaction  
9) Follow the screen’s instructions to set-up reactions and 
enter relevant sample details 
(see T-COR 8TM quick start guide for troubleshooting) 
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rRT-LAMP using the Genie® II 
Materials supplied Additional materials required 
 Genie® II device 
 AC Adapter 
 Genie® II reactions 
(eight reactions per strip) 
 Resuspension buffer  
(in 1 ml aliquots) 
 Genie® II user manual 
 Nuclease-free water 
 Pipettes and tips for 5 µl and 15 µl volumes 
 DNAZap™ DNA Degradation Solutions  
(Thermo Fisher Scientific) 
 
Note: The Genie® II can be powered by battery (one charge is enough for approximately four hours use) or 
through mains power. 
 
Protocol for set-up 
 
 
 
 
Analysis 
Genie® II software will automatically analyse results and report samples as FMDV-positive, 
FMDV-negative or re-test (for instance if the anneal temperature of amplicons is not 
within the defined range for the reaction). Results can be easily saved and shared 
(instructions within the Genie® II user manual).  
 
Note. Alternatively, reactions can be heated in a water bath and analysed using PCRD-2TM lateral-flow devices (Abingdon 
Health, York, UK) as per manufacturer’s instructions (see Waters et al., 2014). The Genie® II should be surface disinfected 
between runs to prevent cross-contamination. Ensure to follow appropriate biosecurity procedures throughout. 
1) Prepare work surfaces and pipettes using DNAZapTM 
2) Remove reactions from the packet and remove the seal 
from the top of the tube strip 
3) Add 15 µl of resuspension buffer to each of the pellets 
4) Add 5 µl of nuclease-free water to each reaction 
5) Add 5 µl of the sample to be tested  
(processed as above)  
6) Pipette up and down ten times to mix reactions 
7) Close the reaction tube lids and tap tubes to remove air 
bubbles 
8) Turn on the Genie® II using the back switch  
9) Insert the reaction strip into either heat block A or B  
10) Select FMDV on the start-up menu and select the heat 
block chosen 
11) Follow the screen’s instructions to set-up reactions and 
enter relevant sample details 
(see Genie® II user manual for troubleshooting) 
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Appendix 9 
Responding to new emerging disease threats 
Preliminary trials were performed on a field-ready real-time reverse transcription PCR 
(rRT-PCR) assay from Tetracore Inc. (MD, USA) to differentiate between foot-and-mouth 
disease virus (FMDV) and Seneca Valley virus 1 (SVV) (Tetracore Ltd., 2017). SVV, a 
vesicular disease of pigs, has recently been linked as one of the possible causes of 
idiopathic vesicular disease in the USA, Canada, Brazil, China and Thailand (Pasma et al., 
2008; Singh et al., 2012; Leme et al., 2015; Vannucci et al., 2015; Wu et al., 2016; Saeng-
Cuto et al., 2017). 
Reactions were performed in duplicate on the T-CORTM 8 (Tetracore Inc.) as stated in 
Chapter 2.3.3. Probes for were modified for multiplex detection using the following 
fluorescence channels: SVV (Dragonfly Orange™ [DFO]), FMD virus (FMDV) (6-fluorescein 
amidite [FAM]) and exogenous internal control (Cy®5).  
To determine the relative diagnostic performance, RNA was extracted from a panel of 36 
clinical samples previously submitted to WRLFMD. These included 27 FMDV-positive 
samples, representing four serotypes (O, A, Southern African Territories [SAT] 2 and Asia 
1) from 11 countries (Table 7.8), seven SVV samples originating from the USA and two 
swine vesicular disease virus (SVDV) samples (specificity controls) (Chapter 2.3.6). Results 
were compared against a reference rRT-PCR for FMDV (performed as stated in Chapter 
2.3.2), SVV (performed as stated in Fowler et al. [2017]) and SVDV (performed as stated 
in Reid et al. [2004]).  
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Table 7.8 Clinical samples to evaluate the performance of a multiplex FMDV/SVV assay 
       Singleplex Multiplex 
Virus / 
Serotype 
WRLFMD sample 
ID 
Topotype Lineage Location Year Type Reference 
rRT-PCR CT 
FMDV 
CT 
SVV 
CT 
IC  
CT 
O TAI/20/2015 SEA Mya-98 Thailand 2015 OF 15.61 19.65  33.55 
 ISR/5/2015 ME-SA PanAsia Israel 2015 OF 26.30 23.70  32.20 
 ISR/4/2015 ME-SA PanAsia Israel 2015 OF 20.46 21.90  32.45 
 TAI/9/2015 SEA Mya-98 Thailand 2015 OF 14.10 17.30  33.40 
 SKR/6/2016 SEA Mya-98 South Korea 2016 OF 29.75 25.15  31.95 
 PAT/2/2015  ME-SA PanAsia Palestine 2015 OF 22.73 24.95  31.75 
 ISR/9/2015 ME-SA PanAsia Israel 2015 OF 17.54 20.30  32.80 
 NEP/15/2015 ME-SA Ind-2001d Nepal 2015 OF 18.28 21.90  32.85 
 NEP/19/2015 ME-SA Ind-2001d Nepal 2015 OF 23.15 22.05  31.90 
 SUD/4/2013 EA-3 unnamed Sudan 2013 OS 20.79 21.50  32.20 
A TAI/15/2015 ASIA Sea-97 Thailand 2015 OF 15.02 17.30  32.95 
 TAI/23/2015 ASIA Sea-97 Thailand 2015 OF 15.02 18.30  32.60 
 SAU/8/2015 ASIA G-VII Saudi Arabia 2015 OS 22.73 24.80  32.10 
 IRN/27/2015 ASIA G-VII Iran 2015 OS 25.26 26.00  31.80 
 PAK/25/2015 ASIA Iran-05FAR-11 Pakistan 2015 OF 23.49  27.05  31.75 
 PAK/55/2015  ASIA Iran-05FAR-11 Pakistan 2015 OS 15.93  20.25  33.90 
 SUD/12/2013 AFRICA G-IV Sudan 2013 OS 27.95 25.40  31.80 
 SUD/10/2013 AFRICA G-IV Sudan 2013 OS 27.85  25.85  31.80 
 SUD/13/2013 AFRICA G-IV Sudan 2013 OS 31.07 27.70  31.80 
SAT 2 ZIM/5/2015 II unnamed Zimbabwe 2015 OS 37.63 35.70  31.70 
 SUD/5/2013 VII Alx-12 Sudan 2013 OS 33.81  33.30  31.90 
 ETH/10/2015 VII Alx-12 Ethiopia 2015 OS 32.99  34.00  32.20 
 SUD/7/2014 VII Alx-12 Sudan 2014 OS 34.86 34.85  31.65 
Asia 1 PAK/27/2015 ASIA Sindh-08 Pakistan 2015 OF 7.82 14.75  33.80 
 PAK/33/2015  ASIA Sindh-08 Pakistan 2015 OS 19.81  21.90  32.45 
 PAK/37/2015  ASIA Sindh-08 Pakistan 2015 OS 21.19 24.35  32.25 
 PAK/54/2015 ASIA Sindh-08 Pakistan 2015 OS 21.94  23.25  31.80 
SVV NJ-90-10324 SVV1  New Jersey 1990  13.07  14.60 33.35 
 LA-97-1278 SVV1  Los Angeles 1997 OS 11.19  13.30 33.70 
 CA-01-131395 SVV1  California 2001  11.92  12.20 33.45 
 IL-92-48963 SVV1  Illinois 1992  13.53  14.70 32.65 
 IA-89-47552 SVV1  Iowa 1989  11.89  12.75 32.95 
 MN-88-36695 SVV1  Minnesota 1988  12.40  13.50 33.15 
 NC-88-23626 SVV1  North Carolina 1988  14.07  15.35 32.95 
SVDV UKG/4/73 SVDV  UK 1973 OS 11.48   31.50 
 UKG/155/80 SVDV  UK 1980 OS 13.17   31.75 
(OS) original suspension; (OF) original fluid e.g. vesicular fluid; (CC) cell culture. Cycle threshold (CT) value is the average 
value across two replicates for real-time reverse transcription PCR (rRT-PCR). (WRLFMD) World Reference Laboratory for 
Foot-and-Mouth Disease; (FMDV) foot-and-mouth disease virus; (SAT) Southern African Territories; (SVDV) swine vesicular 
disease virus; (SVV) Seneca Valley virus 1. 
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